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Major Depressive Disorder is a chronic mood disorder, affecting approximately 320 
million people worldwide. Rumination associated with biased AM recall and anhedonia 
linked to altered reward processing, are two of the most debilitating symptoms of depression 
that could persist in remission and are not successfully targeted by commonly prescribed 
antidepressants. Ketamine, a glutamate receptor antagonist, has emerged in the last two 
decades as a potent antidepressant with robust effects. The drug’s fast acting (2h post drug 
administration) and relatively long-lived antidepressant action (24h-48h after a single 
ketamine infusion) also targets anhedonia and rumination. (Lehman et.,al 2016, Lally et al., 
2014) However, the mechanism by which the drug exerts its antidepressant effects in the 
brain are not well understood.  
The aim of the present study was to identify brain areas that present with 
significantly altered activations 2h after the ketamine administration, when the 
antidepressant effects of the drug become detectable, and are important for reward 
processing and emotionally valenced AM (Autobiographical Memory) recall. For that 
purpose, we recruited remitted depressed volunteers who were scanned while performing 
an AM task (VAMP) and a reward processing task (MID). We hypothesized that ketamine, 
during the MID task would significantly increase striatal activations while during the VAMP 
task, the drug would modulate activations in the PCC, the sgACC and the amygdala, 
compared to placebo. These brain areas could serve as neuroimaging markers that could be 
linked to ketamine’s antidepressant action.  
For this study we recruited 37 remitted-depressed, drug-naïve, male and female 
volunteers who took part in a double-bind, placebo-controlled, cross-over design. Ketamine 
(0.5mg/kg) and placebo ware administered intravenously over a 45min continuous infusion. 
Two hours after the drug administration, participants were scanned while performing the 
MID and the VAMP task. The MID is a reaction time task during which participants need to 
perform fast button presses, in response to a target stimulus, to win different monetary 
rewards (Knutson et al., 2001). A cue that is presented before the target signifies the value 
of the reward that they could win in each trail. The reward anticipation and feedback phases 
of this task were analysed at a whole brain level and activations were also examined at 
predefined ROIs associated with reward processing, namely the striatal regions, the VTA, the 
amygdala and the insula. 
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The VAMP task is a personalised AM task that was developed specifically for this 
study. During the task statements from positive, negative and neutral events are presented 
to participants who are asked to recall those events and rate their emotional valence at the 
time of the scan. The fMRI data from this task were analysed at a whole brain level and a 
task connectivity analysis was performed for predefined ROIs that are associated with 
emotional memory recall and present with altered activations in depression, namely the 
amygdala, the PCC and the sg ACC. 
Scales and questionnaires that measure rumination, anhedonia, subjective well-
being and the dissociative/psychotomimetic effects of ketamine were administered at 
appropriate time points during the study. 
 Ketamine 2h after its administration did not produce any significant changes to the 
anhedonia and the subjective well-being of our participants. Whole brain analysis of the MID 
task did not reveal any significant changes during the anticipation and feedback phase of the 
task, 2h post ketamine, compared to placebo. The ROI analysis of the task revealed 
significant increases in the activation of the VS (Ventral Striatum) and the caudate. These 
increases were identified during the feedback phase of successful and unsuccessful MID trials 
that were associated with low monetary rewards. Also activity in the VTA (Ventral Tegmental 
Area) increased during the feedback phase of unsuccessful trials, irrespective of the reward 
magnitude.    
 Whole brain analysis of the VAMP placebo data revealed that the precuneus, the 
middle frontal gyrus and the thalamus presented with significantly altered activation during 
active AM recall. Ketamine, 2h after its administration and at the whole brain level, did not 
produce any significant changes to the task, compared to placebo. When the task 
connectivity was examined between ketamine and placebo, ketamine decreased 
connectivity between the amygdala and the visual cortex for positive and negative memory 
recall, compared to neutral. Decreased connectivity between the amygdala and the 
hippocampus was also identified for positive memory recall compared to neutral, when 






Ketamine, 2h after its administration, when its concentration in the blood is very 
low, significantly altered activations in brain areas that are important for anhedonia and 
emotionally valenced AM recall. The increases in the activation of the VS and the caudate 
during low in reward magnitude trials, could be linked to the participants’ increased 
sensitivity to these trials under ketamine, compared to placebo. This effect would be relevant 
to the drug’s antidepressant action which could have a positive impact on motivational 
processes engaged during the MID.  
The decreased connectivity that was identified after ketamine between the 
amygdala and the visual cortex, could be associated with ketamine reducing the visual 
imagery that is associated with emotionally valenced AM recall. This reduction in the 
connectivity occurred during positive and negative memory recall, compared to neutral and 
could be associated with reconsolidation processes that might alter the emotional valence 
of the recalled memory. This would suggest that ketamine as an antidepressant could have 







Statement of work 
 
The present research study of ketamine’s delayed effects in remitted depressed 
volunteers was funded by Johnson and Johnson via a research grant to King’s College London. 
My tuition fees and stipend were covered via a scholarship from the BRC (Biomedical 
Research Centre). 
I was involved in all the stages of ethics approval, volunteer recruitment, data 
collection and analysis. Specifically, I contributed to the ethics application, amendments and 
extensions in collaboration with my supervisor Prof Mitul Mehta. I was solely responsible for 
the recruitment of participants, the data collection and the analysis.  
For the analysis of the results and the write up of this thesis I have received guidance 
and feedback from my supervisor Prof Mitul Mehta. 
 Preliminary results of this research have been presented to British Association of 
Psychopharmacology Meeting (2019) as well as the CINP (International College of 







This thesis would have never been possible without the genuine interest and selfless 
contribution of my amazing volunteers, the constant support of our research team and the 
trust of our funders. Steph and Ndaba, thank you for making every study day unique and 
enjoyable. I am very grateful to you both since with your experience and genuine interest for 
the well-being of the participants made me, and most importantly them, feel comfortable 
and safe! 
 The recruitment for this study was not easy and Dr Declan Jones with Dr Maura Furey 
were extremely patient, supportive and encouraging throughout that process. Thank you! 
 A very special thank you to my friends! Barbara, Daniel, Ottavia and Panos (in 
alphabetical order to avoid ruining our friendship…) you are my family away from home and 
you have given me the most joyful memories! I hope we will share many more beautiful 
moments together!  
 The four years of this PhD research would have been very difficult without the 
support of my office mate! Pete, thank you for sharing ideas with me, discussing my 
problems, supporting me during tough times. You are an excellent colleague and a very dear 
friend! 
A very special thank you to Dr Carlos Zarate and Dr Argyris Stringaris who gave me a 
lot to look forward to during the last tough months of writing-up! 
Last but not least, I would like to extend a very special and heartfelt thank you to my 
supervisor, Prof Mitul Mehta. Mitul, thank you so much for your trust in me. Your guidance 
and your support have been constant and unwavering throughout the six years that we have 
worked together. Your enthusiasm and genuine interest for research are indeed 
inspirational. I am looking forward to collaborating more with you in the future. Thank you! 
Finally, a very special thank you to my little niece Filothei-Thalia. My dearest Thalia, 
your love and your laughter have emotionally nurtured me and supported me in all my days 
since I first met you. You are my inspiration! When close to you I feel able and strong. 




1 Table of Contents 
Abstract .......................................................................................................................................... 1 
Statement of work .......................................................................................................................... 4 
Acknowledgments .......................................................................................................................... 5 
Introduction .................................................................................................................................. 13 
Depression .................................................................................................................... 13 
1 General characteristics with focus on rumination, biased AM recall and anhedonia ........ 13 
2 Depression and Autobiographical Memory ..................................................................... 14 
2.1 Autobiographical Memory definition. Encoding and recall of autobiographical 
memories ........................................................................................................................... 14 
2.2 The Autobiographical Memory recall network of brain regions ............................... 16 
2.3 Biased recall of Autobiographical Memories in depression ..................................... 19 
3 Depression and Rumination ........................................................................................... 21 
3.1 Rumination definition ............................................................................................ 21 
3.2 Brain areas and networks that are important for rumination .................................. 21 
4 Autobiographical Memory, Rumination and Depressive Symptoms................................. 23 
4.1 The CaR-FA-X model .............................................................................................. 23 
4.2 The cognitive model of depression ......................................................................... 24 
5 Depression and Anhedonia............................................................................................. 28 
5.1 Consummatory anhedonia ..................................................................................... 28 
5.2 Motivational anhedonia ......................................................................................... 29 
5.3 Neuronal components of anhedonia ...................................................................... 30 
5.4 Reward processing in the healthy brain .................................................................. 30 
5.5 Brain areas that are important for stimulus reward value, predictive reward value 
and prediction error ........................................................................................................... 31 
5.6 The MID task ......................................................................................................... 32 
6 Altered reward processing in depression ........................................................................ 34 
Antidepressant action of ketamine .............................................................................. 37 
7 General overview of the most common treatments of depression .................................. 37 
8 Glutamatergic system- Alternative treatments for depression ........................................ 38 
8.1 The glutamatergic system ...................................................................................... 38 
8.2 The role of the glutamate system in depression ..................................................... 40 
8.3 Altered brain anatomy and function in depression: evidence from preclinical models 
and human neuroimaging studies ....................................................................................... 40 
8.4 Glutamatergic agents as antidepressants ............................................................... 43 
9 Ketamine ....................................................................................................................... 44 
9.1 Pharmacology of ketamine .................................................................................... 44 
9.2 Neuronal and molecular mechanism ...................................................................... 45 
9.3 Ketamine’s effects in the brain: an insight from neuroimaging studies.................... 47 











Methods ....................................................................................................................................... 53 
Participants .................................................................................................................. 53 
Study design ................................................................................................................. 54 
1 Behavioural Assessments ............................................................................................... 58 
1.1 The RRS (Rumination Response Scale) .................................................................... 58 
1.2 The SHAPS (Snaith-Hamilton Pleasure Scale) .......................................................... 59 
1.3 The SNK-W ............................................................................................................ 59 
1.4 The PSI (Psychotomimetic States Inventory) ........................................................... 60 
1.5 Correlations of scale scores with fMRI data ............................................................ 60 
1.6 MRI battery of tasks ............................................................................................... 60 
MR Acquisition and Pre-processing of MR images ........................................................ 61 
Study Tasks ................................................................................................................... 62 
2 General 1st level and 2nd level modelling ......................................................................... 62 
3 The MID (Monetary Incentive Delay) task ....................................................................... 63 
3.1 Modelling the MID task .......................................................................................... 64 
4 The Valenced Autobiographical Memory Paradigm......................................................... 70 
4.1 Task Development ................................................................................................. 70 
4.2 The LEDS interview ................................................................................................ 72 
4.3 Administration of the VAMP .................................................................................. 74 
4.4 Scanning ................................................................................................................ 75 
Modelling of the VAMP task ............................................................................................... 76 
Behavioural data .......................................................................................................................... 81 
1 Introduction ................................................................................................................... 81 
2 Results ........................................................................................................................... 83 
2.1 General Sample characteristics .............................................................................. 83 
2.2 Rumination ............................................................................................................ 84 
2.3 Performance on Memory Tests .............................................................................. 85 
2.4 Measures of Anhedonia and Subjective Well-being ................................................ 86 
2.5 Ketamine: Pharmacodynamics and the dissociative effects of the drug .................. 88 
3 Discussion ...................................................................................................................... 91 
3.1 Ketamine and its metabolites ................................................................................. 91 
3.2 Memory and Rumination levels in our cohort ......................................................... 94 
3.3 The effects of ketamine ......................................................................................... 97 
3.4 Anhedonia and Subjective Well Being .................................................................. 100 
4 Conclusions .................................................................................................................. 103 
The MID task .............................................................................................................................. 105 
1 Introduction ................................................................................................................. 105 
2 Results ......................................................................................................................... 107 
Performance .................................................................................................................... 107 
2.2 Neuroimaging Results .......................................................................................... 110 
3 Discussion .................................................................................................................... 123 
Introduction ..................................................................................................................... 123 
Summary of findings in the placebo group ........................................................................ 123 
Summary of findings for ketamine session vs placebo session ........................................... 124 
3.1 The MID task in the placebo group ....................................................................... 125 
3.2 The Effects of ketamine’s on the MID task............................................................ 130 




The VAMP ................................................................................................................................... 135 
1 Introduction ................................................................................................................. 135 
2 Results ......................................................................................................................... 137 
2.1 Behavioural Analysis ............................................................................................ 137 
2.2 Neuroimaging results ........................................................................................... 138 
3 Discussion .................................................................................................................... 146 
Summary of Findings ........................................................................................................ 146 
3.1 The VAMP task- placebo group ............................................................................ 147 
3.2 The effects of emotional valence in AM retrieval .................................................. 150 
Task-connectivity analysis in the placebo group ................................................................ 151 
Ketamine’s effects on task connectivity ............................................................................ 154 
4 Conclusions .................................................................................................................. 157 
General Discussion...................................................................................................................... 158 
Introduction................................................................................................................ 158 
Anhedonia .................................................................................................................. 161 
1 Anhedonia and reward processing in remitted depressed volunteers ........................... 161 
1.1 The mid task ........................................................................................................ 162 
2 Current antidepressants and anhedonia ....................................................................... 163 
Rumination ................................................................................................................. 165 
3 Emotionally valenced AM recall in remitted depressed volunteers................................ 166 
4 The effects of ketamine on the VAMP task ................................................................... 167 
5 Current antidepressants and rumination ...................................................................... 169 
Considerations and limitations ................................................................................... 170 
Future directions ........................................................................................................ 172 
References .................................................................................................................................. 174 
Appendix A.................................................................................................................................. 192 
Appendix B .................................................................................................................................. 198 
Appendix C .................................................................................................................................. 215 
Appendix D ................................................................................................................................. 216 
Appendix E .................................................................................................................................. 217 
Appendix F .................................................................................................................................. 220 
Appendix G ................................................................................................................................. 221 












FIGURE 1 PROVIDES A SUMMARY OF THE PROPOSED MECHANISMS OF KETAMINE’S 
ANTIDEPRESSANT ACTION (A, B, C, D AND E). THE TWO MOST PROMINENT MECHANISMS 
PROPOSE THAT KETAMINE EITHER VIA INDIRECT INHIBITION THROUGH GABAERGIC 
INTERNEURONS (A) OR DIRECTLY VIA BINDING OF (2R,6R)-HNK ON AMPARS (D) LEADS TO 
ENHANCED GLUTAMATERGIC FIRING. ACTIVATION OF THE DOWNSTREAM MOLECULAR 
PATHWAYS COULD INCREASE BDNF SYNTHESIS WHICH IS ASSOCIATED WITH SUSTAINED 
SYNAPTIC PLASTICITY. THIS IS NECESSARY FOR THE STRENGTHENING OF THE EXCITATORY 
SYNAPSE AND A SUSTAINED ANTIDEPRESSANT RESPONSE. THE PICTURE WAS PUBLISHED IN 
(ZANOS ET AL., 2018) .............................................................................................................. 46 
TABLE 1. THE TABLE CONTAINS A BRIEF DESCRIPTION OF THE PRE, DURING AND POST INFUSION 
ASSESSMENTS THAT TAKE PLACE OUT OF THE MRI SCANNER AND NOTES THE TIME OF THEIR 
ADMINISTRATION................................................................................................................... 57 
FIGURE 2. THE MID TASK HAS BEEN DESIGNED SPECIFICALLY FOR FMRI STUDIES. THE DESIGN OF THE 
TASK ALLOWS THE EXAMINATION OF THE ANTICIPATION AND FEEDBACK PHASES OF THE TASK 
SEPARATELY. .......................................................................................................................... 66 
FIGURE 3. THE VAMP IS A PERSONALISED AM TASK. THE RETRIEVAL PHASE OF TRUE STATEMENTS IS 
THE ONE USED FOR THE ANALYSIS OF THE FMRI DATA FROM THIS TASK. ................................ 76 
FIGURE 4. THE CONSORT DIAGRAM SHOWS HOW MANY PARTICIPANTS, WERE SCREENED, 
RANDOMISED AND FINALLY ANALYSED FOR THIS STUDY. ........................................................ 83 
TABLE 2. THE MEAN AGE AND RRS SCORES IN OUR COHORT. A TWO SAMPLE T-TEST DID NOT 
REVEAL GENDER SIGNIFICANT (P<.05) DIFFERENCES IN RUMINATION. .................................... 84 
TABLE 3. THE IMMEDIATE AND DELAYED RECALL MEASURES OF THE RAVLT AND WESCHLER 
MEMORY SCALE DID NOT REVEAL SIGNIFICANT DIFFERENCES IN  THE COGNITIVE 
PERFORMANCE OF OUR COHORT BETWEEN SESSIONS (PAIRED T-TEST, P>.05). ...................... 85 
FIGURE 5. ANHEDONIA DID NOT CHANGE 2H AFTER KETAMINE (WILCOXON SIGNED RANK TEST, 
P>.05). IN THE PLACEBO SESSION A SIGNIFICANT REDUCTION IN ANHEDONIA WAS IDENTIFIED 
(WILCOXON SIGNED RANK TEST, P<.05) .................................................................................. 86 
FIGURE 6. MULTIPLE REGRESSION REVEALED A SIGNIFICANT EFFECT OF TREATMENT IN THE 
KETAMINE SESSION (F (23,1) =8.11, P<.05) BUT THE EFFECT OF TREATMENT OVER TIME WAS 
NOT SIGNIFICANT (F (23,1) = 0.69, P>.05) ............................................................................... 87 
FIGURE 7. THE AVERAGE VALUES OF KETAMINE AND ITS MAJOR METABOLITES AT THE END OF A 
40MIN I.V INFUSION AND 2H POST INFUSION. SIGNIFICANT CHANGES WERE IDENTIFIED FOR 
ALL METABOLITE LEVELS 2H AFTER THE DRUG ADMINISTRATION (PAIRED T-TEST., P<.05) ...... 89 
FIGURE 8 INDIVIDUAL LEVELS FROM KETAMINE’S METABOLITES AT THE END OF A 40MIN I.V 
INFUSION AND 2H POST THE KETAMINE ADMINISTRATION. MISSING VALUES REPRESENT 
PARTICIPANTS WHERE THE METABOLITE LEVELS WERE BELOW DETECTABLE 
CONCENTRATIONS. ................................................................................................................ 89 
TABLE 4. THE LEVELS OF KETAMINE’S METABOLITES AT THE END OF A 40MIN I.V INFUSION AND 2H 
POST THE KETAMINE. ............................................................................................................. 89 
FIGURE 9. KETAMINE PRODUCED SIGNIFICANT CHANGES IN THE PSI SCORES COMPARED TO 
PLACEBO. SIGNIFICANT INCREASES WERE IDENTIFIED FOR THE SIX SUBSCALES, INCLUDING 
ANHEDONIA (PAIRED T-TESTS, P<.05) ..................................................................................... 90 
TABLE 5. THE MEAN PSI SCORES FOR EACH OF THE SUBSCALES FOR THE PLACEBO AND KETAMINE 
SESSION. ................................................................................................................................ 90 
FIGURE 10.  CUMULATIVE RESPONSE RATE (WITH SD BARS) OVER DURATION OF THE TASK ON 
TRIALS THAT REQUIRED A RESPONSE (NEUTRAL TRIALS, LOW WIN TRIALS AND HIGH WIN 
TRIALS). KETAMINE DID NOT SIGNIFICANTLY ALTER (PAIRED T-TEST, P>.05) THE TRIAL WISE 
RESPONSE PERFORMANCE. .................................................................................................. 108 
FIGURE 11.  THE MEAN REACTION TIME AND THE TOTAL AMOUNT OF MONEY WON PER TRIAL DID 
NOT SIGNIFICANTLY CHANGE BETWEEN THE KETAMINE AND PLACEBO SESSIONS (PAIRED T-
10 
 
TEST, P> .05). A SIGNIFICANT REDUCTION WAS IDENTIFIED IN THE REACTION TIMES OF HIGH, 
LOW AND NEUTRAL WIN TRIALS FOR BOTH KETAMINE(REPEATED MEASURE ANOVA, F(2, 
36)=23.17, P<.001) AND PLACEBO (REPEATED MEASURE ANOVA, F(2, 36)=34.27, P<.001) .... 109 
FIGURE 12.  A WHOLE BRAIN ANALYSIS REVEALED THAT SEVERAL BRAIN REGIONS PRESENTED WITH 
SIGNIFICANT INCREASED (RED) AND DECREASED (BLUE) ACTIVATIONS IN THE PLACEBO GROUP. 
THE CONTRAST THAT WAS EXAMINED HERE COMBINED THE ANTICIPATION PHASE OF HIGH 
AND LOW WIN TRIALS AND COMPARED TO ANTICIPATION PHASE OF THE NEUTRAL TRIALS, 
WHERE NO REWARD IN EXPECTED........................................................................................ 110 
TABLE 6.SEVERAL SIGNIFICANT CLUSTERS PRESENT WITH SIGNIFICANTLY INCREASED ACTIVATIONS 
WHEN THE ANTICIPATION PHASE OF HIGH REWARD AND LOW REWARD WIN TRIALS IS 
COMPARED TO THE NEUTRAL TRIALS.................................................................................... 111 
TABLE 7. THE CLUSTERS THAT PRESENT WITH SIGNIFICANTLY DECREASED ACTIVATIONS WHEN THE 
ANTICIPATION PHASE OF HIGH REWARD AND LOW REWARD WIN TRIALS IS COMPARED TO THE 
NEUTRAL TRIALS. .................................................................................................................. 111 
FIGURE 13.  WHEN THE ANTICIPATION PHASE OF LOW REWARD AND HIGH REWARD TRIALS WERE 
COMPARED, SIGNIFICANT INCREASES (RED) WERE IDENTIFIED IN FRONTAL AND OCCIPITAL 
BRAIN AREAS. ....................................................................................................................... 112 
TABLE 8. THE CLUSTERS THAT PRESENTED WITH INCREASED ACTIVATION, WHEN REWARD 
MAGNITUDE WAS EXAMINED, ARE PRESENTED HERE ALONG WITH THE BRAIN AREAS (MIN 
COORDINATES) WHERE THE PEAK OF THE CLUSTER IS LOCATED............................................ 112 
FIGURE 14. SIGNIFICANT DECREASES (BLUE) IN THE ACTIVATION OF FRONTAL BRAIN AREAS DURING 
THE FEEDBACK PHASE OF SUCCESSFUL HIGH REWARD AND LOW REWARD TRIALS WHEN 
COMPARED TO THE FEEDBACK COMPONENT OF NEUTRAL TRIALS. ....................................... 113 
TABLE 9.  THE CLUSTERS THAT PRESENTED WITH DECREASED ACTIVATION DURING THE FEEDBACK 
PHASE OF THE SUCCESSFUL MID TRIAL ARE PRESENTED IN TABLE 4 ABOVE. THE MNI 
COORDINATES OF THE PEAK OF THE CLUSTER IS ALSO INCLUDED. ........................................ 113 
FIGURE 15.  OCCIPITAL, PARIETAL AND TEMPORAL BRAIN AREAS PRESENTED WITH SIGNIFICANTLY 
INCREASED ACTIVATIONS DURING FEEDBACK OF UNSUCCESSFUL  TRIALS COMPARED TO 
FEEDBACK FROM NEUTRAL MID TRIALS. SIGNIFICANTLY DECREASED ACTIVATIONS WERE 
IDENTIFIED IN THE POST CENTRAL REGION FOR THE SAME CONTRAST. ................................. 114 
TABLE 10. THE CLUSTERS THAT PRESENTED WITH SIGNIFICANTLY INCREASED AND DECREASED 
ACTIVATIONS DURING THE FEEDBACK PHASE OF THE UNSUCCESSFUL MID TRIALS ARE 
PRESENTED IN THIS TABLE. THE MNI COORDINATES OF THE PEAK OF THE CLUSTER ARE ALSO 
INCLUDED. ........................................................................................................................... 114 
FIGURE 16.  THE CINGULUM PRESENTED WITH SIGNIFICANTLY DECREASED ACTIVATION WHEN THE 
FEEDBACK PHASE OF  HIGH REWARD MID TRIALS WAS COMPARED TO THE FEEDBACK PHASE 
OF A LOW WIN TRIALS. ......................................................................................................... 115 
TABLE 11.  ONE CLUSTER OF SIGNIFICANT DECREASES IN BRAIN ACTIVITY WAS IDENTIFIED WHEN 
REWARD MAGNITUDE WAS EXAMINED FOR THE FEEDBACK PHASE OF MID TRIALS. THE MNI 
COORDINATES OF THE PEAK CORRESPOND TO THE LEFT MIDDLE CINGULATE CORTEX. ......... 115 
TABLE 12.THE MEAN ACTIVATION VALUES ARE SHOWN HERE FOR EACH BILATERAL ROI ALONG 
WITH THE SD. THE VALUES IN RED ARE THE ONES THAT HAVE SURVIVED THE BONFERRONI 
CORRECTION FOR MULTIPLE COMPARISONS ........................................................................ 117 
FIGURE 17. KETAMINE, DURING THE ANTICIPATION OF A LOW REWARD COMPARED TO NEUTRAL, 
SIGNIFICANTLY INCREASED THE ACTIVATION OF THE BILATERAL AND LEFT CAUDATE. THE RED 
ASTERISK INDICATES THAT THE CHANGE WAS STILL SIGNIFICANT AFTER BONFERRONI 
CORRECTION. ....................................................................................................................... 118 
FIGURE 18.  KETAMINE, 2H POST THE DRUG ADMINISTRATION, SIGNIFICANTLY MODULATED THE 
ACTIVATION OF THE VENTRAL STRIATUM AND THE INSULA DURING THE FEEDBACK PHASE OF A 
SUCCESSFULLY OBTAINED REWARD. THE RED ASTERISK INDICATES THAT THE CHANGE WAS 
STILL SIGNIFICANT AFTER BONFERRONI CORRECTION. IN OUR EXPLORATORY ANALYSIS, THE 
LEFT VENTRAL STRIATUM AS WELL AS THE LEFT INSULA AND THE LEFT PUTAMEN WERE ALSO 
SIGNIFICANTLY MODULATED BY KETAMINE FOR THAT CONTRAST. ....................................... 119 
11 
 
FIGURE 19.  DURING THE FEEDBACK PHASE OF MID TRIALS WHERE A HIGH REWARD WAS 
ANTICIPATED, THE BILATERAL INSULA, PRESENTED WITH INCREASED INVOLVEMENT AFTER 
KETAMINE COMPARED TO THE PLACEBO SESSION. THE RED ASTERISK INDICATES THAT THE 
CHANGE WAS STILL SIGNIFICANT AFTER BONFERRONI CORRECTION. THE LEFT AND RIGHT 
INSULA WERE ALSO SIGNIFICANTLY MODULATED BY THE DRUG. .......................................... 120 
FIGURE 20. THE BILATERAL CAUDATE APPEARS TO BE SIGNIFICANTLY MORE ACTIVATED AFTER 
KETAMINE COMPARED TO PLACEBO WHEN FEEDBACK FOR UNSUCCESSFUL LOW REWARD MID 
TRIALS IS PRESENTED TO PARTICIPANTS. THE RED ASTERISK INDICATES THAT THE CHANGE WAS 
STILL SIGNIFICANT AFTER BONFERRONI CORRECTION. THE LEFT AND RIGHT CAUDATE ALSO 
PRESENT WITH INCREASED ACTIVATIONS FOR THAT CONTRAST. .......................................... 121 
FIGURE 21. WHEN THE FEEDBACK PHASE FOR HIGH AND LOW REWARD UNSUCCESSFUL  TRIALS WAS 
EXAMINED BETWEEN THE KETAMINE AND PLACEBO SESSIONS, WE FOUND THAT THERE 
INCREASED INVOLVEMENT FOR THE BILATERAL VTA AND THE LEFT AMYGDALA FOR THAT 
CONTRAST. THE RED ASTERISK INDICATES THAT THE CHANGE WAS STILL SIGNIFICANT AFTER 
BONFERRONI CORRECTION.  THE LEFT VENTRAL STRIATUM AND LEFT VTA ALSO PRESENT WITH 
INCREASED INVOLVEMENT FOR THAT CONTRAST. ................................................................ 122 
FIGURE 22.  WHOLE BRAIN ANALYSIS OF THE VAMP IN THE PLACEBO GROUP REVEALED SIGNIFICANT 
INCREASES (RED) AND DECREASES (BLUE) IN THE ACTIVATION OF SEVERAL BRAIN AREAS, 
DURING RECALL OF POSITIVE, NEGATIVE AND NEUTRAL MEMORIES COMPARED TO THE 
CONTROL CONDITION. .......................................................................................................... 138 
TABLE 13. ACTIVE RETRIEVAL DURING THE VAMP TASK, COMPARED TO THE CONTROL CONDITION 
REVEALED INCREASED ACTIVATIONS IN THREE CLUSTERS AND SIGINIFICANT DECREASES IN 
TWO. THE MNI COORDINATED FOR THE PEAK OF EACH CLUSTER ARE ALSO PRESENTED. THE 
VALENCE OF THE RECALLED MEMORY IN THE PLACEBO GROUP ............................................ 139 
FIGURE 23. SIGNIFICANT CHANGES (P<.05, FDR CORRECTED) IN THE CONNECTIVITY BETWEEM THE 
BILATERAL AMYGDALA AND SEVERAL BRAIN AREAS WERE IDENTIFIED WHEN THE RETRIEVAL 
PHASE OF THE POSITIVE AND NEUTRAL EVENTS WAS EXAMINED IN THE PLACEBO GROUP. THE 
BRAIN AREAS WHERE CONNECTIVITY WITH THE AMYGDALA INCREASED (RED) INCLUDED A. 
THE PRECUNEUS  B. THE PRECENTRAL GYRUS(BILATERAL) C. THE LATERAL OCCIPITAL CORTEX 
(BILATERAL) D. THE POST CENTRAL GYRUS (BILATERAL) E. THE OCCIPITAL POLE (BILATERAL) F. 
THE TEMPORAL POLE (BILATERAL) G. THE CEREBELLUM-CRUS1(LEFT) H. THE INSULAR CORTEX 
(BILATERAL) I. THE THALAMUS (RIGHT) J. THE OCCIPITAL FUSIFROM GYRUS (BILATERAL) K.THE 
PUTANEN L. THE HIPPOCAMPUS (RIGHT). BRAIN AREAS WHERE CONNECTIVITY WITH THE 
AMYGDALA DECREASED (BLUE) INCLUDED: A. THE PARAHIPPOCAMPAL GYRUS (BILATERAL) B. 
THE PARACINGULATE GYRUS (BILATERAL) C. THE INTRACALCARINE CORTEX (BILATERAL) AND D. 
THE OCCIPITAL POLE (LEFT) D. THE MIDDLE TEMPORAL GYRUS (RIGHT) E. THE SUPERIOR 
TEMPORAL GYRUS (BILATERAL) F. THE HIPPOCAMPUS (LEFT) G. THE CAUDATE (BILATERAL) H. 
INSULA (BILATERAL) AND I. THE PUATMNEN ......................................................................... 140 
FIGURE 24. BRAIN AREAS THAT PRESENT WITH INCREASED (RED) AND DECREASED (BLUE) 
CONNECTIVITY WITH THE BILATERAL AMYGDALA DURING RECALL OF NEGTIVE COMPARED TO 
NEUTRAL EVENTS ARE PRESENTED (P<.05 FDR CORRECTED)  IN THIS FIGURE. SIGNIFICANT 
INCREASES IN CONNECTIVITY WERE IDENTIFIED IN THE A. ORBITAL FRONTAL CORTEX 
(BILATERAL) B. MIDDLE TEMPORAL GYRUS (BILATERAL) C. PRECUNEUS (BILATERAL) D. MIDDLE 
FRONTAL GYRUS (BILATERAL) E. INFERIOR FRONTAL GYRUS (BILATERAL) F. THE CEREBELLUM-
CRUS2 (LEFT) G. THE SUPERIOR TEMPORAL GYRUS (BILATERAL) H. THE LATERAL OCCIPITAL 
CORTEX (BILATERAL) I.THE OCCIPITAL FUSIFROM GYRUS (BILATERAL).  SIGNIFICANTLY 
DECREASED CONNECTIVITY WERE IDENTIFIED BETWEEN THE BILATERAL AMYGDALA AND A. THE 
THALAMUS (BILATRAL) B. THE HIPPOCAMPUS (BILATERAL) C. THE PARAHIPPOCAMPAL GYRUS 
(BILATERAL) D. TEMPORAL POLE (BILATERAL AND E. THE PARAHIPPOCAMPAL GYRUS 
(BILATERAL). ......................................................................................................................... 141 
FIGURE 25.  WHEN THE EFFECT OF THE VALENCE OF THE RECALLED MEMORY WAS EXAMINED,  
SIGNIFICANT  (P<0.05, FDR CORRECTED) INCREASES AND DECREASES INCONNECTIVITY OF THE 
BILATERAL AMYGDALA WITH THE REST OF THE BRAIN WERE IDENTIFIED. INCREASED 
12 
 
CONNECTIVITY WAS IDENTIFIED BETWEEN OUR SEED REGION AND  A. THE LATERAL OCCIPITAL 
CORTEX (BILATERAL), B. THE PRECUNEUS (BILATERAL), C. SUPERIOR FRONTAL GYRUS 
(BILATERAL), D. TEMPORAL AND OCCIPITAL FUSIFORM GYRUS (BILATERAL), E. THE SMA 
(BILATERAL) F. MIDDLE TEMPORAL GYRUS. SIGNIFICANT DECREASES WERE IDENTIFIED FOR A. 
THE THALAMUS (BILATERAL), B. THE HIPPOCAPUS (BILATERAL), C. THE INFERIOR FRONTAL 
GYRUS (LEFT) AND D. THE INFERIOR TEMPORAL GYRUS (BILATERAL). ................................... 142 
FIGURE 26 THE AVERAGE VAS RATINGS OF THE POSITIVE, NEGATIVE AND NEUTRAL EVENTS. A 
PAIRED T-TEST REVEALED THAT THE RATINGS DID NOT CHANGE BETWEEN THE KETAMINE AND 
PLACEBO SESSIONS (P>0.05) ................................................................................................. 143 
TABLE 14. THE MEAN VAS SCORE FOR THE POSITIVE, NEGATIVE AND NEUTRAL EVENT DID NOT 
DIFFER (PAIRED T-TEST, P<.05) BETWEEN KETAMINE AND PLACEBO, 2H AFTER THE DRUG 
ADMINISTRATION. ................................................................................................................ 143 
FIGURE 27. A. KETAMINE, 2H AFTER ITS ADMINISTRATION SIGNIFICANTLY INCREASED THE 
CONNECTIVITY BETWEEN THE BILATERAL AMYGDALA AND A. THE TEMPORAL POLE 
(BILATERAL), B. MIDDLE TEMPORAL GYRUS (BILATERAL),AND  C. THE INFEROR TEMPORAL 
GYRUS (BILATERAL)D. THE PRECUNEUS (BILATERAL) F. PRECENTRA GYRUS (BILATERAL) DURING 
THE RETRIEVAL PHASE OF POSITIVE MEMORIES COMPARED TO NEUTRAL. SIGNIFICANTLY 
DECREASED CONNNECTIVITY WAS IDENTIFIES BETWEEN OUR SEED REGION AND A. THE 
OCCIPITAL FUSIFORM GYRUS (BILATERAL), B. THE PARAHIPPOCAMPAL GYRUS (BILATERAL) C. 
THE OCCIPITAL POLE (BILATERAL) D. THE INSULAR CORTEX (BILATERAL). B. WHEN THE 
CONNECTIVITY OF THE AMYGDALA WAS COMPARED BETWEEN THE KETAMINE AND PLACEBO 
SESSIONS FOR THE RETRIEVAL PHASE OF NEGATIVE MEMORIES COMPARED TO NEUTRAL, 
SIGNIFICANT INCREASES WERE IDENTIFIES FOR OUR SEED REGION AND A. PRECUNEUS 
(BILATERAL), B. THE FRONTAL OCCIPITAL CORTEX (BILATERAL), C. MIDDLE AND INFERIOR 
FRONTAL AREAS (BILATERAL) D.  THE MIDDLE AND SUPERIOR TEMPORAL GYRUS (BILATERAL). 
DECREASED CONNECTIVITY DURING NEGATIVE MEMORY RETRIEVAL WAS IDENTIFIES BETWEEN 
THE AMYGDALA AND A. THE INSULAR CORTEX (BILATERAL), B. THE PARAHIPPOCAMPAL GYRUS 
(BILATERAL),  C.THE HIPPOCAMPUS(LEFT), D.THE THALAMUS (BILATERAL), E.THE FUSIFORM 








1 General characteristics with focus on rumination, biased AM recall 
and anhedonia 
 
Major depression is a common illness that severely limits psychosocial functioning and 
diminishes quality of life. In 2008, WHO (World Health Organisation) ranked major 
depression as the third cause of burden of disease worldwide and projected that the disease 
will rank first by 2030. The most probable period for onset of depression extends from mid-
adolescence to mid-40s, but 40% of individuals experience an episode before they reach 20 
years of age. Across the lifespan, depression is as prevalent in men as in women (Malhi and 
Mann, 2018). Depressed mood and anhedonia are considered the fundamental symptoms 
of the illness with neurocognitive as well as neurovegetative symptoms also present.  
Overgeneral memory, specifically in relation to recall of autobiographical memories, and 
rumination are also amongst the most common cognitive characteristics of depression 
(Hamlat et al., 2015 Williams, 2006). Although they are not considered necessary for a formal 
diagnosis of the illness, these cognitive symptoms appear to play a central role for the 
initiation and maintenance of a depressive episode (Williams, 2006).  These two cognitive 
characteristics are also key points of focus for several theoretical models which have been 
developed in order to link dysfunctional cognitive processing with depressive symptoms 
(Disner et al., 2011, Williams, 2006, Dalgleish and Werner-Seidler, 2014). Overgeneral AM 
recall along with a bias towards easier negative memory retrieval and increased rumination 










2 Depression and Autobiographical Memory 
 
2.1 Autobiographical Memory definition. Encoding and recall of autobiographical 
memories 
 
AM (Autobiographical Memory) encompasses our recollection of specific, personal 
events and it is very important for the individual’s sense of self.  It is important to ensure 
self- coherence as well as to guide individuals towards goal directed activities (Rubin et al., 
2003). AM has been broadly conceptualized to be divided into personal semantic information 
(facts about one’s self) and personal episodic information (unique events) (Tulving, 1972). 
One striking feature of this type of memory is that for each event different levels of detail 
specificity are being contained (Williams et al., 2007).  
The recall of AMs appears to be a multi-level process that becomes dysfunctional 
during several affective disorders (Kohler et al., 2015).  Generally, when recalled, AMs have 
specific characteristics that play a very important role in the understanding of how these 
memories are encoded and consequently retrieved (Williams et al., 2007). Although they can 
vary in their level of specificity, AMs are organized into coherent narratives enriched with 
contextual details and when retrieved, these memories are usually accompanied by a feeling 
of vividness and rich sensory and perceptual details (Conway, 2005, Conway and Pleydell-
Pearce, 2000).  
Generative and directive recall seem to be the two main pathways for retrieval of a 
specific AM and were first described by Norman and Bobrow in 1979. Generative recall is 
usually activated by a particular “cue” and the process involves the initial accessing of AMs 
in a general- categorical- level. As the process develops, more specific AMs are being 
retrieved which are relevant to the specific cue. The process of generative recall concludes 
when a specific memory is recalled.  Direct retrieval refers to the spontaneous activation of 
an AM. This manner of recall  bypasses the general stage of non -specific/categorical recall 
and leads to an immediate recollection of a specific event (Conway and Pleydell-Pearce, 
2000). Although both generative and direct retrieval are equally effective mechanisms for 
the recollection of AMs, the former is a more controlled process which allows different levels 
of specificity during memory retrieval depending on which stage of generative recall this 
process is aborted (Holland and Kensinger, 2010). Termination of this process at the very 
general – categorical – level of recall has been linked to overgeneral memory and is 
important for depression (Warne et al., 2019).  
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Despite the manner by which they are recalled, the quality of AMs seems to be 
closely related to the way they are encoded and maintained. The maintenance of a memory 
is not a static process but rather one that continues in the hours, days and years following 
an experience (Kim, 2019). Several factors of the experience itself would influence the way 
AMs can be assembled, retained and afterwards retrieved (Fivush, 2011). The arousal and 
consequentiality of the event as well as its emotional valence seem to be among the key 
factors that could influence the quality of AMs  (Holland and Kensinger, 2010). 
The presence of arousal appears to trigger a cascade of neurochemical interactions, 
the end result of which would be the formation of a particularly durable memory. Events 
related to strong personal involvement elicit physiological responses such as the release of 
glucose and adrenal hormones into the blood stream that often result to strongly encoded 
memories (McGaugh, 2004). These cumulative effects of emotion would also influence the 
consolidation phases of the memory and would increase the person’s ability to remember 
that event. Moreover, events with high personal involvement or self-relevance, concepts 
closely tied to the idea of consequentiality are more likely to be remembered than events 
with less personal relevance (Fivush et al., 2011, Sharot et al., 2007).  When information is 
encoded in a self-referential fashion, distinct mechanisms are engaged which boost the 
strength of the encoded memory and make it more resilient to forgetting (Klein, 2012).  
Beyond arousal and consequentiality, the valence of an experience could also 
influence the likelihood of remembering an AM as well as the accuracy with which each event 
can be remembered (Kim et al., 2018, Wisco and Nolen-Hoeksema, 2010). In several studies 
that have looked at healthy volunteers, positive events seem to come to mind more readily 
than negative ones. Some of this mnemonic benefit for positive events may stem from the 
fact that positive experiences are more likely to be encoded as strongly self-relevant and may 
also be more easily integrated into a person’s conception of themselves that could thus lead 
to a facilitated retrieval of that event.  Although negative memories could also be associated 
with high-arousal,  negative emotions such as fear or anger, the way however,  that these 
negative feelings could shape the manner in which negative experiences are been encoded 






The bias towards positive memory recall which is detected in healthy volunteers 
appears to be reversed in depressed individuals who tend to recall more negative memories 
(Williams et al., 2007). Whether this bias towards negative memory recall is due to deficits 
in the process underlying positive memory retrieval or whether negative memory recall is 
facilitated due to psychological processing remains a debate. In order to be able to resolve 
this issue we need to examine the brain areas that are important for AM recall and how their 
function is altered in depression or could be influenced by psychological factors such as 
mood. In the section that follows we will try to investigate the role of some of the most 
prominent brain areas for AM recall, namely the medial temporal lobe, cortical brain areas 
and the amygdala. In order to understand the role of those brain region in the formation and 
recall of AMs, evidence would be drawn from post-mortem studies as well as neuroimaging 
research.  
2.2 The Autobiographical Memory recall network of brain regions 
 
  The medial temporal lobe is one of the key brain areas that seem to have a central 
role in AM processing. The important role of that area in AM encoding has already been 
highlighted in Alzheimer’s disease where patients with medial temporal lobe damage are 
unable to register life events into long-term memory (Buchanan et al., 2006, Buchanan et al., 
2005). In fact, the medial temporal lobe, and the hippocampal complex more specifically, is 
referred to as a hub for the AM system (Greenberg et al., 2005). Damage to the hippocampal 
complex does not prevent information from being processed but rather it prevents the 
organised binding and indexing of future events (Ryan et al., 2001).  Hippocampal damage 
therefor, results in anterograde amnesia by preventing new information from becoming 
bound together in a fashion that allows them to be retrieved. It also results in retrograde 
amnesia because the damage destroys the indices that would have pointed to components 
of past experiences (Fournier et al., 2019) thus preventing their retrieval.  
The medial temporal lobe, however, does not act alone to encode and/or retrieve 
autobiographical experiences. Research has revealed that memories are not stored within a 
single area of the brain. A distributed network of activity throughout the cortex seems to be 
implicated in mnemonic processing (Lin et al., 2016, Desalaar et al., 2008, Kohler et al., 1998). 
Indeed, research has revealed, that memories are not stored within a single area of the brain. 
There is evidence indicating that during AM retrieval all the brain regions that have been 
activated during the encoding in memory of a specific event (Kohler et al., 1998, Wheeler 
and Buckner, 2004, Kahn et al., 2004) are also active. Moreover, the specific regions that are 
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activated during AM recall and the magnitude of activity within those regions could vary 
according to the level of details that are remembered (Richter et al., 2016). Commonly 
activated regions during AM recall include the medial and lateral prefrontal cortex, the 
medial and lateral parietal cortex, the amygdala and sensory cortices within the occipital and 
temporal lobes (Wheeler et al., 2006, Nawa and Ando, 2019). Among those areas the 
amygdala and their role in AM has been significantly studied. 
Research indicates that the role of the amygdala in AM is rather complex. There is 
evidence indicating that when amygdala activity is strong, during encoding of emotional 
events, these events are more likely to be remembered (Dolcos et al., 2012, Hamann, 2009). 
This could suggest an interplay between the strength of the encoding, the emotional valence 
of the memory and amygdala activity. However, amygdala activity does not lead to enhanced 
memory of all the details of that emotional experience. Engagement of the amygdala would 
boost the retention of some event details (Kensinger and Schacter, 2005), have no effect on 
the retention of other details (Dougal and Rotello, 2007, Onoda et al., 2009) and even 
sometimes impair memory for other types of information (Strange et al., 2003).  
Despite the mixed relations between amygdala activity and subsequent memory of 
the details for a specific event, amygdala activity during encoding seems to correlate with 
the emotional quality of recall. AMs that have been linked to enhanced amygdala activation 
during their encoding  appear more vivid when recalled and individuals seem to be highly 
confident as to the accuracy of these AMs (Mickley and Kensinger, 2008). The reason of this 
strong connection between amygdala activation and the emotional quality and accuracy of 
AMs remains a topic of ongoing investigation. A possible suggestion could be that individuals 
ascribe vividness and confidence on the basis of their memory for only a subset of details, so 
that by enhancing memory for select details, amygdala activity may also be enhancing the 
confidence or vividness with which people will later re-experience an emotional event 
(Phelps and Sharot, 2008). Although a lot of research has focused on the amygdala, as we 
mentioned before, that brain area does not act in isolation but is part of a larger network of 
bran regions that play a role in AM recall.  
A particularly interesting interplay takes place between two brain circuits that are 
activated only when individuals have personal involvement in the AMs (Lindquist et al., 
2012). These two brain circuits are the one connecting the left hippocampus to the medial 
prefrontal cortex and another linking the medial prefrontal cortex to the right amygdala. 
They both appear to be in synchrony only during recall of events in which the individuals had 
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been directly involved (Muscatell et al., 2010). The hippocampus is thought to support the 
retrieval of AMs with rich contextual detail thus, the activation of the hippocampus 
corresponds with the ability to remember the spatial and temporal context in which life 
experiences occurred (Maguire, 2001, Svoboda et al., 2006). By contrast, amygdala 
engagement during retrieval does not seem to correspond with retrieval of these type of 
contextual details but instead seems to reflect the processing of affectively rich, internal 
information (Buchanan, 2007). These systems, of perceptual and conceptual retrieval, 
respectively, may work together to integrate internal and external details, but only when 
information is high in personal involvement (Sheldon et al., 2019). 
The interaction between the amygdala and the hippocampus is not only important 
for memory retrieval but also for memory consolidation (Nieuwenhuis and Takashima, 
2011). Memory consolidation is a difficult process to isolate mostly because it refers to a 
series of processes that occur over time and thus, it is very hard to capture a snapshot of a 
point when consolidation has occurred. Most of the research on memory consolidation 
seems to be focusing on sleep. In a study where participants were asked to retrieve negative 
emotional and non-emotional information after a 12- hour delay that either induced a night 
of sleep or a day spent awake, the hippocampus was activated during successful retrieval of 
negative memories regardless of whether participants have slept or not (Payne and 
Kensinger, 2011). However, sleep led to a shift away from a diffuse memory network 
(including lateral prefrontal and parietal cortices) and toward a more refined and integrated 
network of limbic regions (consisting of the amygdala and ventromedial prefrontal cortex) 
(Nieuwenhuis and Takashima, 2011, Payne and Kensinger, 2011).  
The aforementioned findings indicate that the hippocampus has a broader role 
during AM recall, which seems to be independent of reconsolidation processes. The 
amygdala on the other hand seem to be involved in the fine tuning of recall by controlling 
aspects such as the vividness of the AM as well as the level of detail of those memories 
(Kensinger, 2009). Apart from the temporal regions and the amygdala, other brain areas such 
as the OFC (orbitofrontal cortex)  (LaBar and Cabeza, 2006) and occipital areas (Vuilleumier 
and Driver, 2007) also appear to involved in AM encoding and retrieval. All those brain 
regions and their implication in AM formation, however, have been studied in healthy 
volunteers. Patients with depression present with AM deficits that could alter the 
characteristics of their AM recall and could be the result of differential activations in these 
brain areas.  
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2.3 Biased recall of Autobiographical Memories in depression 
 
2.3.1 Overgeneral memory  
 
Individuals with MDD demonstrate a tendency to retrieve fewer specific and more 
categorical AMs compared to healthy controls (Kohler et al., 2015). Interest in overgeneral 
memory has been fostered by findings suggesting that this phenomenon could be closely 
associated, and might have a causal link with, other important aspects of physiological 
functioning which are affected in depression.  Specifically, overgeneral memory has been 
associated with a. impaired problem-solving (Raes et al., 2005, Goddard et al., 1996) b. 
difficulties in imagining future events (Williams et al., 1996) as well as c. delayed recovery 
from episodes of affective disorders (Dalgleish et al., 2001, Peeters et al., 2002). The 
phenomenon of overgeneral memory has also been deemed important because memory 
remains overgeneral in those with a history of emotional disorder, even if not currently in an 
episode (Mackinger et al., 2000). This is significant since it means that overgeneral memory 
can be observed without needing to be activated by low mood and might therefore act as a 
before or between episode marker of future vulnerability to depression.  
Several cognitive models have been developed in order to explain overgeneral 
memory recall in depression. As mentioned earlier, according to the Conway and Pearce 
model, retrieval of AMs could be either generative or directed (Conway and Pleydell-Pearce, 
2000). Overgeneral memory arises when individuals truncate their search during generative, 
top-down retrieval at too high a level, when only general descriptive information could be 
assessed (Ros et al., 2018). Generative retrieval is usually activated by specific cues which 
allow the individual to access memories at a very general- categorical level- and then, more 
specific memories that are linked to the specific cue, are retrieved and evaluated in order to 








According to the Conway and Pearce model, depressed individuals seem to suffer 
from a “mnemonic interlock” which maintains recall of autobiographical memories at a 
general event-knowledge level. This retrieval strategy could potentially have a protective 
role for the individual. If the retrieval mechanisms were to proceed further the individual 
risks to access among other- intense negative memories- which could worsen someone’s 
mood or trigger ruminative processes. As a result, depressed and suicidal patients abort 
memory searches for a specific event prematurely, when only the general description stage 
of a particular autobiographical event has been reached (Norman and Bobrow, 1979). This 
truncated search is called a “dysfacilitation” of the retrieval process and is assumed to 
underlie the retrieval of overgeneral memories (Dearing and Gotlib, 2009, Gillihan et al., 
2007). 
2.3.2 A bias towards negative memory recall  
 
A few studies have suggested that depression might be characterized by reduced 
positive processing, which could demonstrate as a tendency to recall more negative than 
positive AMs, rather than increased negative processing (Kohler et al., 2015). This supports 
the idea of an “optimism bias” which could indicate that mentally healthy people are 
unrealistically positive thus “positive bias” reduces as depressive symptoms emerge. 
Although depressed individuals might appear as more negative, it is unclear whether this is 
because they are more likely to attend to or remember negative information or less likely to 
attend to or remember positive information or even whether both are occurring (Lewis et 
al., 2017). It is also unclear whether the alterations in negative and/or positive processing 
precede or follow depressive symptoms.   
One of the key questions that the difficulty in positive AM recall raises is whether 
this difficulty manifests as a general change of brain function and/or anatomy that would 
impair the recall of all AMs or whether it is specific to positive memories.  If AM recall 
engages the same set of brain areas irrespective of the special characteristics of the memory 
(alertness, valence and consequentiality) the issue of impaired negative and neutral memory 





3 Depression and Rumination 
 
3.1 Rumination definition 
 
Rumination is an emotionally evocative experience, during which an individual 
repeatedly thinks about past experiences, focusing on the feelings, meanings and 
consequences of those events (Schafer et al., 2017). Rumination is a central process for 
depression as well as a well-known risk factor for developing MDD especially during mid-life 
(Bromberger et al., 2015). The intensity of ruminative thinking could also predict the onset 
of new episodes and the severity and duration of existing depressive episodes(Abela and 
Hankin, 2011). Brooding and reflection are the two aspects of rumination (Nolen-Hoeksema 
et al., 2008). Brooding involves the tendency to dwell on negative consequences of one’s low 
mood (Treynor et al., 2003). Reflective pondering involves attempts to understand the 
reasons for one’s depression. Brooding is considered to be the most maladaptive of the two 
aspects of rumination and has mainly been implicated in mental health problems (Luca, 
2019).  
3.2 Brain areas and networks that are important for rumination 
 
Although intense ruminative thinking has been associated with low mood and 
depression, rumination is a thought process that occurs to healthy individuals as well 
(Watkins, 2008). Several studies, using neuroimaging have tried to identify the brain areas 
that are activated while ruminating. Intense self-focus but also retrieval and reconsolidation 
of AMs are involved during ruminative thinking and as we have already mentioned before, 
these processes could be highly influenced by the mood state of the individual(Thomsen, 
2006). Rumination is a very difficult process to study with fMRI (Ferdek et al., 2016).  It 
requires intense focus, which is difficultly achieved in the noisy scanning environment, 
moreover, it is very difficult to ensure that individuals remain focused for the duration of the 
scan.  Another factor that should also be considered is that recalling past AMs could be 







The fMRI studies that examined rumination have mainly looked at brain connectivity 
as a whole rather than focusing on individual brain areas. These studies have revealed that 
the DMN (Default Mode Network) and specifically the PCC, which is considered the main hub 
of that network play an important role during rumination. The PCC along with the medial 
prefrontal cortex and angular gyri show increased activation during ruminative thinking 
(Hamilton et al., 2015). The DMN is a network that is activated when individuals are self-
focused and not engaging on a specific task although studies have shown that its activity 
could also be task related (Smith et al., 2018). Some of the areas that form part of this 
network including temporal regions are also important for AM recall (Grieder et al., 2018). 
In depression, it is believed that the DMN appears to be overactive making it easier for 
depressed patients to remain focused on the recall of negative AMs, rumination thus 
becomes a very relevant process for depression (Sheline et al., 2009, Lehmann et al., 2016).  
Rumination is also one of the key factors that have been linked to cognitive 
vulnerability in depression. It has been suggested that rumination could act as a potent 
mediator between stressors and prolonged stress-related processes (Michl et al., 2013). 
Specifically, ruminative thinking could facilitate the mental representation of specific 
stressors that would contribute to negative mood and prolong depressive symptoms 
(Watkins, 2008). The interplay between rumination, AM recall and depression has been in 
the core of several theoretical cognitive models that try to explain the initiation of a 
depressive episode and the prolongation of depressive mood. Here, we will discuss the most 
prominent of these models that have mostly influenced the design and hypotheses of 













4 Autobiographical Memory, Rumination and Depressive Symptoms 
 
4.1 The CaR-FA-X model  
 
The CaR- FA-X model was first proposed by Williams in 2006 and it owns its name to the 
three key processes that could lead to overgeneral memory recall and depression: Capture 
and Rumination, Functional Avoidance and finally eXecutive control (Williams, 2006).  
Capture and Rumination occur when ruminative processes are activated and are 
accompanied by disrupted retrieval processes. These dysfunctional retrieval processes 
include the potential facilitation in the recall of negative AMs as well as truncated generative 
AM recall. More specifically, the model suggests that difficulties accessing specific AMs could 
result from the Capture (Ca) of memory search efforts by consolidated categorical themes 
which are prone to cause depression-depressogenic themes (Barnhofer et al., 2002).  These 
depressogenic themes could, in their own turn, engage analytical and evaluative brooding 
rumination. Brooding rumination often appears maladaptive and could further contribute to 
depressive mood (Luca, 2019). 
 The capture mechanisms could further be exacerbated by an ingrained Functional 
Avoidance (FA) that characterises depressed individuals as well as those in high risk of 
depression (Hallford et al., 2018). Functional avoidance is a means of regulating negative 
affect by avoiding autobiographical content associated with distress. Depressed individuals 
tent to actively avoid retrieving specific details of distressing autobiographical events which 
as mentioned before, traps the AM recall at a categorical level where whole groups of AMs 
are accessed but none of them specifically recalled (Barnhofer et al., 2002). The ability to 
counteract these dysfunctional processing mechanisms is further compromised by the 
limited eXecutive control (X) which is a consistent feature of depression (Watkins and Brown, 
2002).  
EXecutive control (X) refers to broad range of cognitive strategies used to manage, focus 
on, plan and carry out tasks (Roberts, 1996). Executive function is a product of executive 
control. Deficits in executive control are hypothesised to interfere with the retrieval of 
specific AMs because of the need to hold information in mind (updating working memory) 
and ignore irrelevant information. The CaR-FA-X model mainly tries to interpret overgeneral 
AM recall in depression (Conway and Pleydell-Pearce, 2000) without particularly focusing on 
other aspect of the disorder.  The cognitive processes however, that are discussed in this 
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model are central for the understanding of the disorder and this model has influenced many 
research hypotheses that investigate the cognitive aspects of depression.  
4.2 The cognitive model of depression  
 
Beck’s cognitive model of depression was developed about 40 years ago and is based on 
evidence demonstrating that depressed individuals show deficits in attention, the processing 
of emotional stimuli, as well as biased rumination and recall of negative memories. The 
model integrates cognitive and neurobiological processes which could be undermined by 
genetic and/or environmental factors. When activated, these processes would initiate a 
negative cognitive bias which then persists due to the attenuated cognitive control of 
depressed individuals.  
In this model, biased acquisition and processing of information has a primary role in the 
development and maintenance of depression since it could lead to the development of 
depressive schemas. Depressive schemas are characterised by negative self-referential 
beliefs and could be the outcome of adverse events that occur to an individual’s life. These 
negative self-referential beliefs are further exacerbated due to the biased acquisition and 
processing of emotional information in depression. Environmental stressors could activate 
these schemas which when activated confer vulnerability for depression. Specific biases in 
attention and memory which result from inhibitory deficits, such as deficits in executive 
control, could further contribute to the development of a ruminative response that 
perpetuates negative thoughts about one’s self, the world and the future.  Beck’s model of 
depression is considered one of the most complete models that explain the cognitive aspects 
of the illness, however, it offers no insight to the brain areas that could be important for the 
cognitive processes that are involved in the model and appear to be dysfunctional in 











4.2.1 Biased attention, increased self-focus, emotion over-reactivity 
 
 In an effort to better understand the neurobiological mechanism that could be 
implicated in Beck’s model of depression Disner et al. have tried to provide a link between 
Beck’s model and neuroimaging findings (Disner et al., 2011). Specifically, the known 
differences that depressed individuals present with, concerning the activation of different 
brain areas, have been associated with the neuronal processes that are relevant to the model 
thus providing the neurobiological basis for Beck’s theory.  
Specifically, depressed patients show decreased activity in the right DLPFC (DorsoLateral 
PreFrontal Cortex), right VLPFC (VentroLateral PreFrontal Cortex) and right superior parietal 
cortex (Beevers et al., 2010, Fales et al., 2008, James, 2012, Passarotti et al., 2009). This could 
account for the biased attentional focus on a negatively valenced stimulus which could block 
out the processing of other more positive information.  The biased attention to negative 
stimuli in individuals with depression could also be enhanced by their inability to disengage  
from this particular negative stimulus due to increased self-focus (Corbetta et al., 1998). 
Depressed individuals also present with greater ACC activation when successfully inhibiting 
attention to negative stimuli, suggesting that contrary to healthy individuals depressed 
patients require greater cognitive effort to divert attention away from negative stimuli 
(Drevets et al., 2008b). 
Excessive amygdala reactivity in individuals with depression could provide the 
neurobiological basis for the increased emotional reactivity of these individuals. The 
overactivation of the amydagala persists even when an aversive stimulus is no longer present 
(Young et al., 2012, Young et al., 2016). Increased amygdala reactivity creates bottom-up 
signals which are processed in higher cortical areas and could alter the perceptions of the 
environment leading to persistent negative information processing. The neurological deficits 
that could underlie this altered environmental perception could be associated with the 
reduced cognitive control over the amygdala associated with aberrant activation of the 






A parallel neurological pathway that could also contribute to sustained processing of 
negative stimuli in individuals with depression is the thalamocortical pathway. This pathway 
plays an important role for the organisation and processing of environmental stimuli. 
Elements of this pathway include the thalamus, a brain region which distributes afferent 
signals in several other areas including the dorsal ACC (Sherman and Guillery, 2002). The 
dorsal ACC also receives input form the DLPFC and the subgenual cingulate cortex which 
integrates emotional feedback from the limbic system and projects to higher order cognitive 
structures (Ray and Zald, 2012). During a depressive episode, individuals show increased 
thalamic activity (Greicius et al., 2007). This increase in thalamic activity could be interpreted 
as a compensatory mechanism attempting to make up for the reduced functional 
connectivity between the medial thalamus and the dorsal ACC (Brown et al., 2017). The 
dorsal ACC exerts less inhibitory influence over the limbic system in depressed individuals 
and more depressive limbic feedback is able to be processed via bottom-up pathways 
through the sgACC upstream to higher order regions (Banks et al., 2007). This in its turn, 
could lead to increased processing of negative stimuli and an inability to shift attention to 
external distractors in depression.  
4.2.2 Rumination and biased recall of negative autobiographical memories 
 
Prolonged processing of emotional experiences in people with depression- a result of 
ruminative thought- is probably maintained by impaired top-down cognitive control over 
limbic areas which is generally associated with hypoactivation in the left DLPFC and VLPFC 
concurrent with rumination. More specifically, DLPFC and VLPFC hypoactivity are correlated 
with altered patterns of rostral ACC activity which is thought to contribute to rumination by 
facilitating the inhibition of positive information and impeding the inhibition of negative 
information (Koseki et al., 2013).  
Furthermore, individuals with depression, recall with more ease negative AMs, 
compared to positive AMs. The neuronal correlates that underlie this bias towards the recall 
of negative information involve brain areas that could facilitate a stronger encoding of 
negative AMs. Stronger encoding of negative AMs could lead to an easier retrieval of those 
memories and that could be attributed to the hyperactivity of the right amygdala which has 
been associated with better encoding of negative stimuli, but not positive or neutral (Young 




During encoding of negative AMs, amygdala activity is correlated with increased 
hippocampus, caudate and putamen activity which in turn would facilitate recall of negative 
but not positive information (Young et al., 2016). Moreover, the MPFC (Medial Prefrontal 
Cortex) is hyperactive during recall of self-relevant happy events and hypoactive during recall 
of self-relevant sad events in individuals with depression (Disner et al., 2011). As a result, 
depression requires greater cognitive effort – mediated by the MPFC -to recall happy 
personal memories whereas recall of negative memories requires less top down influence. 
Taken together, these finding indicate that there is indeed a neurobiological basis 
for the cognitive model of depression as well as the CaR-FA-X model of overgeneral memory. 
However, the evidence that supports these models is the result of disperse neuroimaging 
studies that have used different samples and diverse methodologies and analyses in order 
to validate their hypotheses.  As a result, it is very difficult to draw strong conclusions about 
the brain areas that are in the centre of the cognitive processes that appear altered in 
depression. It would be useful to investigate in more detail and in a more consistent manner, 
using neuroimaging, some of the key brain areas that seem to be implicated in depression in 
order to elucidate their role in the illness and also perhaps, provide pharmacological research 

















5 Depression and Anhedonia  
 
Anhedonia refers to an individual’s inability to gain pleasure from normally 
pleasurable experiences. It is a core clinical feature of depression, schizophrenia, and other 
mental illnesses. The term anhedonia, by clinical definition, considers impairments in both 
reward motivation -motivational anhedonia- as well as a reduced ability to experience 
pleasure- consummatory anhedonia (Argyropoulos and Nutt, 2013). Several questionnaires 
as well as tasks have been developed in order to measure motivational and consummatory 
anhedonia which are both present in depression. Here, we will provide more details about 
the two components of anhedonia as well as the methods that have been used to capture 
these in depression. 
5.1 Consummatory anhedonia 
 
There are two main ways to capture consummatory anhedonia: a. via the 
administration of questionnaires that are asking volunteers to estimate how much pleasure 
they would experience in response to a given event and b. via different tasks that deliver a 
pleasurable stimulus and ask volunteers to rate how much they like it.  
The SHAPS (Snaith-Hamilton Pleasure Scale) is a brief assessment scale for the 
estimation of the degree to which a person can experience pleasure or the anticipation of a 
pleasurable experience. The scale consists of 14 items that relate to common experiences 
which include interest/pastimes, social interaction, sensory experiences and food/drink 
which are most likely to be enjoyable to most people (Snaith et al., 1995). The SHAPS has 
been used to assess hedonic capacity among adults with major depression (Nakonezny et al., 
2015) but also to examine the antidepressant effect of different pharmacological compounds 
in depressed patients (Lally et al., 2014, Gargoloff et al., 2016). Studies that have conducted 
a psychometric evaluation of this scale in large cohorts of patients with MDD have concluded 
that the scale has excellent internal consistency, with construct validity, and is 
unidimensional in assessing anhedonia among adults with MDD (Nakonezny et al., 2015).The 






Questionnaires such as the SHAPS however, ask volunteers to imagine how much 
pleasure they would draw from a particular experience and rate it accordingly. When 
measures of “in the moment” experience of pleasure were compared between depressed 
volunteers and healthy controls no differences were detected between the two groups 
(Sherdell et al., 2012). In the case of measuring the “in the moment” experience of pleasure, 
the rating was taken right after a specific reward was delivered. This could imply that 
depressed individuals might have difficulties in imagining how much pleasure they would 
draw from a given experience when in fact they would enjoy certain activities as much as 
healthy volunteers (Sherdell et al., 2012). The low mood of these individuals as well as their 
bias towards negative thinking could also be contributing to that effect. 
5.2 Motivational anhedonia 
 
The most common way to assess motivational anhedonia is to examine how much 
effort volunteers are willing to make in order to obtain a specific reward. Both the EEfRT 
(Effort Expenditure for Reward Task) as well as the MID (Monetary Incentive Delay) task have 
been used to measure motivational anhedonia in healthy populations as well as mental 
health patients.  
The EEfRT requires participants to decide how much effort they are willing to invest 
for different probabilities of obtaining a specific reward (Treadway et al., 2009).  The MID 
task is a reaction time task which requires individuals to perform fast enough button presses 
as a response to a specified stimulus, in order to obtain a monetary reward. A specific cue 
that appears before the stimulus, indicates the magnitude of the reward they will receive if 
they make a sufficiently quick response when the stimulus appears (Knutson et al., 2000).  
The MID task has been used in neuroimaging studies to measure motivational anhedonia in 
patients with MDD as well as schizophrenia (Keren et al., 2018, Nielsen et al., 2012).  
In the paragraphs that follow we will try to describe the neuronal components of 
reward processing and anhedonia in healthy volunteers, mainly drawing evidence from 
neuroimaging studies bit also animal research. Furthermore, we will try to explain how these 
processes could be altered in depression and linked to some of the symptoms of the disorder. 
Finally, emphasis will be given on the MID task and how it has been used to study the 




5.3 Neuronal components of anhedonia 
 
Consummatory as well as motivational anhedonia are extremely complex constructs 
that encompass several neuronal processes. Impairments in reward anticipation as well as in 
the integration of information required in order to outweigh the costs and benefits of specific 
rewards along with low mood and bias towards negative thinking could all contribute to 
deficits in the individual’s hedonic capacity (Rizvi et al., 2016). The neuronal pathways that 
underlie these processes are rather complex and could involve several neurotransmitter 
systems as well as an interplay between many brain areas. Most of our knowledge around 
the brain regions that are important for reward processing comes from animal 
studies(Moreau, 2002, Scheggi et al., 2018) but also more recently from neuroimaging 
studies (Enneking et al., 2019, Gorwood, 2008). Most animal behavioural experiments as well 
as human neuroimaging studies use tasks designed in a way which allows researchers to 
examine separately the anticipatory phase of getting a reward as well as the actual gain or 
loss of a specific reward, feedback phase.  
5.4 Reward processing in the healthy brain 
 
In order to understand anhedonia and how changes in the activation of different 
brain regions during depression could contribute to deficits in reward processing, we need 
to firstly understand reward processing in the healthy brain. Reward processing in the brain 
is an iterative learning process involving goal directed behaviour and adaptive decision 
making in response to a stimulus. Stimulus presentation, followed by receipt of reward, 
increases the likelihood of a behaviour occurring again (O’Doherty, 2017). The anticipation 
of a reward creates motivational salience, and the consumption of the reward reinforces 
motivational salience.  
The neuronal substrates of reward processing in the brain as they have arisen form 
research in both humans and animals include the ventromedial prefrontal cortex -
encompassing orbital and medial prefrontal regions- the amygdala, the striatum and the 
dopaminergic midbrain. These highly interconnected brain regions form a “reward network” 
(Wilson et al., 2018). Several regions of this network along with other brain areas are 
activated both during the anticipation of an expected reward as well as the receipt of an 




5.5 Brain areas that are important for stimulus reward value, predictive reward 
value and prediction error 
 
The orbitofrontal cortex and the amygdala are the two main brain areas that have 
emerged from the literature as activated during coding for stimulus reward value. Human 
neuroimaging studies show that the orbitofrontal cortex is activated while coding reward 
value for different types of sensory stimuli, including olfactory, somatosensory, auditory, and 
visual cues but also during the coding of reward value of more abstract stimuli such as 
monetary rewards (Rolls, 2000, Rushworth et al., 2011). The activity of this brain area has 
been shown to increase while attributing reward value to specific cues. However, after 
receipt of the actual reward activity in the orbitofrontal cortex decreases indicating a unique 
role of that brain area during the learning phase of the reward value of a stimulus (Noonan 
et al., 2011).  
The amygdala is another brain area that is important during the processing of reward 
stimuli. This brain region is activated during the presentation of both pleasant as well as 
aversive stimuli (Morrison and Salzman, 2009). Experiments that have examined the 
activation of the amygdala during the presentation of rewarding stimuli that were matched 
for valence but differed in intensity and vice versa show that the amygdala seem to be 
particularly sensitive to the difference in the intensity of valence-matched rewards (Murray, 
2007).  
In addition to responding to a rewarding and/or punishing stimulus, it is also 
important to be able to predict in advance when a reward or punishment would occur so 
that our behaviour could be organized prospectively. Prediction of the value of specific 
reward or punishment involves activation of the orbitofrontal cortex, the amygdala as well 
as the ventral striatum (Murray and Izquierdo, 2007). These brain regions are activated 
during the presentation of different stimuli that have been associated with specific rewards 
and thus have predictive value for those rewards.  
A very interesting research question relates to how the brain acquires predictive 
value representations. Research done in primates indicates that learning occurs through 
prediction error which signals the discrepancy between expected and actual reward or 
punishment. The phasic activity of dopamine neurons has emerged from primate research 
as possible neuronal substrate of that signal (Schultz, 2016b, Schultz et al., 1993, Ljungberg 
et al., 1992). Unexpected omission of a reward after a presentation of a stimulus that could 
have predictive value for that reward results in a decrease in the neuronal activity form 
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baseline (negative prediction error).  The unexpected presentation of a reward however, 
after omission and/ or presentation of the stimulus with predictive value for that reward, 
results in an increase in the neuronal activity of dopaminergic neurons from baseline 
(positive prediction error). Over the course of learning, dopamine neurons that initially fire 
during the actual receipt of the reward or punishment shift their activity to the anticipatory 
phase of the reward which is signalled by the presentation of a stimulus with predictive value 
(Ljungberg et al., 1992, Schultz, 2016a, Schultz et al., 1993). 
Functional MRI (Mori et al., 2019, Wolke et al., 2019) studies as well as PET (Dubol 
et al., 2018, Schott et al., 2008, Urban et al., 2012) studies have shown activation in 
prominent target areas of dopamine neurons as well as increases in the dopamine release in 
the striatum during reward prediction. However, striatal activity seems to be very important 
not only for prediction errors but also for coding the salience of a stimulus as well as during 
aversive learning.  Moreover, striatal activity has also been detected during the presentation 
of non-rewarding stimuli such as distractor cues and the omission of a stimulus could also 
cause deactivation of some parts of the ventral striatum, especially when the omission of the 
stimulus is then followed by punishment (Schultz, 2016b, Schultz, 2016a). These findings 
indicate that striatal activity is not unique to reward prediction but is necessary for coding 
the saliency of different stimuli and could also mediate affective processing. 
5.6 The MID task 
 
The MID task was firstly developed during the latter half of the 1990s. During that 
time neuroimaging techniques were starting to emerge, and the MID was particularly 
designed in order to leverage the spatial and temporal resolution of fMRI to localize affective 
responses in the brain. The task examines reward processing, when the possibility of gaining 
money is offered to participants (Knutson et al., 2000). The use of money as a stimulus for 
this task is rather convenient. Money could be assigned either a positive value- money could 
be gained – or a negative value- money could be lost. Moreover, it could be cued as well as 
delivered and as such the MID task allows reward processing to be parsed into at least two 
distinct components namely, “anticipation” and “feedback”. Finally, monetary rewards could 
be assigned different attributes signifying valence, magnitude and probability and thus could 
allow for a more elaborate distinction of the different processes that take place in the brain 




Since its development,t the MID task has been extensively used in neuroimaging 
research and several meta-analyses have tried to summarize the research that has already 
been conducted using that task. According to the meta-analysis conducted by Wilson et al 
(2017) and which focuses only on the reward anticipation phase of the task, brain areas that 
are part of the salience network appear to be strongly activated or deactivated when 
anticipation of an actual reward is contrasted to the neutral condition of the task. These 
brain areas include the anterior insula and anterior and posterior cingulate cortex along with 
the NAc (Nucleus Accumbens), the caudate, the putamen as well as the cerebellar vermis. 
Specifically, the anterior insula presented with bilateral deactivation during reward 
anticipation. The insular cortex is considered a major cortical target of ascending 
interoceptive and visceromotor signals which pass through thalamic nuclei. The insular 
cortex is also functionally connected to the amygdala, the dorsomedial thalamus and the 
hypothalamus periaqueductal grey matter (Wilson et al., 2018).  
The core of the DMN, the posterior cingulate cortex, was also bilaterally activated 
during reward anticipation (Andrews-Hanna, 2012). The PCC could be implicated in the 
monitoring of the environment and its activation could underlie learning and memory 
retrieval processes that are necessary in order to establish the links between the stimuli and 
the rewards that they are supposed to represent. Activation in that region could also signal 
a positive self-appraisal upon receipt of a reward (Andrews-Hanna et al., 2014, Yeo et al., 
2011). Many temporal brain areas such as the parahippocampal gyri as well as the left 
hippocampus form part of the pattern of brain areas whose activation changes during reward 
anticipation. Activation in these regions could be associated with salience processing(Seeley 
et al., 2007). The cerebellum is known to have an important role for motivational salience, 
and animal studies have suggested a role in encoding expectation of reward (Cutando et al., 
2013). The MID is also a motor processing task and as such broad bilateral activation of the 
primary motor cortex is observed, including the somatosensory cortex, the supplementary 
motor area and the multiple thalamic nuclei. 
 It is worth mentioning the lack of significant  activations in brain regions such as the 
amygdala, which have emerged from the literature as important for reward anticipation 
during the MID (Hommer et al., 2003). This does not mean that these brain regions are not 
important for the task, but it might be that they do not present with consistent changes in 
their activation amongst all individuals performing the MID and thus do not survive the 




Although most of the literature around the MID task focuses on the reward 
anticipation phase of the task, several studies have look at the actual reward outcome- 
feedback- of the task. The brain regions whose activation is altered during delivery of a 
reward compared to the neutral condition, include the OFC (Orbital Frontal Cortex) and the 
vmPFC (ventral medial Prefrontal Cortex) as well as the PCC (Oldham et al., 2018). The OFC 
is potentially engaged in processing the value of gain and the vmPFC in encoding and 
strengthening the relationship between the stimulus and its outcome (Kennerley and 
Walton, 2011). These two brain areas have previously been identified in the literature as 
important for the delivery phase of an abstract reward, like money (Breiter et al., 2001, 
Kennerley and Walton, 2011). The activation of these brain regions could be associated with 
the subjective experience of pleasure. Dysfunction in these regions has also been linked to 
anhedonia (Rolls, 2000). 
6 Altered reward processing in depression 
 
The MID task, as mentioned before, has been extensively used in neuroimaging 
studies that aim to investigate reward processing in healthy individuals. The task has also 
been used in order to understand how the neuronal activity underlying these process could 
be altered in specific disorders. Anhedonia, and consequently altered reward processing, is 
one of the most common and persistent symptoms of depression and several neuroimaging 
studies have used the MID along with other reward tasks to investigate how reward 
anticipation and feedback could be altered in depression. Here we will provide an overview 
of these studies.  
One of the first studies to examine affective cognition in depression used PET 
(Positron Emission Tomography) to scan depressed patients and healthy controls performing 
the Tower of London task. The task has three feedback phases, one with positive, one with 
negative and one with no feedback at all. Responses in the medial caudate and ventromedial 
OFC to positive and negative feedback were blunted in depressed patients, supporting 
studies that have found blunted behavioural responses to reinforcement in MDD (Elliott et 





Similar studies have also replicated these findings using different tasks. When the 
feedback phase of the MID task was examined by Pizzagalli et al. (2008) they found 
attenuated VS responses in depressed patients compared to healthy controls. These results 
were interpreted by the authors as evidence of the reduced hedonic capacity which primarily 
involves the NAc. This finding was also accompanied by a poorer overall performance in the 
task from depressed individuals (Pizzagalli et al., 2008). Reduced VS responses have also been 
identified during positive feedback of a gambling task in which depressed patients performed 
significantly worse (Must et al., 2013). Taken together, these findings could indicate that 
frontostriatal deficits could be associated with the failure of depressed patients to learn from 
feedback and adequately perform these tasks. Reduced VS responses were also identified in 
treatment naïve MDD patients during anticipation of gain and loss in the MID task and 6 
weeks of treatment with escitalopram were able to reverse that hypoactivation suggesting 
that some of the reward related deficits could be reversed after treatment (Stoy et al., 2012).  
 A recent study using primary rewards, such as chocolate, suggested that 
frontostriatal dysfunction could be a trait marker for depression, persisting even during 
remission. Moreover, this altered brain activity observed in MDD could be denoting risk for 
the disease even in the absence of symptoms. Compared  to healthy control subjects, 
remitted depressed patients showed decreased responses to primary rewarding stimuli in 
the VS, caudate, and cingulate cortex, even though their subjective ratings and taste cortex 
responses were the same. In response to primary aversive stimuli (e.g., moldy strawberries), 
however, the between-group differences were more complex: enhanced responses in the 
caudate and blunted responses in the lateral OFC (McCabe et al., 2010). Such pattern of 
increased subcortical responses and flattened PFC responses might explain how patients can 
have both an automatic negative bias but also an inability to integrate this information into 
appropriate behavioural plans. These findings are particularly compelling because they 
suggest that remitted patients, who lack clinical symptoms, nonetheless exhibit 
reinforcement–processing abnormalities, potentially contributing to their elevated risk for 








Besides to responding differently to reward and punishment, depressed patients 
also show altered neural responses during anticipation of reinforcement. When 
unmedicated depressed patients and control subjects were scanned during the MID, it was 
shown that during reward anticipation the activation in the dorsal anterior cingulate 
cortex (ACC) increased in patients with MDD when they were anticipating increasing gains. 
Control subjects however, showed increased dorsal ACC activity when anticipating increased 
loss (Knutson et al., 2008). The authors argued that, given the role of the ACC in uncertainty 
or conflict, healthy individuals experienced affective conflict during anticipation of avoidable 
losses, whereas depressive subjects experienced affective conflict during anticipation of 
attainable gains (Botvinick et al., 1999, Carter et al., 1998). Alternatively, the dorsal ACC 
response might simply be a marker of dysfunctional reward-related decision-making on the 
part of depressed patients (Drevets et al., 2008b), although patients did not differ from 
control subjects behaviourally. Importantly, a subsequent study using a gambling task did 
not replicate the dorsal ACC finding but did find reduced striatal responses in MDD patients 
while anticipating reward. 
 
One way to interpret these neuroimaging findings is in terms of dysfunctional 
network integration, particularly top-down control. For example, in a reversal learning task 
where participants had to ignore occasional misleading negative feedback, Taylor Tavares et 
al., found that, compared with control subjects, depressed patients showed reduced PFC 
responses during response reversal as well as greater amygdala responses after misleading 
negative feedback. Furthermore, in control subjects but not in depressed participants, PFC 
and amygdala responses correlated with the ability to withhold an incorrect switch after 
misleading feedback(Taylor Tavares et al., 2008). Thus, maladaptive responses of depressed 
patients in this task might be related to impaired PFC-amygdala functional integration during 
negative feedback. This explanation complements a finding from Siegle et al., who reported 
elevated amygdala responses when rating emotional words and reduced dorsolateral PFC 
responses when sorting digits in depressed patients (Siegle et al., 2007). These findings 
indicate that further research is required in order to better explore whether depression is 








Antidepressant action of ketamine 
7 General overview of the most common treatments of depression 
 
Antidepressant medication and mainly SSRIs (Serotonin Reuptake Inhibitors) and 
MOIS (Monoamine Oxidase Inhibitors) are the mainstream treatment for MDD. However, 
there remains considerable debate about the effectiveness of those groups of 
antidepressant treatments and the potential differences on effectiveness and tolerability 
between groups of antidepressant medication. This is mainly because the short-term 
benefits of antidepressants are on average, modest; the antidepressant effects take weeks 
or months to demonstrate and the long-term balance of benefits and side-effects is often 
understudied.  
A recent meta-analysis investigated the efficacy and acceptability of 21 commonly 
prescribed antidepressant treatments in adults with MDD. The compounds included in the 
meta-analysis have different mechanisms of action that target different receptor systems 
and were all compared to placebo (Cipriani et al., 2018).The meta-analysis showed that 
antidepressant treatment was in general more efficacious than placebo. However, 
detectable antidepressant effects of those drugs were usually reported after several weeks 
of treatment. The considerable delay between initiation of antidepressant treatment and the 
improvement of depressive symptoms could, at least partly account, for the relatively high 
drop-out rates that were reported in most treatment trials. Participants who drop out of 
trials early tend to have poorer responses than those who remain on treatment till the end 
of the trial and this could obscure the findings on the effectiveness of these treatments.  
The novelty of the treatment is another an important factor for the efficacy of the 
compound since it was shown that antidepressant medication tended to have better efficacy 
profiles when they were novel and mostly when they were used as experimental treatments, 
compared to when they had become old (Cipriani et al., 2018). The results of this meta- 
analysis along with other research investigating antidepressant treatments further 
emphasize our poor understanding of the factors that could contribute to the efficacy and 
acceptability of treatments and could perhaps lead to the development of novel 




Research for novel and more effective antidepressants, has traditionally targeted the 
monoamine neurotransmission systems. Blockade of noradrenaline, dopamine and /or 
serotonin reuptake by acting on selective transporters (NET, DAT and SERT respectively) and 
inhibition of monoamine break-down by monoamine oxidase enzyme are the most 
established mechanisms of pharmacological action for antidepressant drugs (Feighner, 1999, 
Ferguson, 2001). However, other drugs that reduce NMDA receptor function and thus 
modulate glutamatergic transmission, present with antidepressant-like effects (Mathews et 
al., 2012). 
Relatively recently, ketamine, a glutamatergic receptor antagonist has emerged as a 
potent, fast acting antidepressant. The US FDA has granted ketamine “breakthrough 
therapy” designation and has in March 2019 approved the nasal spray (esketamine), in 
conjunction with an oral antidepressant, for treatment of depression in adults that have tried 
other antidepressant medications but have not benefitted from them. In order to 
understand, however, how ketamine and other glutamatergic agents could exert their 
antidepressant action, we need to give a brief overview of the glutamatergic system focusing 
on the Central Nervous System.  
8 Glutamatergic system- Alternative treatments for depression 
 
8.1 The glutamatergic system 
 
Glutamate is the main excitatory neurotransmitter in the mammalian CNS. Glutamate 
mediates its effects via two classes of receptors, the fast-acting ligand gated ion channels 
(ionotropic receptors) and the much slower in response G-protein coupled receptors 
(metabotropic receptors). The binding of glutamate on both classes of receptors is 
responsible for the immediate basal excitatory neurotransmission however, activation of the 
glutamate receptors has also been implicated in longer-lasting neuronal processes such as 
LTP (Long-Term Potentiation) and LTD (Long-Term Depression). LTP and LTD are very 
important neuronal processes with a central role in learning and memory thus, compounds 
that target the glutamatergic system could have potential therapeutic effects in mood 
disorders, cognitive impairment (ex. Alzheimer’s disease) and condition such as epilepsy that 




The glutamate gated ion channel receptors could be subdivided in to three main 
families of receptors: AMPA receptors, kainate receptors and NMDA receptors (Gunduz-
Bruce, 2009). Ketamine acts as an NMDA receptor antagonist and as a result focus will be 
given on the NMDA receptor subgroup (Mathews et al., 2012). By converging specific 
patterns of neuronal activity into long term changes in synaptic structure and function, 
NMDARs play a very important role in mnemonic processes and brain plasticity. At a 
molecular level, NMDARs assemble as heterotetramers consisting of two GluN1 and two 
GluN2 subunits (Gunduz-Bruce, 2009).  
The GluN1 subunit is expressed in the CNS at all stages of development whereas the 
GluN2 subunit has four different subtypes: GluN2A, GluN2B, GluN2C and GluN2D. The GluN2 
subunit subtypes have differential developmental and anatomical profiles (Zhu and Paoletti, 
2015). The diversity in the expression, and consequently the function, of the GluN2 subunit 
subtypes confers NMDARs with distinct biophysical and pharmacological properties. In the 
embryonic brain the GluN2B and GluN2D subunits predominate while the GluN2A and 
GluN2C are absent and their expression starts right after birth (Paoletti et al., 2013). 
Anatomically, the GluN2A and GluN2B subunit subtypes are mainly expressed in the 
forebrain while the GluN2C subunit is mostly confined in the cerebellum and the GluN2D 
subunit is mainly restricted in areas of the midbrain, specifically, the hippocampus, 
amygdala, ventral nuclei of the thalamus and the olfactory bulb (Paoletti et al., 2013, Zhu 
and Paoletti, 2015).  
At a subcellular level, diverse NMDAR subtypes co-exist at the level of different 
neuronal types, but their expression also varies within individual neurons and even at 
individual synapses. In most neurons the density of the NMDARs is higher in dendritic spines, 
within the post-synaptic shaft and the somatic membrane. In the perisynaptic and 
extrasynaptic spaces NMDA receptors that are enriched with the GluN2B subunits 








8.2 The role of the glutamate system in depression 
 
Drugs that target the glutamate receptors have been speculated to have 
antidepressant action before there was evidence that the glutamatergic system might be 
important for mood disorders (Mony et al., 2009). Animal models of depression as well as 
the neuroimaging techniques in humans along with the use of drugs that could modulate 
glutamatergic transmission have more recently allowed us to shed some light on the rather 
complicated role of the glutamatergic system in depression.  Here we will provide an 
overview of the role of the glutamatergic system in depression, drawing evidence from 
animal research and neuroimaging human studies. We will also give a brief overview of the 
glutamatergic drugs that have been tested as potential antidepressant treatment. Finally, we 
will focus on ketamine, its possible mechanism of action in the molecular, cellular and 
neuronal level, as well as the potential models that could explain its unique antidepressant 
profile.  
8.3 Altered brain anatomy and function in depression: evidence from preclinical 
models and human neuroimaging studies 
 
Chronic stress animal models have been used in research in order to examine key 
features of depression. Preclinical studies in rodents and non-human primates have reported 
structural brain changes in areas including the hippocampus and PFC and these alterations 
were mainly present in chronic stress models (Krishnan and Nestler, 2011, Lucassen et al., 
2014). Decreased grey matter volume has also been reported in the hippocampus and PFC 
of depressed patients using neuroimaging (Drevets et al., 2008a, Grieve et al., 2013). These 
brain areas receive dense glutamatergic input and the loss in grey matter volume correlated 
with the severity of the illness and the duration of treatment. There is also evidence that this 
decrease could be reversed after successful treatment (Drevets et al., 2008a).  In animal 
models of chronic stress, there is also evidence that the loss of hippocampal and PFC volume 
could be reversed after discontinuation of the stress factors (Grieve et al., 2013). Structural 
changes, mainly volume decreases have also been observed in the insula whereas depression 






Functional brain imaging studies have also reported several alterations in the 
connectivity patterns of the main brain networks of depressed patients compared to heathy 
controls. The majority of these studies indicate that the DMN presents with increased 
connectivity in depressed individuals compared to healthy controls whereas the SAL 
(Salience Network) and CEN (Central Executive Network) networks present with decreased 
connectivity (Helm et al., 2018). These findings are consistent with increased rumination and 
introspection that characterises most of depressed individuals as well as a decreased 
association with external stimuli (Hamilton et al., 2015). A potential issue however, that 
could arise from neuroimaging studies that recruit depressed patients is the understudied 
effects that antidepressant medication could have on the connectivity of brain networks 
during rest.  As a result, in research studies where depressed patients were scanned while 
on antidepressants, it is difficult to disentangle which of the differences in brain connectivity 
are due to the nature of depression and which could be a potential effect of antidepressant 
treatment (McCabe and Mishor, 2011, McCabe et al., 2010). 
In an effort to understand the connectivity changes that occur in depression without 
having to take into consideration the effect of treatment we summarised all the connectivity 
studies that have included depressed patients who were drug-naïve at the time of the scan 
or have been abstaining from antidepressant medication for at least 3 months prior to 
scanning (Table Summary in Appendix A). The DMN has been a central focus point for most 
of these studies however, there are no consistent changes that could be identified either 
between as well as within the DMN regions (Zhu et al., 2012, Zhu et al., 2017) Moreover, 
studies that have used different connectivity methods failed to replicate this finding. For 
example,  a study that have used an ICA approach did not significant connectivity changes in 
the DMN between depressed individuals and healthy controls (Veer et al., 2010). The findings 
from most of these studies are not easy to summarise.  Both increases as well as decreases 
in the connectivity between several brain networks as well as brain regions within the same 
network have been identified. Moreover, the different experimental hypotheses that each 
study has chosen to investigate along with the different methodologies that have been 






Changes in the connectivity in MDD could be related to disruption in the 
glutamate/excitatory neurons of these brain areas which could also contribute to the 
structural alterations that are observed in these areas (Helm et al., 2018). In addition, these 
brain regions also receive extensive GABAergic input. The interplay between glutamatergic 
excitatory neurons and inhibitory GABAergic interneurons which determines the balance 
between inhibition and excitation in frontal brain areas is considered of great importance 
during depression (Tremblay et al., 2016).  In models of chronic stress, the strongest evidence 
for altered glutamatergic transmission comes from morphological changes in excitatory 
principle neurons. This change in glutamatergic transmission demonstrates as a decrease in 
the dendritic length and branching of hippocampal pyramidal neurons (Duman et al., 2019). 
Chronic stress also decreases the number and function of synapses in pyramidal cells. These 
findings could indicate that chronic stress could decrease the structure and number of 
glutamatergic neurons (Duman et al., 2019).  
Preclinical studies of chronic stress also report reductions in the levels of GABA 
synthetic enzymes and neuropeptides in medial PFC and other cortical brain regions. The 
alterations in GABA levels could influence the function of the three major and non-
overlapping GABA interneuron subtypes (Banasr et al., 2017, Luscher and Fuchs, 2015). 
These interneurons are classified based on their morphology, as well as electrophysiological 
and molecular characteristics, particularly the expression of SST (somatostatin), PV 
(parvalbumin) or 5-HT3a receptors. Chronic stress models the SST and PV neurons are mostly 
affected. SST interneurons target dendrites and regulate their excitability. PV interneurons 
target the soma and initial axons of pyramidal neurons(Tremblay et al., 2016). Vulnerability 
of the GABA interneurons could influence the tonic activity of these neurons and affect the 
excitatory output that these interneurons control. These alterations in the balance between 
excitation and inhibition could be accountable, at least partly, for the connectivity changes 
observed in depression and makes these two neurotransmitter systems potential targets for 








8.4 Glutamatergic agents as antidepressants 
 
Several compounds that target the glutamate system have been tested for their 
antidepressant actions. D-cycloserine, a tuberculosis antibiotic, was one of the first 
compounds with action on the NMDA receptors that was shown to produce significant mood 
improvement in depressed patients. In 1959 Dr George Crane reported the effects of D-
cycloserine in mood improvement of depressed patients within two weeks of treatment. 
More than a decade after Crane’s findings, a placebo-controlled trial confirmed the initial 
findings by reporting a significant progressive improvement in the depressive symptoms of 
patients over 6 weeks of treatment with D-cycloserine (Heresco-Levy et al., 2013). This 
compound has a very unique mechanism of action since it acts as a partial agonist on the 
NMDARs that contain GluN2A and Glun2B subunits and as a full agonist on NMDARs that 
consist of the GluN2C and GluN2D subunits (Sheinin et al., 2001).  
The next agent that was studied was amantadine, a partial NMDAR antagonist which 
is used for the treatment of Parkinson’s disease. Another similar compound is memantine 
which was also tested for its antidepressant properties. However, the outcomes of these 
studies did not yield very promising results and were rather inconclusive (Vale et al., 1971). 
Another low affinity NMDAR antagonist that shows promising antidepressant effects is 
AZD6765. The human trials for this compound produced promising results (Zarate et al., 
2013). Following these early clinical studies, animal models of depression were developed 
and used to access the antidepressant effects of several glutamatergic compounds (Pilc et 













In the last decade, the non-competitive NMDAR antagonist ketamine, has emerged 
as a fast-acting and robust antidepressant by improving core depressive symptoms, including 
anhedonia, which is not usually targeted by conventional treatments (Salvadore and Singh, 
2013). Remarkably, these actions are observed within hours after a single ketamine dose IS 
administered and persiste on average for 1 week. Since the results of the first ketamine study 
were published by Berman et al 2000 several other studies have been conducted in order to 
assess the tolerability of single as well as repeated ketamine administration in different 
patient populations (Berman et al., 2000, Zarate et al., 2006, Strong and Kabbaj, 2018). 
Moreover, possible ways have been investigated to maintain the antidepressant response of 
the drug (Chiu et al., 2014, Strong and Kabbaj, 2018). In order to better evaluate the findings 
of these studies we need to understand the pharmacology of ketamine and what is known 
so far about its mechanism of action.  
9.1 Pharmacology of ketamine 
 
Ketamine was first developed in the 1960s and is still used as an anaesthetic. 
Ketamine is a racemic mixture of R- and S-enantiomers. The S-enantiomer, also known as 
esketamine, displays an in vitro approximately fourfold greater affinity for the NMDA 
receptor compared to R-ketamine (Zanos et al., 2016). In human studies, esketamine has a 
greater analgesic and anaesthetic activity with less psychotomimetic effects than the racemic 
mixture or the R-enantiomer and therefor has a greater potential efficacy and tolerability as 
an antidepressant (Morris et al., 2017, Zanos et al., 2016). The nasal spray that has currently 
been approved as an MDD treatment by the FDA concerns esketamine. In animal models of 
depression however, R-ketamine shows higher and longer – lasting antidepressant potency 
when compared to S-ketamine (Zhang et al., 2014). The mechanism of action of ketamine is 
not currently entirely known. Most recently, it was proposed that the antidepressant activity 
of ketamine could be related to the R-enantiomer and more specifically to one of the 






Ketamine could be administered intravenously, intranasally, intramascularly, 
sublingually, rectally, orally and topically. In the liver, ketamine undergoes extensive 1st pass 
metabolism by liver enzymes to norketamine via N-methylation. Other ketamine metabolites 
include hydroxyketamine, dehydroxyketamine and hydroxynorketamine (HNK). Ketamine’s 
plasma half-life is between 1h and 3h and norketamine’s plasma half-life is 12h.  After 
ketamine administration (2S, 6S-2R, 6R)-HNK is the major metabolite found in the plasma 
and brain of mice as well as humans (Clements et al., 1982). In the section that follows we 
will try to describe the mechanism through which ketamine exerts its antidepressant action 
at the molecular and neuronal level.  
9.2 Neuronal and molecular mechanism 
 
Upon administration, ketamine’s main metabolite noreketamine, binds on and 
causes continued blockade of NMDARs. The blockade of NMDARs by ketamine results in 
increased glutamate efflux, which would then stimulate non-NMDA glutamate receptors 
such as AMPA and kainate receptors (Gould et al., 2019). The functional antagonism of the 
NMDARs expressed in GABAergic neurons has been postulated as the main mechanism 
through which ketamine causes its dissociative, psychosis-like effects whereas the activation 
of AMPA receptors is particularly important for the antidepressant action of the drug (Zanos 
et al., 2018). The NMDA blockade disrupts glutamatergic inhibition not only in GABAergic but 
also serotonergic and noradrenergic neurons thus leading to disinhibition of major excitatory 
pathways and increased extracellular glutamate levels (Zanos and Gould, 2018) .  
Although ketamine has the same and relatively low affinity for all the different 
subtypes of NMDA receptors, NMDA receptors that contain the GluN2B subunit are 
considered to be particularly important for the antidepressant actions of the drug (Gould et 
al., 2019). Compounds that selectively act on this subunit, for example Ro25-6982 and 
CP101.606 also demonstrate antidepressant action (Nash et al., 2004, Poleszak et al., 2016). 
The GluN2B subunit is mostly expressed at the extrasynaptic sites and seems to mediate the 
phosphorylation of eEF2 (eukaryotic elongation factor 2), BDNF (Brain Derived Neurotrofic 
Factor) as well as mTOR (mammalian Target of Rapamycin). Phosphorylation of all these 
factors activates molecular cascades that lead to an increase in synaptic density as well 
neurogenesis (Scheuing et al., 2015).For the potential mechanisms of ketamine’s 




Depression, as mentioned before, is characterised by atrophy of pyramidal neurons 
as well as loss of the dendritic spines leading to reduced synaptic activity (Duman and 
Duman, 2015). The glutamate increase that accompanies ketamine’s administration is 
followed by an increase in the number of spine synapsis and rapid reversal of the effects of 
chronic stress in animal models of depression (Scheuing et al., 2015). The activation by 
ketamine, of molecular pathways that could reverse those deficits could explain the 
antidepressant action of ketamine at the cellular and molecular level. Moreover, 
synaptogenesis requires the transcription and translation of new proteins which could at 
least partly explain the delay in the initiation of ketamine’s antidepressant action but also its 
relatively long-lived antidepressant effects (Zanos and Gould, 2018). 
 
Figure 1 Provides a summary of the proposed mechanisms of ketamine’s antidepressant action (a, b, c, d and e). 
The two most prominent mechanisms propose that ketamine either via indirect inhibition through GABAergic 
interneurons (a) or directly via binding of (2R,6R)-HNK on AMPARs (d) leads to enhanced glutamatergic firing. 
Activation of the downstream molecular pathways could increase BDNF synthesis which is associated with 
sustained synaptic plasticity. This is necessary for the strengthening of the excitatory synapse and a sustained 
antidepressant response. The picture was published in (Zanos et al., 2018)  
The activation of the BDNF and mTOR pathways which promote protein synthesis 
and increase synaptic plasticity are thought to be mediated by ketamine via its indirect 
activation of the AMPA receptors (Henley and Wilkinson, 2016). Specifically, ketamine’s 
binding on the inhibitory GABA-ergic interneurons could lead to the disinhibition of 
pyramidal neurons which induces enhanced glutamatergic firing. The excess glutamate 
would then bind on the AMPA receptors and thus initiate the activation of the BDNF and 
mTOR pathways (Duman et al., 2016). Recently however, a more direct mechanism for the 
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activation of AMPA receptors by ketamine has been proposed (Kavalali and Monteggia, 2018, 
Zanos et al., 2018).  
This alternative mechanism for ketamine’s antidepressant action involves one of 
ketamine’s active metabolites, (2R,6R)-HNK. This metabolite which is the major metabolite 
found in the plasma and brain of mice as well as humans after ketamine administration, does 
not functionally inhibit the NMDA receptors but in hippocampal slice records, (2R,6R)-HNK 
causes a robust increase in AMPAR mediated excitatory post synaptic currents (Zanos et al., 
2017). When HNK was isolated, a single dose of the metabolite was sufficient to produce a 
robust antidepressant effect in animal models of depression. Although some studies that 
have isolated (2R,6R)-HNK have failed to reproduce the aforementioned findings (Shirayama 
and Hashimoto, 2018), the idea that ketamine’s antidepressant action could be linked with 
one of the more long-lived metabolites of the drug would explain the unique antidepressant 
profile of the compound and requires further thorough investigation.  
 
9.3 Ketamine’s effects in the brain: an insight from neuroimaging studies 
 
In order to be able to understand the effects that ketamine produces in the brain we 
need to bear in mind that ketamine, depending on the dose of administration, could produce 
rather diverse and complicated pharmacological effects. In high doses ketamine is an 
anaesthetic that has been extensively used in paediatrics and veterinary medicine. In low 
subanaesthetic doses, the antidepressant properties of the drug initiate but with a 2h delay 
between the administration of ketamine and the initial detection of any mood improvement. 
Finally, in higher subanaesthetic doses the drug produces analgesia and psychotomimesis. 
The psychotomimetic effects of ketamine include delirium, dissociations and hallucinations. 
These effects appear shortly after the administration of the drug, peak around 15min after 
the start of an intravenous infusion and dissolve almost immediately after the end of the 
infusion (White et al., 1982). 
 The dissociative effects of ketamine which are present as part of the anaesthetic 
use, and also present when ketamine is administered at sub-anaesthetic doses, make the 
drug an excellent model for the positive symptoms of psychosis which have mostly been 
associated with underlying glutamatergic deficits (Moghaddam and Javitt, 2012). Several 
neuroimaging studies have looked at the acute/psychotomimetic effects of the drug by 
administering ketamine to healthy volunteers while they were lying in the scanner. Overall, 
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ketamine produced an increase in brain connectivity as demonstrated by GBC (Global Brain 
Connectivity) studies. When the connectivity of specific brain networks was examined, 
ketamine increased connectivity within the DMN, the visual and sensorimotor networks. The 
increased connectivity of these networks could account for the dissociative effects of acute 
ketamine administration as well as the visual and auditory hallucinations that sometimes 
occur (for review of these finding see (Frohlich and Van Horn, 2014)).  
Research studies have demonstrated that subanaesthetic doses of ketamine could 
disrupt the encoding of semantic memories as indicated by the impaired retrieval of these 
memories(Honey et al., 2005). However, already encoded memories remain untouched by 
ketamine. The hippocampus plays a key role in memory formation and as such there is 
evidence that its activity would be modulated by ketamine (Honey et al., 2005). Several 
pharmacological neuroimaging studies have explored the effects of acute ketamine 
administration in hippocampal connectivity. These studies show that under ketamine, 
connectivity between the hippocampus and areas of the limbic system, such as the 
amygdala, but also brain regions including the precuneus, present with increased 
connectivity. Moreover, increases were identified between the hippocampus and the 
auditory and somatosensory networks (Mueller et al., 2018). These findings indicate that 
ketamine could alter hippocampal connections with brain areas that are important for 
emotional regulation and sensory perception. These processes have previously been 
discussed for their important role during the encoding and consequent retrieval of AMs.  
9.3.1 The delayed effects of ketamine in healthy volunteers 
 
 Only two studies have examined the delayed effects of ketamine on brain 
connectivity of healthy volunteers (Lehmann et al., 2016, Scheidegger et al., 2012). Both 
studies have scanned individuals, 24h post the drug administration and special emphasis was 
given on the effects of ketamine on the connectivity of DMN. The ketamine doses that were 
used for these studies were sufficient to induce the antidepressant effects of the drug. In the 
study by Scheidegger et al (2012) a marked reduction in resting state functional connectivity 
between key nodes of the DMN was identified. These nodes included the PCC, the dorsal 
nexus, the pgACC as well as the MPFC. The decrease in the connectivity of the dorsal nexus, 
is particularly important since that brain area presents with increased connectivity with 
emotional processing and attention related networks (Sheline et al., 2010). Ketamine’s 
effects on the dorsal nexus, in healthy controls, could indicate a potential antidepressant 
mechanism for ketamine (Scheidegger et al., 2012).  
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 The second study that looked at the effects of ketamine, 24h post the drug 
administration, focused on the effects of the drug on areas that are key for resting state 
connectivity networks and are activated in emotional processing. An emotional processing 
task that involved positive and negative stimuli was presented to individuals and it was 
shown that increased activations in the pACC were present only during the processing of 
negative stimuli. This finding was more prominent in those individuals who presented with 
increased self-focus. Moreover, during the resting state, connectivity between the PCC and 
pACC was decreased.  Since activation of the pACC, is important for emotional regulations 
(Northoff, 2005) and the decreased connectivity between the PCC and pACC could mediate 
a switch in individuals’ attention from the self to external cues (Sheline et al., 2010), it was 
hypothesized that ketamine as an antidepressant, would attenuate a potentially pathological 
increase in self-focus (Lehmann et al., 2016).  
9.3.2 The delayed effects of ketamine in depression 
 
 The results from ketamine’s delayed effects- 24h post administration- on healthy 
volunteers, show that ketamine as an antidepressant could cause changes in functional 
connectivity, that would work towards reversing some of the changes in brain activity that 
are observed in depression. However, in order to be able to understand ketamine’s actions 
as an antidepressant we need to examine the drug effects in depressed individuals. The 
literature examining the antidepressant effects of ketamine is in its infancy. Therefore we 
identified only two studies that used fMRI and examined the effects of ketamine 24h post 
the drug administration.   
 The first of these studies has used resting state to look at global brain connectivity 
in patients with MDD and healthy controls and examined the effects of ketamine on global 
brain connectivity 24h past the drug administration. The study identified reduced global 
brain connectivity in the PFC of patients with MDD compared to healthy controls at baseline, 
but increased connectivity in the PCC, precuneus and lingual gyrus as well as the cerebellum. 
Ketamine, 24h after its administration, significantly increased connectivity in the right lateral 
PFC and reduced connectivity in the cerebellum. Moreover, when the MDD group was split 
into ketamine responders and non-responders, it was shown that ketamine responders had 
increased connectivity in the lateral PFC, caudate and insula compared to non-responders 




 In another study, ketamine’s antidepressant effects, 24h after the drug 
administration were examined in a TRD (Treatment Resistant Group) group. The study used 
two separate emotion perception tasks to examine the effects of ketamine in patients with 
TRD and compare them to baseline. It was shown that ketamine increased neural responses 
in the right caudate and these increases were specific to positive emotion. Increased 
connectivity in the right caudate at baseline, was also associated with greater improvement 



























Aims and hypothesis of our study 
 
 The findings from the neuroimaging studies that examine the effects of ketamine, 
24h after the drug administration, although limited, seem to be mainly localised in areas that 
present with altered activations in depression and have a particularly important role in 
emotional processing and motivation for rewards (Abdallah et al., 2017, (Murrough et al., 
2015). Some of these brain areas include the amygdala and the pACC as well as the caudate. 
This observation is in line with the cognitive models of depression, where altered emotional 
perception and focus on negative affect in combination to the increased self-focus of 
individuals, are the key factors that could contribute to the initiation and prolongation of a 
depressive episode (). However, in order to be able to understand how ketamine’s 
antidepressant effects are mirrored in the brain and how this could relate to the 
improvement in depressive symptoms that ketamine produces, a better understanding of 
the altered neural processing in depression is required along with more research around 
ketamine’s antidepressant action. 
 Although there are several fMRI studies in depressed individuals that focus on better 
understanding the brain activations that underlie altered cognitive and emotional processing 
in depression, these studies are often confounded by antidepressant treatment(). A possible 
solution to that problem would be the study of remitted depressed volunteers who might 
still present with some of the cognitive and emotional deficits of depression, such as 
rumination and anhedonia, but are asymptomatic and most often drug naïve.  
As far as ketamine’s antidepressant action is concerned, research has focused mainly 
on examining the changes in brain activity induced by the drug, at the peak (24 h post 
administration) of its antidepressant action (). Very little is known as to how the 
antidepressant effects of ketamine are mirrored in the brain when they are first detectable, 
2h-4h after the infusion.  It is also unknown whether these effects present differently in the 
brain, depending on the time point when they are examined or they remain unaltered 







 Our study is looking at medication free remitted depressed volunteers who receive 
ketamine (0.5mg/kg) and placebo (saline) intravenously, following the standard protocol for 
antidepressant treatment with ketamine. The aim of the study is to identify brain areas with 
known function in AM recall and anhedonia that might present with significantly altered 
brain activity 2h post the ketamine administration, compared to placebo. These brain regions 
could serve as neuroimaging markers for the early antidepressant effects of ketamine and 
could help us understand how the drug might affect rumination and anhedonia related 
processes in the brain.  
Specifically, we have used the MID task to investigate how ketamine, 2h after its 
administration, would alter brain activity in areas that are associated with reward processing. 
Specifically, we have looked at the striatum, the amygdala, the insula and VTA. We 
hypothesise that ketamine, compared to placebo, would increase the activity of these 
reward processing areas. Moreover, we believe that this increase would be associated with 
the magnitude of the expected reward during the task. The VAMP task was specifically 
developed to examine rumination and recall of AMs with different emotional valence 
(positive, negative, neutral) in our study. We believe that ketamine, would decrease the 
activation of the brain areas such as the PCC, the sgACC and the amygdala, that are 

















The current study was conducted in remitted, depressed individuals. 36 volunteers 
aged between 19 and 47 years, with a confirmed history of depression completed the study. 
All participants were in remission at the time of the scan and free from any antidepressant 
medication. A minimum of three months of no antidepressant treatment was required 
before participants could be included in the study (the CONSORT in page 84 provides the 
exact number of screened and randomised participants). The sample size for this study was 
determined after conducting a power analysis that would allow us to investigate the effects 
of ketamine, compared to placebo, in the whole sample but also examine the effect of 
session by identifying any potential differences in the behaviour and brain activations of 
those participants who had ketamine on their first session, compared to placebo. Our power 
analysis was based on the activations produced by a very similar autobiographical memory 
task in the amygdala and the hippocampus (Nicholson et al., 2016).  
In more detail, our inclusion criteria required at least one confirmed episode of 
depression and a current state of remission. The exclusion criteria involved: any history of 
other psychiatric or neurological disorder, except depression; a previous adverse response 
to ketamine; any medical conditions that affect hepatic, rhenal or gastrointestinal  functions 
as assessed using standard laboratory-based blood tests and urinalysis; cardiac abnormalities 
as identified by a standard 12-lead ECG; hypertension; a significant history of drugs of abuse 
or positive drugs of abuse test; excessive use of nicotine (>= 5 cigarettes/day), alcohol (>=28 
units/week) and caffeine (>=6 cups/day); other MRI contraindications.   
Our study participants were identified via advertisements mainly posted at the King’s 
College internal website dedicated to research 
(https://www.kcl.ac.uk/ioppn/depts/pm/research), but also newspaper advertisements 
and word of mouth. Those who expressed an interest in taking part in the study were 
approached mainly via e-mail and were provided with a copy of the information sheet. A 
telephone screening followed, to establish the suitability of those interested to continue with 
the study. The volunteers that successfully passed the telephone screening were then invited 
for a screening visit at the CNS (Centre for Neuroimaging Sciences). More details about the 




Study design  
The current study adopted a randomised, double-blind, placebo controlled, within 
subjects, cross over design for the investigation of the delayed effects of ketamine in the 
brain. Volunteers suitable for this study needed to have suffered from depression in the past 
and were on remission at the time of the scan. The mental health history of the volunteers 
was assessed using the MINI (Mental International Neuropsychological Interview) version 
6.0.0 (January1, 2006). The MINI was administered once, during the screening visit as 
indicated in the more detailed description of the study procedure that follows. The study 
was approved by King’s College London’s Psychiatry, Nursing and Midwifery Research Ethics 
Committee (REC Reference Number: HR-14/15-0650) and funded by Johnson and Johnson 
via a grant attributed to UCL. A copy of the ethics approval letter can be found in Appendix 
H. 
Having responded to study advertisements, potential participants were asked a 
number of screening questions via telephone in order to establish their suitability for the 
study. They were then invited to the Centre for Neuroimaging Sciences (CNS) for a more 
detailed screening which lasted approximately 90min. The screening visit involved taking a 
detailed medical and mental health history (MINI), a urine test, a pregnancy test (when 
applicable) and a blood screen. Participants were also introduced to the tasks they would 
undertake before and during the MRI scan and were given the opportunity to practice them. 
On the screening day, volunteers were also introduced to the MR environment in the mock 
scanner and were asked to complete the RRS (Ruminative Response Scale), a rumination 
scale which measures how much participants ruminate about their positive and negative 
past experiences, especially during times when they feel sad or depressed (Treynor et al., 
2003).  
For those volunteers deemed eligible to participate in the study, arrangements were 
made for an interview which took place on a separate day and lasted approximately 1hour. 
During the interview participants were asked to describe, in a detailed manner, their most 
positive, their most negative and one neutral personal experience. The interviewees were 
encouraged to share experiences that dated up to 12 months prior to taking part in the study 
in order to ensure a detailed and accurate recollection of the positive and negative events. 
However, if something more positive and/or negative had taken place further back in time, 
participants could talk about that event provided that they could share a lot of details around 
it.   
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During the interview, participants were encouraged to talk freely about the events 
they were comfortable to share with the interviewers. However, when guidance from the 
interviewer was necessary, the questions used for that purpose were based on the LEDS (Life 
Events and Difficulties Schedule) interview which was especially adapted to the demands of 
this study. A copy of the amended LEDS version, used in our study, can be found in Appendix 
B. The interviews were recorded with the participants' consent and the events were rated 
independently by the study’s medical doctor and the researcher, using the LEDS rating scale, 
for their objective emotional valence. Only “Severe” events were included in the study to 
ensure equal emotional valence for all events across all participants. During the study days, 
as part of a valenced-AM, personalized task (VAMP task), the statements from the most 
positive, negative and neutral event were presented to the participants in the scanner, and 
they were asked to think about those events and rate their emotional valence using a VAS     
(Visual Analog Scale) scale. More details about the LEDS interview, the LEDS rating scale and 
the VAMP task are provided in the sections that follow. 
Two separate visits at the CNS followed the interview day and each of them was 
about 6 hours long. These two visits were arranged to the participants' convenience and 
were 7-14 days apart. The schedule was kept identical for both study days with only the drug 
administered on each day being different. Volunteers were given either ketamine or placebo. 
Initially, on each study day, participants underwent a medical examination and completed 
questionnaires that provided us with detailed information about their current mental and 
emotional state (see Table 1. for details on out-of-the-scanner assessments performed on 
each day). The RAVLT (Rey Auditory Verbal Learning Test) as well as part of the Wechsler 
Memory battery were administered in order to measure of the cognitive state of participants 
that we could compare between study sessions. A blood sample was also collected and was 
used to measure cytokine blood levels prior to ketamine administration (this analysis is not 
reported as part of this thesis). The participants were then administered ketamine 







The drug or saline administration lasted 45 min and was delivered via a 
programmable intravenous infusion pump following a continuous infusion protocol identical 
to that currently used for treatment of depression. Typical infusions, where ketamine is 
administered as an antidepressant, last for 40min.  In our study however, we allowed an 
additional 5min in order to make sure that the blood sample used to measure the levels of 
ketamine and its metabolites was collected and enough time was given to participants in 
order to complete the tasks that were performed during the infusion. Twenty minutes after 
the infusion started- participants were asked to complete a neuropsychological test battery 
which comprised of two computerized tasks. The first task administered was the auditory 
hallucination task, which is designed to capture the ketamine experience. After this task, 
participants were asked to complete the EEfRT which measures their hedonic 
capacity(Treadway et al., 2009). At the end of the infusion, as mentioned before, a second 
blood sample was collected to help us determine the peak plasma levels for ketamine and 
its metabolites.  
Immediately after the end of the infusion the cannula was removed in order to 
minimize any discomfort caused to participants. After the cannula was removed and our 
participants recovered from any side-effects produced during the infusion, they were asked 
to complete the PSI which is designed to capture any dissociative effects that they might be 
experienced during the ketamine administration (Mason et al., 2008). The SNK-W (Subjective 
Well-Being under Neuroleptic Treatment Scale) (Vothknech et al., 2011) is also administered 
in order to examine the effects of an intravenous infusion of either ketamine or placebo, on 
the participants’ well-being. Approximately 1.5 hours after the drug infusion we collected a 
third and final blood sample and then participants were invited to enter the MRI machine for 
scanning. When the scan was completed, the neuropsychological test battery was repeated 
in order to help determine any changes in mood and hedonic capacity caused by ketamine.  
The table that follows contains a brief description of the pre, during and post infusion 







Pre-infusion SHAPS (Snaith-Hamilton Pleasure Scale) This 14-item, self-
administered, scale is used to 
measure the present state of 
anhedonia. 
 SNK-W A self-administered, 20 item 
scale designed to measure 
subjective well-being.  
 Wechsler Memory Scale This task is designed to 
measure working memory. 
 RAVLT (Rey Auditory Verbal Learning Task) This task evaluates short term 
auditory verbal learning and 
memory. 
During the infusion 
(20 min after the 
start of the infusion) 
White Noise Task This task is designed to detect 
any auditory hallucinations 
produced by ketamine 
infusion. 
 EEfRT The task measures anhedonia. 
Post infusion-
Immediate 
PSI (Psychotomimetic States Inventory) This index is used to capture 
any psychotomimetic effects 
experienced during the drug 
infusion. It measures the 
intensity of 29 different 
symptoms. 
 SNK-W This scale is repeated in order 
to capture any changes in well-
being. 
Post infusion-120min SHAPS This scale is repeated in order 
to detect changes in 
anhedonia. 
 SNK-W The scale is repeated to assess 
any changes in subjective well-
being. 
 EEfRT This task is repeated in order 
to evaluate the antidepressant 
effects of ketamine on 
anhedonia. 
 Probabilistic Learning Task This task measures response 
bias towards the most 
frequently rewarded stimuli. 
Table 1. The table contains a brief description of the pre, during and post infusion assessments that take place 




The questionnaires and tasks administered during this study have been designed in order 
to provide us with a broad overview of the effects that ketamine could produce acutely but 
also 2h after its administration when the antidepressant effects of the drug are first 
detectable. The present thesis focuses on the delayed (2h post administration) effects of 
ketamine on anhedonia and AM recall and rumination as those would be captured by the 
MID and the VAMP tasks. As a result, in our analysis we have only included data from out-
of-the-scanner assessments and questionnaires that are relevant to our study aims, namely 
the RRS, the SHAPS, the SNK-W and the PSI.  The section that follows will provide more details 
on those questionnaires, however, for completion, when the study design was explained, we 
briefly described all the assessments and tasks administered during the study day. 
1 Behavioural Assessments 
 
1.1 The RRS (Rumination Response Scale) 
 
The RRS was developed as a more direct and reliable measure of assessing 
rumination that is related to but not confounded by depression (Treynor et al., 2003). The 
scale consists of 22 items that measure the two aspects of rumination: brooding and 
reflective pondering. The RRS items are rated on a four-point scale as follows: “1- Almost 
Never”, “2- Sometimes”, “3-Often”, “4-Almost Always”. The scores of this scale range 
between 22 and 88 points with higher scores indicating more frequent and intense 
ruminative thinking. 
In our study the RRS was administered during the screening visit in order to give us 
a quantitative measure of ruminative thinking that our participants experience especially 







1.2 The SHAPS (Snaith-Hamilton Pleasure Scale) 
 
The SHAPS is an instrument developed for the assessment of hedonic capacity. It is 
a 14-item, self-report scale that has been specially designed to minimise cultural, gender and 
age biases in the evaluation of the individuals’ ability to enjoy pleasant activities (Snaith et 
al., 1995).  Each of the items on the SHAPS has a set of four response categories: “Definitely 
Agree”, “Agree”, “Disagree”, “Strongly Disagree” with either the “Disagree” responses 
receiving a score of 1 and either the “Agree” responses receiving a score of 0. The SHAPS is 
thus scored as the sum of the 14 items so that total scores ranged from 0 to 14. A higher 
total SHAPS score indicates higher levels of present state of anhedonia.   
This scale was administered twice during each study day and was used in order to 
measure anhedonia in our remitted depressed volunteers. Comparison of the scores 
between the ketamine and placebo sessions would help us identify and effects that ketamine 
and/or placebo might have on anhedonia. The SHAPS as was administered in our study can 
be found in Appendix E. 
1.3 The SNK-W 
 
The SNK-W (Subjective Well-Being under Neuroleptic Treatment Scale) is a self-
administered scale developed to measure the clinical relevance of subjective well-being as a 
measure of illness, treatment experiences and overall life satisfaction among mentally ill 
patients (Vothknecht et al., 2011). In this study we have used the short version of the scale 
which consists of 20 statements (10 positive and 10 negative). The scale has 5 subscales 
measuring: 1. mental functioning 2. self-control 3. emotional regulation 4. physical 
functioning and 5. social integration. Each subscale consists of four questions. The total score 
for the SNK-W ranges between 20 (bad subjective experiences) and 120 (perfect subjective 
experiences). In scoring terms, 10 of the items of the scale are scored in reverse and they are 
equally distributed among the 5 subscales. The scale can be found in Appendix F. 
Although our participants were not currently receiving any antidepressant treatment 
and did not experience any depressive symptoms this scale was administered three times 
(baseline, right after the infusion and 2h post infusion) in order to capture the participants’ 
well-being at key time points during the study and help us identify and changes related to 
the drug administration or the delayed- 2h post infusion- effects of ketamine. 
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1.4 The PSI (Psychotomimetic States Inventory) 
 
The is a self-administered, 48-item questionnaire that has been developed in order 
to assess psychotomimetic symptoms after administration of psychoactive drugs such as 
cannabis and ketamine. Individuals rate statements describing their current experiences 
from 0 (not at all) to 3 (strongly). The PSI has 6 subscales measuring delusional thinking, 
perceptual distortions, cognitive disorganisation, anhedonia, mania and paranoia (Mason et 
al., 2008). The PSI can be found in Appendix D. 
1.5 Correlations of scale scores with fMRI data 
 
As part of our analysis the scores from these scales were correlated with the fMRI 
data. These correlations were performed based on our hypothesis about the relationship 
between the effects that ketamine would have on behaviour and the changes that the drug 
might produce on brain activations, 2h after its administration.  
 
1.6 MRI battery of tasks 
 
The scan lasts 90 min in total. While in the scanner, structural scans are acquired 
from our participants, followed by a resting state scan and the administration of two 
computerized tasks as well as a spectroscopy scan. During the resting state scan volunteers 
are asked to lie as still as possible and stare at a fixation cross. The first task is the VAMP task 
during which statements from personal events are presented to the participants and they 
are given some time to think about these events and rate how positive, negative or neutral 
they feel thinking about these events now. This task lasts approximately 30 min and was 
especially designed for this study and in order to measure AM recall. In the second task, the 
MID task, participants are asked to react to a target stimulus in order to win a signalled 
reward. MRS (Magnetic Resonance Spectroscopy) data are then acquired for the ACC. 
Following sections provides more details on the VAMP and the MID task including how those 





MR Acquisition and Pre-processing of MR images 
All scans were acquired using a GE750 3 Tesla scanner and a 16 channel head coil. 
T1-weighted MPRAGE scans were used for the DARTEL template and consequent 
normalisation of the functional data. Functional scans were obtained using a T2* sensitive 
gradient echo planar imaging (repetition time [TR]= 2000ms, echo time [TE]= 30ms, flip 
angle= 750, slice thickness = 3mm, number of slices = 42). The initial four volumes for each 
timeseries were discarded in order to minimise non-steady-state effects.  
All functional and structural data were analysed using SPM-12. Standard pre-
processing steps were used for the fMRI data and included: a.  slice timing correction to 
account for the temporal differences between the acquisition of the slices b. realignment of 
the functional volumes using rigid body transformations, involving rotations and translations 
along the x, y, z axis in order to align each volume with a reference volume c. co-registration 
of the functional images of each participant to the structural ones from the same individual, 
to provide more precise spatial localization of any signal changes that might be revealed 
during the analysis d. normalization of all the functional data with the use of a DARTEL 
template.  
The DARTEL (Diffeomorfic Anatomical Registration Through Exponentiated Lie 
algebra) template is created from grey matter and white matter segments acquired from the 
structural scans of the participants, and therefore, it is unique for a specific data set 
(Ashburner, 2007). This template allows for improved characteristics of brain shapes and a 
more precise inter – subject alignment. We did not expect ketamine to produce any changes 
in brain anatomy, nor did we expect significant anatomical changes to occur within our 
subjects between the two study visits thus we chose to use the structural scans from the 
participants’ first session as the segments that were used to construct the template. The 









The VAMP and the MID task are the main focus of our study. In the following sections 
we will provide more details on how those tasks were modelled and analysed. Moreover, 
since the VAMP was specifically developed for this study, we will also describe the steps that 
lead to its development.  
 
2 General 1st level and 2nd level modelling 
 
Prior to examining the effects of ketamine’s delayed action on the MID as well as the 
VAMP task, each participant’s functional time series required modelling according to the 
experimental conditions of each task. The standard approach for fMRI data, is to model, 
within each subject, the activations of each individual voxel in isolation using the GLM 
(General Linear Model) approach. In this way a design matrix is created for each individual, 
which incorporates all the task manipulations (task-related conditions) as well as potential 
nuisance parameters such as motion (motion-related regressors), which could influence 
brain activity. The design matrix for each subject shows how much each regressors could 
account for the activations observed in each particular voxel during each experimental task 
condition.  
In order to examine, at an individual subject level, the differences in the BOLD signal 
between the task-related regressors, t-contrasts, are created which allow us to compare the 
task-related conditions to each other and identify statistically significant changes between 
conditions. At a group level, these contrasts are compared to each other using appropriate 
statistical testing in order to identify whether there are significant changes between different 
experimental conditions for the whole group or between the ketamine and placebo sessions 
-2nd level analysis. The results of the 2nd level analysis could identify significant clusters of 
brain voxels in which the activation between the different experimental conditions and/or 
between the two drug sessions is significantly different and thus allows us to identify brain 
areas which are important for the task manipulations but are also potential targets for the 




3 The MID (Monetary Incentive Delay) task 
 
The version of the MID task used in this study is mostly comparable to the one used 
by Knutson and colleagues 2001 (Knutson et al., 2001). Prior to performing the task in the 
scanner, both during the screening visit as well as during the actual study days, volunteers 
were trained for this task. Training for the MID involves the presentation of a cue which 
participants learn to associate with a specific monetary reward. In the scanner, and in order 
to win the monetary reward, participants need to press the left button of their button box 
as fast as they can, every time they see a white square on the screen. Before the white square 
appears, one of the three cues that are part of this version of the task is presented. The cues 
consist of: a circle with one line which signifies that participants could win £0.20 (Low_win 
trial). A circle with two lines, which signifies that participants could win £2.00 (High_win trial) 
and a triangle which means that participants do not win anything (Neutral trial) but they still 
have to respond to the white square when it appears on the screen. Sometimes, an “X” 
appears on the screen and participants are told to not make any response (Passive_Trial). 
Figure 2 shows how the task is shown in the scanner.  
In each trial of this task, different delay intervals exist between the presentation of 
the cue and the presentation of the white square. During that delay period the fixation cross 
appears on the screen.  Participants win the monetary reward, signalled by the cue, only if 
they respond fast enough, by pressing the left button, when they see the white square. At 
the end of each trial a written statement informs the volunteers whether they won or not. If 
participants press the button during the fixation cross- premature responses-or a maximum 
of 100ms after the presentation of the square, the trial will register as unsuccessful. In this 
study, a total of 96, randomly arranged trials were presented. In order to ensure that there 
is no learning of the trial sequence, two different playlists were created and were presented 










3.1 Modelling the MID task 
 
For the purpose of better understanding as well as modelling the task for analysis, 
we can divide each trial of the MID into three phases. First, during the anticipation phase, 
the visual cue (circle or triangle) appears which represents the valence of the forthcoming 
reward. The presentation of the cue during that phase of the MID elicits motivational 
salience and is followed by an interval period of variable length during which the fixation 
cross appears on the screen. Afterwards, the target (square) initiates the participants’ 
behavioural response in order to obtain the reward that was signalled during the anticipation 
phase (second phase). Finally, during the feedback phase, participants learn whether they 
have obtained or lost the expected reward. During the anticipation phase, the visual cue 
could signify the delivery of a big or smaller reward as well as a neutral outcome where no 
win occurs. As a result, by contrasting the anticipation and feedback phases of task trials 
where a monetary reward could actually be obtained, with the corresponding task phases of 
a neutral trials we can identify the brain areas that are important for winning or not, a big or 
smaller reward.   
3.1.1 On an individual subject level 
 
On an individual subject level, three conditions were defined for the anticipatory 
phase of the task –“High_win”, “Low_win” and “Neutral”-according to the cue (circle with 
one line, circle with two lines, triangle, respectively) that was presented to the participants. 
For each of these task conditions the duration of the anticipatory phase included the cue 
presentation but also the delay interval during which the fixation cross remained on the 
screen (phases one and two, as mentioned in Section 2.1). Since the duration of the delay 
interval is variable, the duration of these conditions also varied and was between 4050ms 
and 4400ms. The response to the target square was modelled as a separate task condition. 
Depending on how fast participants responded to the target the duration of this condition 







Two conditions were created to model the successful trial outcome of the expected 
high –“High_win_succ” -and low –“Low_win_succ”- reward. Another two were used to 
model the unsuccessful outcome of high- “High_win_unsucc”-and low- “Low_win_unsucc”- 
reward trials. Finally, a neutral condition “Neutral_feedback” was created for the feedback 
phase of those trials where no win was expected. The feedback phase conditions had a fixed 
duration of 1450ms. Finally, the passive trials were modelled all together as one condition 
with a duration of 4250ms. Missed trials, where participants failed to make any response, 
were also modelled as a separate condition. In this case, the three phases of this trial were 
modelled as one condition with a total duration of 10secs. If more than 10% of the total 
number of trials were missed on each scanning visit the data from this visit was excluded 
from the analysis.  
 
3.1.2 On a group level 
 
 Reward anticipation and feedback for all the successful trials was the primary 
contrast of interest of the MID task in the group level. However, analysis of the level of 
reward (reward magnitude) on both anticipation and feedback was also examined.  
Specifically, for the analysis of the anticipation phase of the MID, the “High_win” and 
“Low_win” conditions were contrasted with the “Neutral” condition and in order to examine 
the role of reward magnitude, the “High_win” and “Low_win” conditions were compared to 
each other.  For the analysis of the feedback phase of the MID trials, the “High_win_succ” 
and “High_win_unsucc” as well as the “Low_win_succ” and Low_win_unsucc” conditions 
were compared with the “Neutral_feedback” condition. The role of reward magnitude 
during feedback was examined by comparing the “ High_win_succ” with “Low_win_succ ” 









In order to examine which brain areas are important for each phase of the task, the 
placebo session was analysed separately, and a one-sample t-test was performed for each 
condition of interest. Comparisons between the ketamine and placebo sessions were made 
using a paired t-test that allowed us to investigate the delayed effects of ketamine 
administration (2h post infusion) on the brain areas that are activated for each condition of 
the MID task.  Finally, the effect of session was examined by isolating data from participants 
who received ketamine in their first session and comparing them to the first session placebo 
data. This analysis was performed using a two sample t-test. 
 
 
Figure 2. The MID task has been designed specifically for fMRI studies. The design of the task allows the 














3.1.3 Correlations with behavioural data 
 
The participants’ performance to the SHAPS, before the administration of ketamine 
or placebo, was used as a regressor in order to explore whether baseline anhedonia would 
correlate with the brain activations observed during the MID, under placebo. Moreover, the 
difference (Delta) score between the baseline SHAPS scores and those obtained when the 
scale was completed, 2h after the ketamine administration, was used as a regressor in our 
analysis. The aim was to explore whether changes in anhedonia would correlate with 
changes in brain activity observed between the ketamine and placebo sessions for the 
anticipation and feedback phases of the MID. In addition to the SHAPS, anhedonia is also 
measured acutely, at the end of the drug infusion, with the PSI which contains an anhedonia 
related subscale. The anhedonia scores captured by the PSI were also correlated with the 
changes in brain activation produced by ketamine, compared to placebo. 
3.1.4 Region of Interest Analysis 
 
In addition to examining the MID task at a whole brain level, ROIs (Regions of 
Interest) were identified a priori and were used for a more targeted exploration of the role 
that these brain areas might have during reward anticipation and feedback for the MID task. 
These ROIs were derived from the literature around reward processing as well as previous 
fMRI studies that have examined the MID task. The activations in these regions were 
examined after placebo administration and were compared between the ketamine and 
placebo sessions. The effect of session in the activation of these ROIs, during different 
contrasts, was also explored. In the sections that follow, we describe how those ROIs were 













The striatum is located in the forebrain and it is the largest anatomical structure and 
main input module of the basal ganglia. The striatum receives glutamatergic input from many 
brain areas including the cerebral cortex and other parts of the limbic system such as the 
amygdala, hippocampus and thalamus. Moreover, the striatum receives ascending 
dopaminergic input form the midbrain. It can be anatomically subdivided into the ventral 
striatum and dorsal striatum. The NAc (Nucleus Accumbens) and the olfactory tubercle form 
the ventral striatum whereas the dorsal striatum comprises of the putamen and the caudate.   
The striatum is a critical component of the motor system and it plays a central role 
in reward processing and cognition (Wilson et al., 2018). Specifically, the ventral striatum is 
mainly involved in reward processing, reinforcement and motivational salience, whereas the 
dorsal striatum is mainly involved in cognitive processing (O'Doherty, 2004). There is 
evidence indicating that striatal function in relation to reward processing could be altered in 
depression (Pizzagalli et al., 2008). Moreover, due to the glutamatergic input that the 
striatum receives, activations in that brain area could also be modulated by ketamine 
administration (Malhotra et al., 1998).  
In order to investigate the role of the dorsal  striatum during the MID task and 
examine how ketamine might alter the activations in that region we created probabilistic, 
bilateral and unilateral,ROIs for the putamen (dorsal striatum) and the caudate (dorsal 
striatum) separately as well as the NAc. The definition of these ROIs was according to the FSL 
Harvard-Oxford atlas. The probabilistic ROIs created for the dorsal striatum brain areas were 
thresholded at 0.20 and binarized using the fslmaths tool as implemented in fslutils 
(Jenkinson et al., 2012). A bilateral and unilateral ventral striatal ROI (including the NAc) was 
also defined  (Montgomery et al., 2006).These ROIs were also combined with SPM 
probabilistic grey matter mask (threshold 0.20) to ensure that no areas extending into non-








3.1.4.2 VTA (Ventral Tegmental Area) 
 
The VTA comprises of a group of neurons located in the midbrain.  From the VTA 
originate the dopaminergic neurons of the mesocorticolimbic dopamine pathway. These 
mesocorticolimbic dopaminergic neurons are implicated in the brain’s reward circuitry. 
Moreover, the VTA plays an important role in cognition, motivation as well as emotional 
processing (Lisman and Grace, 2005) . Neurons from that brain area project to the prefrontal 
cortex and the brain stem as well as several brain regions in between. The VTA ROI used for 
this analysis was based a study examining VTA activity during resting state (Murty et al., 
2014). Bilateral as well as unilateral VTA ROIs were created and the activation of that brain 
area was examined for all the contrasts of interest.   
3.1.4.3 Amygdala 
 
  The amygdala is a set of nuclei which is located deep and medially within the 
temporal lobes of the brain. Research has shown that this brain region which is part of the 
limbic system, is important for memory, decision making as well as emotional responses 
(Kensinger, 2009).The amygdalae share direct connections with the ventral striatum and the 
VTA and are sensitive to dopaminergic modulation during reward processing. Moreover, the 
connectivity and activation of the amygdala appears to be altered in depressed as well as 
remitted depressed individuals (Young et al., 2014, Young et al., 2016).A bilateral amygdala 
ROI was defined using the FSL Harvard-Oxford subcortical atlas. The role of the left and right 













4 The Valenced Autobiographical Memory Paradigm 
 
4.1 Task Development 
 
 The VAMP is a novel personalised autobiographical memory task that was designed 
and developed specifically for this study and in order to be used in the MRI scanner. 
Inspiration for the design of this task was drawn from the classic version of the AMT 
(Autobiographical Memory Test) as well as from another task that was used in a study by 
Nicholson and colleagues (Nicholson et al., 2016) and which examined AM recall in 
conversion disorder.   
In the classic version of the AMT which was developed based on methodology by 
Williams and Broadbent (1986), participants are presented with a series of cue words, for 
which they are asked to produce a specific memory. The memories provided are then 
classified according to their level of specificity. Different versions of the AMT have been 
employed across different studies and these versions vary in the number of cue words 
presented to participants as well as the emotional valence of the words used for the task 
which could be positive, negative or neutral (Liu et al., 2013). Several studies have also used 
prompt words, which are presented to participants when they fail to produce a specific 
memory after a cue word is presented. Prompting is supposed to increase the specificity of 
AM retrieval. Finally, different versions of the AMT provide participants with different time 
windows during which they could recall a specific memory. The length of these windows 
ranges between 30 secs to 60 secs whereas there are some studies in which recall time is not 
at all restricted and participants are free to set up their own pace for this task (Griffith et al., 
2012). 
The AMT is a well validated task and has been successfully used to capture deficits 
in the specificity of AM recall in depressed patients. It has also been used in remitted 
depressed volunteers as well as individuals with a high risk of developing depression (Liu et 
al., 2013). The task focuses on the number of AMs recalled and their specificity, these are 
the main outcomes of the task and are used to assess AM. Although in depression 
overgeneral AM persists during remission (Warne et al., 2019), and thus we expected it to 
be also present in our group of volunteers, ketamine’s delayed effects have not been linked 
directly to improved AM retrieval. We hypothesized, thus, that any positive effects that 
ketamine might produce on AM recall facilitation would be reflected as changes in the 
activation of and the connectivity between brain areas that are important for AM and not on 
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the number and/or the specificity of these memories. Moreover, we expected that ketamine 
would modulate brain activation differently, based on the valence of the AMs. As a result, 
the use of cue words and prompts to generate recall of positive, negative and neutral AMs, 
as in the AMT, needed to be adjusted to our specific needs. 
The use of fMRI in our study, and the complicated statistics that are involved in fMRI 
data analysis required the development of a task that consisted of several repetitions of a 
specific condition in order to provide us with enough statistical power. Moreover, in order 
to capture any effects of ketamine on brain activation, we needed a task that would provide 
participants with sufficient time to recall and ruminate on specific AMs. The fact that we use 
a cross-over design with the same volunteers receiving both ketamine and placebo during 
two separate sessions, made it necessary to design a task during which the same memories 
would be recalled on both sessions. That would ensure that any changes in brain activation 
produced by the drug and identified during the task would be due to the effects of ketamine 
and not the result of the difference in the valence and quality of memories recalled on each 
session.  
In order to control for the valence of memories that participants would be asked to 
recall both between session but also between participants we drew inspiration from a study 
conducted by Nicholson et al. (2016). In this fMRI study participants with motor conversion 
disorder were scanned while presented with blocks of statements (1block = 8 statements) 
for three different event types that were classified as “severe” using the LEDS (Life Events 
and Difficulties Schedule). At the end of each block, participants were asked to rate how 
upsetting thinking about each specific event has been for them. Although in the Nicholson 
study participants were not provided with sufficient, for our purposes, time to think about 
the events, the use of a semi-structured interview such as the LEDS in order to interview the 
participants and rate the severity of their experiences would ensure that equally severe 
events, for all participants, would be used during the task. As a result, the LEDS interview 
was adapted to the demands of our study and fMRI task. The interview can be found in 
Appendix B. Moreover, rating of the valence of the event at the time of the scan, also 
implemented by Nicholson et al. (2016) and would allow us to capture any effects that 
ketamine might have on mood and anhedonia during the study day and would provide us 
with a measure of emotional valence of the retrieved AMs that we could use as a control 




4.2 The LEDS interview 
 
The LEDS interview is a well validated tool that has been used in order to provide a 
classification of the severity of life events that could sometimes be considered triggers for 
certain psychiatric conditions such as depression or conversion disorder. The interview is 
semi-structured and life experiences are classified as either life-events or difficulties (Brown 
and Harris).  According to the LEDS a difficulty is an ongoing struggle that lasts for at least 4 
weeks whereas a life event (it will be referred to as event from now on) has a much shorter 
duration. There could be several events within a specific difficulty. For the purposes of our 
study, and in order to ensure that participants could remember in detail their experiences 
during the limited time of the fMRI task we focused only on events and not difficulties.  
According to the LEDS rating scale, negative life events could be classified in 9 
different categories which are further subdivided into different subgroups. For example, 
category 4 focuses on “Money/Possession” related events and it encompasses a. financial 
crises/debts, b. financial gains, c. loss, damage threat to property etc. Each event is classified 
by the interviewer in one of those categories and then the events are rated according to their 
degree of unpleasantness. There are 4 degrees of 1. Marked unpleasantness 2. Moderate 
unpleasantness 3. Some unpleasantness and 4. Little or No unpleasantness. Each event 
receives a contextual rating which is based solely on the event, without taking into account 
the feelings of the person/persons involved, and a reported rating which takes into account 
the narrator’s way of talking about that particular event.  
The LEDS interview has been developed with a focus on negative life events that 
could trigger certain psychiatric conditions(Brown et al., 1988). However, a rating of positive 
events also exists and was used for the purposes of our task. Positive events, as defined by 
the LEDS, are always associated with symptom improvement in affective disorders. An ad 
hoc examination of cases where improvement was observed after a depressive episode, 
revealed that events which took place close to the time when a marked improvement in 
depressive symptoms was observed were all characterized by a “fresh start” for the 






Positive events usually involve some action or change that led to a marked reduction 
of some difficulty and they always involved the respondent personally. Although this 
definition of a positive event might be sufficient for the LEDS, we believe that it could be 
rather restrictive for our participants who are not currently depressed. For that purpose, the 
definition of the positive events was adjusted and all events that were remembered as 
pleasant experiences by the individuals were included in our task provided that participants 
had a good recollection of the event and that they would still feel positive thinking about it. 
The same 4 point rating system that was used for the negative life events was also applied 
to the positive ones, with “marked” pleasantness to be the top rating for a positive event.  
Neutral life events as well as a control condition were also part of our task. Life 
events could be classified as neutral when they score as ” 4. Little or no 
unpleasantness/pleasantness” in the LEDS rating scale. These events usually involved 
routines, such as going to work or doing the weekly shopping. These experiences were not 
considered to be sad or particularly exciting for both the narrator and the interviewer. The 
choice of an appropriate control condition for this task, was rather difficult. The specifics of 
fMRI analysis required that our control condition would have the same time length as that 
of the active task conditions but would also be emotionally neutral and engage thought 
processes.  We chose a control condition that would require our participants to count silently 
and upwards, in odd numbers, every time starting from a different number. The LEDS 















4.3 Administration of the VAMP  
 
4.3.1 Preparation for the task- interview day 
 
 Preparation for this task started with the administration of the LEDS interview. After 
a successful screening visit and before they attended their first study session, participants 
were invited for an interview day. Before their interview and during the screening visit, 
participants had seen a short demonstration of the VAMP in order to familiarise themselves 
with the task. The LEDS interview was also explained to them in detail and before attending 
their interview day they received an email with detailed instructions around the events that 
would be suitable to the task. Specifically, participants were encouraged to talk about the 
most positive and negative life events that occurred within 12 months prior to taking part in 
the study. However, if they believed that something more severe, either positive or negative, 
had occurred in the recent past, they could go back up to 5 years and talk about that event.  
During the LEDS interview which was recorded participants were instructed to share as much 
contextual information as possible and that was essential for the preparation of the fMRI 
task.  
 
4.3.2 Rating and Statement Preparation 
 
 The positive and negative events were rated by the interviewer as well as another 
independent rater and only those that score “1- Marked” in the LEDS scale were considered 
for the task. Since the task involves recalling autobiographical events the recollection of 
which could be potential unsettling for some of our volunteers a debriefing was offered, and 
details of counselling services could be provided if necessary. For the neutral events a rating 
of “4 Little or no unpleasantness” was necessary.   
Participants were encouraged to talk about more than one positive, negative and 
neutral event. In the case of two or more events of the same emotional valence which also 
received the same LEDS rating, the level of contextual information recalled from the 
participants would determine which event would be used for the fMRI task. For each event, 
20 matched-in-length statements were created and were split into two groups of 10 
statements each. The two groups included different statements from the same event which 




The two groups of statements were presented to participants, one group on each 
study day, in a random order. The statements contained as much contextual information as 
possible while omitting the emotional components of the narrative, since these could 
influence the participants rating of the events. Furthermore, 20% of the statements were 
altered and the details they contained were inaccurate thus ensuring that participants would 
be paying attention to the statements that were presented to them in the scanner. 
 
4.4 Scanning  
 
Scanning took place 2hours after the intravenous infusion of ketamine or placebo 
and the VAMP task was performed right after the resting state scan. Since the VAMP task 
required great level of attention and it could also be emotionally challenging, we chose to 
split the task into two runs. During each run five statements from each of the positive, the 
negative and the neutral life events were presented in that order to the participants. 
Participants had 6 secs to read carefully each statement and decide whether the statement 
was true or false. If the statement was true to the event, then participants had 12 secs to 
recall and ruminate about that event in as much detail as possible. At the end of the 12 secs 
participants were asked to rate, using a VAS scale, how positive or negative they felt thinking 
about this event at the time of the scan. If the statement was false or participants failed to 
respond in time, the task automatically would move on to the next statement.   
The control condition, which asks participants to count upwards, silently and in odd 
numbers, every time starting from a different number was presented in a random order, 
between statements, a total of 12 times during each run. That number (12 times) matches 
the total number of correct statements (positive, negative and neutral) that are presented 
to participants during each run of the task. A 6min structural scan followed end of the 1st 
VAMP run allowing our participants to rest before the task began again.  During the 2nd VAMP 
run of the task different statements, from the same events, were presented while the order 
of the events was kept the same between runs and between participants. Each run could last 
up to 15min, but the actual duration of the VAMP task could vary depending on how many 





Modelling of the VAMP task  
 
4.4.1 On an individual subject level 
 
 For the purpose of modelling the VAMP task for analysis we divided each statement 
presentation into three phases. The first phase is the decision phase during which 
participants are asked to read the statement carefully and decide whether it is “TRUE” or 
“FALSE”. If the statement is identified as “TRUE”, the retrieval phase follows, when 
participants are asked to think about the event that is presented to them in as much detail 
as possible. The rating phase is the final phase of the statement presentation and during that 
participants are asked to rate how positive or negative they feel thinking about this event at 
the time of the scan.  
   
 
Figure 3. The VAMP is a personalised AM task. The Retrieval Phase of TRUE statements is the one used for the 








Four conditions can be identified for the decision phase of the task a. True_correct, 
b. False_correct, c. True_incorrect and d. False_incorrect. All these conditions are 6 seconds 
in length and the first two represent statements that are actually true (a) or false (b) and 
have also been identified correctly as such by the participants. The last two conditions 
represent statements that have not been correctly identified as true (c) or false (d) by the 
participants.  
During the retrieval phase of the VAMP two 12 secs long conditions are modelled. 
These conditions are: True_correct_retrieval and False_incorrect_retrieval. These two 
conditions represent the AM recall period for statements that have been identified as 
“TRUE”. In the False_inocrrect_retrieval condition however, an incorrect decision regarding 
the statement was made and these conditions although part of the task model,  are excluded 
from the analysis. The rating phase is also modelled with a separate condition that is called 
“Rating” and is 4 seconds long. Ratings that correspond only to True_correct conditions of 
the decision phase are part of the final analysis. The control condition is modelled as a whole 
and is 22seconds long. All these conditions are created separately for the positive, the 
negative and the neutral events. During the individual subject level analysis, the two runs of 
the task are modelled together in a single design matrix.  
4.4.2 Group comparisons 
 
The True_correct_retrieval condition is of particular importance for the analysis of 
the VAMP task. This condition would allow us to examine brain activity while participants are 
recalling AMs based on correct statements.  On a group level and just for the placebo session, 
we compared the True_correct_retrieval condition between the positive, the negative and 
the neutral events to see whether the brain areas that are implicated in recall differ based 
on the valence of the retrieved memory. We also contrasted these conditions with the 
control condition to identify brain areas that are important for AM recall. All placebo group 
comparisons were made using a one-sample t-test. The True_true_correct retrieval 
condition was also compared for positive, negative and neutral memories between the 






4.4.3 Correlations with behavioural data 
 
 The participants’ scores on the RRS, were used as regressors in order to explore 
whether general rumination levels would correlate with brain activity in areas that are 
activated during AM recall. Moreover, the scores from the same scale were used to explore 
whether ketamine would modulate brain activity differently based on how much participants 
ruminate in general.  
4.4.4 Connectivity of the VAMP task 
 
Several cortical and subcortical brain areas have been identified, in the literature, as 
important for AM recall. Amongst these brain areas the amygdala, the sgACC and the PCC 
are not only critical for AM retrieval but have also been implicated in the AM deficits 
observed in depression.  
In this study we used PPI (Psychophysiological Analysis) in order to examine the 
connectivity of these regions (seeds) with the rest of the brain. PPI is a task connectivity 
method that allows us to determine whether the correlation in activity between two distant 
areas is different under different task conditions. Specifically, this analysis examines whether 
there is an interaction between the physiological state of the brain during the task and the 
functional coupling between two brain areas, or between a seed region and the rest of the 
brain (O'Reilly et al., 2012).  
We applied the PPI methodology in the VAMP task in order to identify: 
1. In the placebo group, changes in the connectivity between our seed regions and the 
rest of the brain during positive and negative recall compared to neutral. For this 
analysis we examined the connectivity of our seed region during the retrieval phase 
of the positive and negative events and compared it to the retrieval phase of the 
neutral events. 
2. In the placebo group, changes in the connectivity related to the emotional valence 
of the memory. For that purpose, we examined the connectivity between the seed 
region and the rest of the brain, during the retrieval phase of positive events 
compared to negative events. 
3. Whether ketamine, compared to placebo, would produce changes between the 
connectivity of the seed region with the rest of the brain. For that purpose, we 
contrasted the retrieval phase of positive events with that of neutral events and 
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compared it between sessions (ketamine session vs placebo session). We repeated 
the same analysis for the negative event.  
4.  Whether ketamine compared to placebo would produce emotional-valence-specific 
changes in the connectivity of the seed region with the rest of the brain. For this 
analysis, we contrasted the retrieval phase of positive AMs with that of negative AMs 
and then compared the ketamine and placebo sessions.  
4.4.5 ROIs for the VAMP connectivity analysis  
 
4.4.5.1 Amygdala 
The amygdala is a pivotal component of the affective network. This bilateral brain 
structure located deep in the medial temporal lobe in close proximity to the hippocampus. 
The amygdala could act as a hub in a wide range of emotional processing tasks. In patients 
with MDD as well remitted depressed individuals the amygdala appear overactive during AM 
recall but also emotional processing (Young et al., 2014, Young et al., 2016). The connectivity 
of the amygdala with the rest of the brain is also altered in MDD. Specifically, decreased 
connectivity between the amygdala and parahippocampal regions has been identified in 
depression along with increased connectivity between the amygdala and occipital/parietal 
regions, the hippocampus as well as the PCC (Young et al., 2016). A bilateral ROI was created 
for the amygdala based on the FSL-Oxford atlas and was used for the PPI analysis. 
4.4.5.2 PCC 
The PCC along with the angular gyrus and the amPFC (anteromedial Prefrontal 
Cortex) comprise the most commonly activated regions of the DMN. The PCC is a 
heterogeneous brain structure with subdivisions characterized by distinct patterns of 
structural and functional connectivity (Leech et al., 2011). In more detail, activations at the 
ventral PCC functionally correlate with the rest of DMN and that pattern of co-activation is 
present across all self-generate tasks, including those tasks that involve AM recall (Fan et al., 
2019). The dorsal PCC has been linked to autonomic arousal and awareness. It has an 
important function in monitoring behaviourally relevant stimuli as well as environmental 
changes (Fan et al., 2019). Although they present with relatively distinct functions, the dorsal 
and the ventral PCC are anatomically interconnected and also present with strong 
connections with the precuneus (Leech et al., 2012). In our analysis we have examined the 
connectivity of the PCC as a whole, but also the connectivity of the dorsal and ventral PCC. 
Bilateral ROIs were created to examine the distinct roles of the dorsal and the ventral PCC. 
These ROIs were 6mm spheres that were created using MarsBaR.  
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The centre of these spheres ware located at the voxel that presented with peak 
activations for the ventral PCC (MNI 2 -58 28) and dorsal PCC (MNI 2 -34 40) in Leech and 
colleagues(Leech et al., 2011). 
4.4.5.3 sgACC 
 The sgACC is located ventral to the genu of the corpus collosum and has been 
implicated in regulation of emotional behaviour Evidence from neuroimaging studies 
suggests that the area presents with increased connectivity with the amygdala and insula 
which could contribute to altered emotional processing in depression (Connolly et al., 2013, 
Drevets et al., 2008b). Moreover, increased connectivity between the sgACC and the middle 
and inferior frontal gyri significantly correlates with rumination in MDD (Connolly et al., 
2013). According to its anatomical definition, the human sgACC consists of angular cortex 
characterised as BA (Brodmann Area)24 anteriorly and BA25 posteriorly. We have used the 




















Ketamine as a psychoactive drug with antidepressant effects (2h-24h post 
administration) could influence the emotional state and behavioural characteristics of 
individuals. Remitted depressed volunteers, like the cohort recruited for this study, could 
theoretically be even more susceptible to the behavioural effects that ketamine might 
produce, compared to healthy, never depressed volunteers, since these individuals, although 
asymptomatic at the time of the study, might still present their brain activations might 
present with some of the neural correlates of increased rumination and anhedonia (Berman 
et al., 2011, McCabe et al., 2010). In this chapter we will present the general characteristics 
of our study sample including age and gender balance. We will also examine the levels of 
ketamine and its major metabolite, norketamine, at the end of the 40min infusion as well as 
2h post infusion. Recently, HNK (Hydroxynorketamine), another active metabolite of 
ketamine, has gained a lot of interest in the literature as a potential mediator of the drug’s 
antidepressant action (Zanos and Gould, 2018). In our study we have measured the levels of 
HNK in order to investigate how its concentration changes over the course of the study.  
The changes that ketamine might produce in general mood and anhedonia, acutely 
as well as 2h after its administration, are captured by the scales and questionnaires 
administered in the study (all the questionnaires can be found in the Appendices). In order 
to provide us with an understanding of how much our participants engage in rumination, 
especially when they feel sad or depressed (Treynor et al., 2003), the RRS is administered 
during the screening visit (see Appendix C). On the study days, the SHAPS (Snaith et al., 1995) 
is administered twice, at the start of the day and 2h after the drug infusion   (for the scale 
see Appendix E). This scale was included to capture anhedonia symptoms that our 
participants might experience and help us determine whether ketamine would produce any 
significant changes in the SHAPS score. Additionally, the SWN-K scale is administered at three 
time points during the study day - at the start of the day, immediately after the drug infusion 
and 2h post infusion- in order to measure participants’ baseline well-being and any 
significant changes that could be the result of the infusion and/or the delayed effects of 




Shortly after the end of the drug infusion, and once they have recovered from any 
side-effects, participants were asked to complete the PSI, along with the SWN-K. This scale 
has been designed specifically to capture the dissociative effects of psychoactive drugs, such 
as ketamine and cannabis (Mason et al., 2008). In our study, the PSI was administered in 
order to measure the dissociative effects that ketamine produces acutely and would be 
experienced by our volunteers during the 40 min steady-state intravenous infusion (the scale 




























2.1 General Sample characteristics 
 
 For the purpose of our study, we recruited a total of 36 male and female volunteers 
over approximately 36 months.  In order to take part in the study, participants needed to 
have experienced at least one depressive episode in the past. At the time of the study 
however, our volunteers were in full remission from depression and free from any 
antidepressant treatment for at least three months prior to their involvement in the study. 
Their previous mental health history as well as their current mental health state were 
assessed using the M.I.N.I which was administered by the study doctor during the screening 
visit. A total of 150 volunteers were screened for our study. Approximately 2/3 of them still 
experienced significantly low mood, as was reported during the screening, and were thus 
excluded from the study. Moreover, MRI incompatibilities along with the multiple visits and 
the rigid timelines for the study were the main reasons that lead to exclusion from the study.  
 
Figure 4. The CONSORT diagram shows how many participants, were screened, randomised and finally analysed 




2.2 Rumination  
 
 The RRS scale was administered once during the screening visit. Table 2 shows the 
average rumination scores in our cohort, as captured by the scale. The table also includes 
the age and gender balance in our sample.  The range for RRS ratings is between 22 and 88 
and the mean score for our sample is 44.81 (SD, ±14.31).  
 
 
Previous research has shown that there is a gender difference in rumination in the 
healthy population with females demonstrating higher levels of ruminative thinking 
compared to males. According to Nolen-Hoekseman who developed the RRS scale, the mean 
scores for healthy males and females significantly differ, with males scoring 39.6 and females 
42(Nolen-Hoeksema et al., 1999). In our sample of remitted depressed volunteers there are 
no significant differences in the rumination scores between male and female participants. 
Moreover, the total average RRS scores as well as those obtained individually for males and 
females are numerically higher than the general average score and gender specific scores 









Male (42%) Female (48%) 
Mean SD Mean SD 
Age 28.8 ±9.10 28.3 ±7.3 
RRS  45.7 ±14.36 44.29 ±14.69 
Table 2. The mean age and RRS scores in our cohort. A two sample t-test did not reveal gender significant 
(p<.05) differences in rumination. 
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2.3 Performance on Memory Tests 
 
The scores on the RAVLT and Weschler memory test are also included in a separate 
table for each of the two study visits. These memory assessments are administered at the 
start of each study day to provide us with a measure of cognitive function, specific to memory 
encoding and recall at baseline  
 
 
RAVLT Weschler Memory Scale 





























Table 3. The immediate and delayed recall measures of the RAVLT and Weschler Memory Scale did not reveal 
significant differences in  the cognitive performance of our cohort between sessions (Paired t-test, p>.05). 
 
Performance in the RAVLT and Weschler memory scale did not change between the 
study sessions (Paired t-test, p>.05).  Moreover, no effect of session was identified between 
those participants who had ketamine on their first session compared to those who were 
given placebo on their first session (Two sample t-test, p>.05). Both the RAVLT and the 
Weschler memory scale have an immediate and delayed recall component. In Table 3 the 
average scores of the three immediate recall phases (R1, R2, R3) of the RAVLT as well as the 
average score of the delayed (DR) recall of this scale are presented. The average scores from 
the immediate (IM_R) and delayed (DEL_R) recall component of the Weschler memory scale 












 The self-administered SHAPS was completed twice on each study day, at the start of 
the day in order to provide us with a baseline measurement of anhedonia and 2h after the 
infusion, in order to capture any effects that either the ketamine or the placebo 
administration might have on anhedonia. The total SHAPS scores from both the ketamine 
and placebo sessions are shown in Figure 5.  
 
Figure 5. Anhedonia did not change 2h after ketamine (Wilcoxon Signed Rank test, p>.05). In the placebo session 
a significant reduction in anhedonia was identified (Wilcoxon Signed Rank test, p<.05) 
 
The total scores obtained at baseline and 2h post infusion were compared, 
separately for each session. The scores of this questionnaire were not normally distributed 
and thus non-parametric testing was used. We found that for the placebo session, there was 
a significant decrease in anhedonia 2h post infusion, compared to baseline (Mean baseline 
score= 1.47, SD = ± 1.94, Mean Post infusion score = 0.79, SD = ± 1.39, Wilcoxon Signed Rank 
test, p<.05). No significant changes were identified for the scores obtained during the 
ketamine session (Mean baseline score= 1.03 SD= ±1.94, Mean Post Infusion score = 1.11, 
SD= ± 1.85, Wilcoxon Signed Rank test, p>.05) and no significant changes were identified 
between the baseline scores of the ketamine and placebo days (Wilcoxon Signed Rank test, 
p>.05). Moreover, the change between the baseline and post-infusion scores was calculated 
and these differences were compared between ketamine and placebo. No significant 
changes were identified.   
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Finally, the effect of session was also examined and no significant changes in 
anhedonia were found between the baseline and post infusion scores of those participants 
who received ketamine on the 1st session compared to those who received placebo 
(Wilcoxon Signed Rank test, p>.05). The absolute scores of the SHAPS as well as the 
difference in the scores between baseline and placebo were entered into a correlation 
analysis with the brain activations in ROIs that are important for reward processing during 
the MID task. No significant correlations were identified. 
2.4.2 Subjective Well-Being 
 
In this study we have used the SWN-K in order to obtain a measurement of the 
participants’ self-reported well-being at the start of each study day, immediately after the 
drug infusion and the 2h post the infusion. The mean scores from the SWE were for ketamine 
(Mean Baseline score = 95, SD = ±14,87, Mean Post Infusion score = 90.29, SD = ±12.88, Mean 
2h Post Infusion score = 95.07, SD = ± 13.44) and for placebo (Mean Baseline score = 98.71, 
SD = ±12.1, Mean Post Infusion score = 97.79, SD = ±10.96, Mean 2h Post Infusion score = 
97.36, SD = ± 9.52) are normally distributed and a multiple regression analysis was used to 
identify any significant effects of treatment (ketamine vs placebo) and/or the time that the 
scale was administered (start of the day, right after the infusion, 2h post infusion). Figure 6. 
shows the total scores from each timepoint for both the ketamine as well as the placebo 
session.  
 
Figure 6. Multiple regression revealed a significant effect of treatment in the ketamine session (F (23,1) =8.11, 




Overall, there was an effect of ketamine with generally lower scores for the SWN-K 
during the ketamine session compared to placebo. This effect appeared to be driven mainly 
by the much lower scores obtained for this scale right after the ketamine infusion. When we 
examined the effects of treatments vs time, however, we did not identify any significant 
interactions and thus we did not explore this further. Finally, we did not identify any 
significant effects of session for the scores of this scale and there were also no significant 
changes between the baseline scores of the ketamine and placebo sessions (Two sample t-
test, p>.05).  
2.5 Ketamine: Pharmacodynamics and the dissociative effects of the drug 
 
2.5.1 Ketamine Blood levels 
 
The levels of ketamine, norketamine and the two isoforms of HNK ((2S,6S)-HNK and 
(6R,6R)-HNK)) were measured from a blood sample that was taken 5min before the end of 
the i.v infusion as well 2h after the ketamine administration. Seven participants were not 
included in this analysis since they reported intense feelings of dizziness and discomfort 
towards the end of the ketamine infusion and therefore no blood sample was collected at 
that time. In Figure 8 the missing values (gaps in the diagrams) represent metabolites whose 
levels were below detection in the samples. Analysis of the plasma levels from the collected 
samples showed that the average concentration of ketamine reduces considerably 2h post 
the infusion whereas the norketamine levels are stable . HNK levels increase 2h post infusion. 
Figure 7 show the average values of ketamine and its major metabolites at the end of the 
infusion and 2h post infusion. Figure 8. Shows the individual levels of those metabolites from 
all the participants and Table 4, provides the average values of ketamine and its metabolites 











Figure 7. The average values of ketamine and its major metabolites at the end of a 40min i.v infusion and 2h 
post infusion. Significant changes were identified for all metabolite levels 2h after the drug administration 
(Paired t-test., p<.05) 
 
 
Figure 8 Individual levels from ketamine’s metabolites at the end of a 40min i.v infusion and 2h post the 
ketamine administration. Missing values represent participants where the metabolite levels were below 
detectable concentrations. 
 





2.5.2 PSI scores 
 
 On each study day and at the end of the 40min drug infusion, participants were asked 
to complete the PSI. The scale is self-administered and higher scores on this scale indicate 
that participants experience more intense dissociative and psychotomimetic effects during 
the drug administration. After marking the PSI, the total score as well as the scores for the 
six subscales were calculated and compared between the ketamine and placebo sessions 
using paired t-tests. As expected, participants scored significantly higher on the PSI after a 
ketamine infusion, compared to placebo (Mean ketamine score= 48.36 SD= ±22.01, Mean 
placebo score= 15.10, SD= ±10.05). When we compared the scores for the six subscales of 
the PSI between the ketamine and placebo sessions, we found significantly higher scores 
under ketamine compared to placebo for all subscales (Paired t-test, p<0.05). The graph 
below shows the total score as well as the average score for the six subscales.  
 
Figure 9. Ketamine produced significant changes in the PSI scores compared to placebo. Significant increases 
were identified for the six subscales, including anhedonia (Paired t-tests, p<.05) 
 







The PSI was completed at the end of the 45min infusion and once participants have 
recovered from any side effects that they might have experience during the infusion. While 
filling in the PSI, participants were asked to imagine how they felt during the infusion and 




In this chapter we examined the general characteristics of our study sample, we 
looked at ketamine and its metabolites immediately after the infusion as well as 2h post 
infusion and we also explored the acute and delayed (2h post administration) effects of 
ketamine in our volunteers. The PSI was used in order to capture the dissociative and 
psychotomimetic effects that ketamine could produce during the infusion, while the SHAPS 
and SNK-W would help us understand how anhedonia and subjective well-being change over 
the course of each study session (ketamine vs placebo). The RRS scale provided us with a 
baseline measure of how much our participants engage in rumination, especially when they 
feel sad or depressed.  
3.1 Ketamine and its metabolites 
 
Ketamine, after its administration, undergoes extensive metabolism, via nitrogen 
demethylation, to norketamine (Zanos et al., 2018). This reaction is catalysed by the liver 
enzymes of cytochrome P450 and norketamine is further metabolized to DHNK 
(dehydroxynorketamine) and hydroxynorketamine (HNK). According to the 
pharmacodynamic model for ketamine’s metabolism in patients diagnosed with unipolar and 
bipolar depression, norketamine, DHNK and (2R,6R;2S,6S)-HNK are the main metabolites 
detected in the plasma of patients, following a 40min intravenous infusion of 0.5mg/kg 
racemic ketamine (Zarate et al., 2012, Zhao et al., 2012). Specifically, at the end of a 40min 
i.v infusion plasma concentrations for ketamine peak at end of the infusion, whereas 
norketamine peaks at 80min, DHNK at 110min and (2R,6R; 2S,6S)-HNK 230min from the start 




The ketamine, norketamine and HNK concentration levels that we detected in our 
study, both at the end of the 40min infusion as well as approximately 2h post the drug 
administration, seem to be in line with the aforementioned pharmacokinetic model for 
ketamine’s metabolism (Zhao et al., 2012). Indeed, ketamine’s levels seems to peak at the 
end of the infusion whereas they are lower 2h post the drug administration (see Figure 7). 
Norketamine and both the enantiomers of HNK- (2S,6S)-HNK and (2R;6R)-HNK- show an 
increase in their concentration 2h post the ketamine administration compared to the end of 
the infusion (see Figure 7). According to the model however, the peak concentration for 
HNKs is 230min post the infusion, thus, a later collected sample would be required in order 
to capture the peak concentrations of these metabolites in the plasma.  
Amongst the ketamine metabolites, HNKs have recently gained a lot of interest in 
depression research since there is evidence, from animal studies, indicating that they could 
be mediating ketamine’s antidepressant actions. Previous pharmacodynamic studies of 
ketamine and its metabolites have shown that ketamine and norketamine have anaesthetic 
actions and, at lower doses, increase spontaneous locomotor activity in the rat whereas 
HNKs do not demonstrate such effects and thus for years they were considered inactive 
(Singh et al., 2014) 
  Recent studies, however, have shown that the HNK metabolites have antidepressant 
actions. When they were isolated and administered in mice, they induced antidepressant 
behaviours in animal models of depression, such as the FST (Forced Swim Test). Specifically, 
a positive correlation was detected between the antidepressant response and the plasma 
levels of (2R,6R)-HNK and the administration of the metabolite alone was enough to induce 
an antidepressant response. Moreover, in the same study, ketamine’s deuteration 
prevented its conversion to (2S,6S ; 2R,6R)-HNK without changing the total ketamine levels 
in the brain of mice. In that experiment no antidepressant effects were detected((Zanos et 








Although some research has produced controversial findings (Shirayama and 
Hashimoto, 2018). HNKs’ antidepressant actions are rather interesting since they challenge 
the hypothesis that ketamine’s  antidepressant effects are mainly mediated by NMDAR 
inhibition. HNKs’ potential mechanism of action, involves direct activation of the AMPA 
receptors (Aleksandrova et al., 2017) and this finding would be in line with other NMDAR 
antagonists, that do not target the AMPARs and have failed to produce robust 
antidepressant action (Gould et al., 2019). In our study, we measure HNKs at the end of the 
infusion as well as 2h post the infusion. The levels of the metabolites (both enantiomes are 
measured) appear to increase 2h post the drug administration and serve as a useful index of 
the metabolite levels when the scanning commenced.  
The HNK levels in our study did not correlate with the SNK-W or SHAPS scores that 
capture well-being and anhedonia respectively. This is not surprising since the scores of these 
questionnaires do not significantly change during the ketamine session, perhaps reflecting 
the low levels of anhedonia and high levels of well-being in our sample who were not 
depressed at the time of the study. There is limited information on the time course of 
ketamine’s effects in remitted depressed individuals and so it remains possible that later 
assessment times (e.g. aligning with the peak of HNK) or at 24hours post-infusion would 
reveal different effects. It is also possible ketamine does not improve mood and anhedonia 
per se  but attenuates deficits in these symptoms. While the neuroimaging reveals specific 
mechanisms of action on neurocognitive processes (Lally et al., 2014, Lehmann et al., 2016), 
the translation of these to changes in symptoms is not well specified in the literature and 














3.2 Memory and Rumination levels in our cohort  
 
3.2.1 Performance on memory scales 
 
In our study, the cognitive performance of our volunteers was assessed using the 
RAVLT and the Wechsler Memory scale (see Table 3) . Administration of these scales took 
place before the drug infusion and the time of the administration of those scales was kept 
consistent between participants and between sessions. This practice was followed for all the 
assessments that were part of our study in order to ensure that external factors or the 
experimenter bias do not influence performance in these scales.  
The RAVLT could be used to evaluate a wide variety of cognitive functions including 
short term auditory verbal memory, rate of learning as well as retention of information. The 
scale could also be used to detect differences between learning and retrieval (Boone et al., 
2005). In the literature, the RAVLT has mostly been employed in order to examine mnemonic 
functions in cases of disease or during aging (Zhu and Paoletti, 2015). The Wechsler memory 
battery is a neuropsychological set of tests also designed to measure different memory 
functions. In our study, we did not administer the whole battery but selected the logical 
memory test to assess the cognitive performance of our volunteers when asked to memorize 
and subsequently retrieve a short story. The rationale behind choosing those tests was to 
ensure that the cognitive performance of our participants did not significantly differ between 
the two study sessions.  
Several factors such as fatigue, stress and anxiety can negatively affect cognitive 
performance ((Alhola and Polo-Kantola, 2007, Scott et al., 2015) for meta-analyses see 
(Buckman et al., 2018)). Moreover, ketamine has been shown to disrupt memory functions 
by impeding the encoding of novel information. This deficit is only present when novel 
information is encoded right after the administration of the drug and it has been shown that 
ketamine does not influence the retrieval of memories established prior to its administration 
(Honey et al., 2005). However, these findings suggest that ketamine could, to some extent 






In our study, we have used the VAMP, an autobiographical memory fMRI task, to 
examine ketamine’s effects on positive, negative and neutral memory recall. This task does 
not evaluate memories that are encoded during or right after the drug administration and 
involves only the retrieval of old and established AMs.  The administration of the RAVLT and 
the logical memory test of the Wechsler Memory scale however, ensure that the cognitive 
performance of our participants does not differ between session and that when ketamine 
was administered in the first session that did not influence cognitive function in the placebo 
session. This way any neuroimaging differences we detect in the VAMP task, between the 
ketamine and placebo sessions, are due to the effects of ketamine on emotionally valenced 
memory recall.  
We did not expect the performance of our participants on the RAVLT or the logical 
memory component of the Wechsler Memory Scale to significantly differ between 
participants and between sessions (see Table 3). For this study we recruited young 
volunteers and thus we did not expect any serious cognitive impairments related to aging. 
Moreover, the ketamine administration which could influence the encoding of novel 
information as required by those scales, when occurred first, was at least 7 days apart from 
the placebo session. This is enough time for ketamine to be completely metabolised and thus 
we did not expect to detect a session effect for the performance on these scales. 
3.2.2 Rumination 
 
Rumination is one of the most prominent symptoms of depression. The intensity of 
ruminative thinking could predict the duration of a depressive episode as well as the 
treatment outcome of individuals with depression (Alhola and Polo-Kantola, 2007, Jones et 
al., 2008). Moreover, there is evidence indicating that increased rumination persists during 
remission from depression since high levels of ruminative thinking are also present in 
previously depressed individuals, even in the absence of other depressive symptoms 
(Watkins, 2008). In our study, we have used the RRS scale in order to capture rumination and 
examine any potential relationships between rumination levels and other psychological 
measures that were acquired during the study as well as between rumination and brain 





The RRS scale has been developed by Nolen-Hoekseman and her colleagues with the 
purpose to capture and quantify rumination that is not confounded by symptoms and 
behaviours associated with depression (Nolen-Hoeksema, 2001). In a large study using this 
scale in the healthy population, it was shown that there are significant gender differences in 
the rumination scores captured by RRS with the mean score for healthy males to equal 39.6 
whereas healthy females scores around 42 on the scale (Nolen-Hoeksema et al., 1999). In 
our sample, when the RRS was administered during the screening visit we did not detect any 
significant gender differences in the scores of our participants (see Table 2). The numerically 
high scores on the scale, however, indicate that ruination still happens in our group.  
When the relationship between rumination (RRS scores) and anhedonia (SHAPS) as 
well as subjective well-being (SNK-W) were examined no significant correlations were 
identified between the RRS scores and the baseline scores of those scales on both the 
placebo as well as the ketamine sessions. The absence of significant correlations between 
rumination and other behavioural measures in our cohort suggests that there is no direct 
relation between the rumination levels in our remitted depressed volunteers and elevated 
anhedonia or reduced subjective well-being.  
In the literature, rumination has been associated with the DMN which appears to be 
activated during self-referential processing as well as AM recall (Grieder et al., 2018, 
Hamilton et al., 2015). Abnormally increased rumination with a focus on negative AMs,  that 
might be present in depressed and remitted depressed individuals could partly be attributed 
to an over-active DMN (Default Mode Network) as well as increased activation of the 
amygdala (Lehmann et al., 2016, Sheline et al., 2009, Young et al., 2016, Young et al., 2018).  
In several fMRI studies that have used resting state in order to study connectivity 
changes in depression it was shown that key regions that form part of the DMN, mainly the 
PCC and the pACC, present with increased connectivity and that increased levels of DMN 
activation could be associated with higher levels of maladaptive rumination (Lehmann et al., 
2016). Moreover, the PCC along with the amygdala, the hippocampus and temporal areas, 
present with increased activations during autobiographical memory recall in patients with 
MDD as well as remitted depressed individuals and those in high risk of developing 





The administration of ketamine has been shown to reduce the functional 
connectivity between the anterior pACC and posterior parts of the DMN in healthy 
volunteers (Scheidegger et al., 2012). This reduction in the connectivity within the DMN 
might help depressed patients to become less self-focused and more susceptible to external 
stimuli thus relieving them from some of the emotional and psychological burden of intense 
rumination. Although our participants are remitted depressed and thus do not currently 
experience such intense ruminative thinking and low mood, we did examine whether the 
scores of the RRS scale would correlate with the brain activations that we observed during 
the VAMP task. During this task participants are asked to recall positive, negative and neutral 
AMs. We did not identify any significant correlations between the RRS scores and the brain 
activations of these areas.  
 
3.3 The effects of ketamine 
 
3.3.1 Acute effects  
 
In addition to its antidepressant action, ketamine is also a psychoactive drug and as 
such it could alter the subjective qualities of perception, thought and emotion of individuals 
under its influence, often causing altered interpretations of sensory input. Many of these 
changes in emotional and sensory perception resemble psychosis symptoms and thus are 
called psychotomimetic. The psychotomimetic effects of ketamine as well as the acute 
changes in brain activations that the drug produces are of particular interest especially when 
ketamine is used as a model of psychosis (Steeds et al., 2015). In research, ketamine has been 
used in order to validate the glutamate hypothesis of schizophrenia which could explain the 









The PSI scale has been developed specifically in order to capture and quantify the 
psychotomimetic effects produced by psychoactive drugs and has been validated not only 
for ketamine but also for cannabis and other compounds with similar actions (Mason et al., 
2008).  In our study the scale was administered immediately after the ketamine infusion and 
a significant increase was observed (Paired-sample t-test, p<.05, corrected for multiple 
comparisons) in all the psychotic-like symptoms that are measured by the PSI. These 
symptoms include delusory thinking, perceptual distortions, cognitive disorganisation, 
anhedonia, mania and paranoia (see Figure 9). 
 In an anaesthesiology study (Bowdle et al., 1998) which aimed to examine 
ketamine’s dissociative effects in relation to the blood concentration levels of the drug in 
patients recovering from anaesthesia, a linear relationship was identified between ketamine 
blood concentrations and the psychosis like symptoms that were measured. Moreover, 
several phMRI studies have investigated associations between changes in subjective ratings 
of behaviour induced by ketamine and the activation of several brain areas. For example, 
Deakin et al., (2008) have found that deactivation of the subgenual cingulate and medial PFC 
correlated with increases in the CADSS – another scale that measures dissociative states 
(Deakin et al., 2008) while other studies did not identify any correlations between ketamine 
and the PSI or CADSS ratings (De Simoni et al., 2013). Whether they correlate or not with 
brain activations, the dissociative effects observed under ketamine are the result of the drug 
actions on different receptor system including NMDA receptors, sigma and kappa opioid 
receptors.  
Ketamine’s binding on the NMDA receptor causes a surge of glutamate release. The 
excess glutamate and neuronal excitation that follows the NMDA receptor inhibition (for the 
neuronal/molecular proposed mechanisms of ketamine’s action see Figure 1) and 
subsequent GABA disinhibition could impact areas such as the prefrontal cortical structures, 
the anterior insula, the thalamus and the amygdala (for review see(Balu, 2016)). These areas 
play a key role in emotional and self-referential processing and the increased excitation of 






Several of these brain regions are also important for reward processing and appear 
with altered activations in depression as well as remission (Oldham et al., 2018, Young et al., 
2016, Young et al., 2018). However, in our study, the fMRI data were acquired 2h after the 
ketamine infusion when all the symptoms captured by the PSI have already been resolved 
and thus we did not expect to identify any significant correlations between the activation of 
these areas and the dissociative symptoms.  
It worth mentioning at this stage that our study has used, as the majority of clinical 
research involving ketamine in depression, an i.v. infusion protocol with a standard dose of 
0.5mg/kg. Contrary to that, most studies in their area of dissociation and psychosis have used 
a bolus-infusion paradigm. Depression studies that have used a continuous infusion (Berman 
et al., 2000, Krystal et al., 2013, Zarate et al., 2006) reported that although longer in duration, 
the infusion is well-tolerated by the majority of participants. However, to our knowledge no 
study exists that directly compared the tolerability between the two infusion protocols and 
whether they differ in the amount of psychotomimesis that they would induce. In our study, 
the drug infusion was generally well tolerated by our participants and in only two instances 
the infusion was prematurely terminate (5min before the end) due to excessive nausea.  
In general, our participants reported very strong dissociative and psychotomimetic 
effects, which as identified in previous ketamine studies, emerge within 10min from the start 
of the infusion and subside within 40min of the termination of the drug administration 
(Zanos et al., 2018). These dissociations, especially in the absence of any previous 
experiences with psychoactive drugs, were perceived by the majority of our volunteers as 
unpleasant.  
The generally “uncomfortable” state of the volunteers who were experiencing 
notable dissociative effects in a clinical environment was captured, at least partly, as an 
increase in the anhedonia subscale of the PSI (see Figure 9), something that in our group we 
have observed in previous ketamine studies (Wong et al., 2016). Moreover, the reduction in 
the scores of the SNK-W that was also administered right after the drug administration could 
also be attributed to the general discomfort that the ketamine infusion could have caused to 
our volunteers (see Figure 6). The increased anhedonia and reduced subjective well-being 
identified after ketamine’s administration would take time to normalise and that might delay 
the detection a significant improvement of anhedonia produced by ketamine as part of its 




3.4 Anhedonia and Subjective Well Being 
 
In our study anhedonia was not only measured right after the drug administration 
by the PSI subscale, but the SHAPS as well as the SWN-K were also used to asses anhedonia 
and subjective well-being, respectively. These scales were administered at the start of the 
day, right after the drug infusion as well as 2h after the end of the drug administration.  
In our study however, we did not observe a reduction in the SHAPS scores after 
ketamine administration (see Figure 5). In the literature, higher SHAPS scores have been 
associated with poorer treatment outcome in MDD and the scale is also sensitive to the 
“early” antidepressant effects of ketamine (Argyropoulos and Nutt, 2013). Specifically, 
studies that have used the SHAPS to explore ketamine’s effects in anhedonia during 
depression reported a significant reduction in the SHAPS scores as early as 40min post 
ketamine administration, indicating ketamine’s positive and rapid effects on anhedonia (Lally 
et al., 2014). A possible explanation for the absence of any changes in anhedonia 2h after 
ketamine, when the antidepressant effects of the drug should be detectable, could be 
attributed to the fact that for this study we chose to recruit remitted depressed volunteers. 
Our study participants do not experience any depressive symptoms at the time of 
the study and although anhedonia could persist during remission, in our cohort the baseline 
SHAPS scores are very low (see Figure 5). The low baseline scores indicate either the absence 
of anhedonia or its presence in very low levels. If anhedonia is indeed absent from our cohort 
then ketamine is not expected to produce any effect. If however, anhedonia is present but 
in very low levels then it is possible that ketamine, might require more time to produce any 
significant improvements in the hedonic capacity of our participants. It is moreover possible 
that the SHAPS might not have the sensitivity required to capture any very subtle effects that 
ketamine might have on the very low anhedonia levels of our cohort. 
The stressful and unpleasant effects that acute ketamine administration induces and 
have been experienced by the majority of our participants (see Figure 9) could offer an 
alternative explanation for the absence of any significant improvement in anhedonia 2h post 
the ketamine administration. Research has shown that anhedonia and stress are integrally 
related (Pizzagalli, 2014, Stanton et al., 2019, Treadway and Zald, 2011). According to 
Meehl’s theory, the ability to experience pleasure and anticipate it serves to protect us 
against the negative influences of stress and the potential development of psychiatric 
disorders including depression. Consistent with that theory animal models have shown that 
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chronic mild stress decreases the sensitivity to reward and produces anhedonic 
behaviour(Moreau, 2002) but also that dysfunction in the reward system could be reversed 
by antidepressants  as well as  ketamine (Belujon et al., 2014).  
The dissociative effects that are experienced by the majority of our participants 
under ketamine could be perceived as potentially stressful, causing an increase in anhedonia. 
This significant increase in anhedonia during the ketamine administration compared to 
placebo, has been captured by the anhedonia subscale of the PSI (see Figure 9). Moreover, 
the SNK-W scale which was administered right after the infusion, showed lower scores of 
well-being after ketamine administration (see Figure 6).  This finding was not present during 
the placebo session, although the interaction was not statistically significant.  It is thus 
possible that 2h after the ketamine infusion, anhedonia which is reduced due to the 
unpleasantness of the infusion would trend towards normalization. This could be indirectly 
reflected in the SHAPS score which 2h after the ketamine infusion, equals that of the baseline 
(start of the day). No correlations were identified however, between the PSI scores- total 
scores and subscale scores- with the SHAPS scores after ketamine. 
An interesting observation in our study concerns the SHAPS scores of the placebo 
session. A significant reduction in the SHAPS scores was observed between the baseline 
scores and those collected 2h post the saline infusion indicating a decrease in anhedonia. 
This decrease in anhedonia, 2h post the placebo administration, could be attributed to the 
participants’ reduced anxiety on the placebo day and/or the unavoidable stress of an 
intravenous infusion which is rather invasive. A common problem with ketamine studies is 
the absence of a good placebo. In our study and during the ketamine infusion the side effects 
produced by the drug, made it practically impossible to maintain the blind of the study since 
both the participants and the researches could accurately guess when ketamine was 
administered. Anhedonia measured after the infusion, could thus be decreased independent 
of whether the placebo session precipitates or follows the ketamine day, since in both cases 







In addition to the SHAPS, the SNK-W was used in order to assess the subjective well-
being of our participants at the start of each study day, right after the infusion and 2h post 
the drug administration (see Figure 6). The SWN-K is a well validated scale that includes 
questions around mental functioning, social integration, emotional regulation, physical 
functioning and self-control and assesses the “in the moment” well-being of participants. 
The scale has previously been used in order to assess subjective well-being, mainly in 
psychosis (Maurino et al., 2012). This scale was designed with the specific aim of measuring 
patients’ subjective experiences regardless of their mental state and medication 
stabilization. The SWN-K, to our knowledge has never been used before in a depression 
study. However, it has been extensively used in psychosis studies to assess participants’ well-
being in relation to their depressive symptoms and treatment outcome (Haring et al., 2013). 
Moreover, due to the nature of the questionnaire that assess the current mood of individuals 
and without asking them to imagine how they would feel in different scenarios, we believed 
it would be more sensitive to capture mood changes on the study day.  
Our results show that right after the drug infusion the SNK-W scores decrease, 
however, they return to baseline 2h after the ketamine administration. During the placebo 
session there are no significant changes in the scores of this scale. We believe that the lower 
SNK-W scores right after the ketamine infusion could further reflect the stressful experience 
of a psychoactive drug infusion. This effect, as we mentioned before, might also be reflected 

















Analysis of the behavioural data that were obtained from this study helped us better 
comprehend the cognitive characteristics of our volunteers and examine the acute and 
delayed- 2h post infusion- effects of ketamine.  
Rumination was present in our cohort of remitted depressed volunteers, however 
the luck of studies around remitted depressed individuals with the use of the RRS scale and 
the fact that the scores  in our study did not correlate with brain activations during AM recall, 
make it very difficult to link rumination in our cohort with depression-related processes. 
Moreover, in our cohort of remitted depressed volunteers we did not identify significant 
levels of anhedonia (SHAPS) or low mood (SNK-W) at baseline. The absence of anhedonia 
and the presence of rumination, taken together, constitute a rather interesting finding. 
Previous research has shown that anhedonia and rumination are two cardinal symptoms of 
depression that tend to persist, to a lesser extent, during remission (Pizzagalli, 2014, Abela 
and Hankin, 2011). The relationship between these symptoms and the neuronal pathways 
that could mediate reward processing as well as ruminative thinking is still unclear, especially 
in the absence of clinically significant depressive symptoms.  However, it is possible that the 
altered neuronal processes that underlie those symptoms might still be present but not 
behaviourally declared in a detectable way. The absence of anhedonia in our group, for 
example, does not necessarily mean that altered neuronal processing in brain areas 
associated with reward is also absent. 
As far as the drug effects are concerned, the administration of the PSI, right after the 
drug infusion, allowed us to capture the dissociative effects that ketamine produces during 
its administration as well as some of the discomforting and unpleasant aspects of an i.v. 
infusion of a psychoactive drug. The anhedonia and subjective well-being of our participants 
were measured at the start of each study session as well as 2h post the drug administration. 
The data from these scales indicate that 2h after its administration, when the antidepressant 
effects of ketamine are detectable, there are no significant changes in the anhedonia and 
subjective well-being in our cohort. This finding is not very surprising since our remitted 
depressed volunteers do not report high levels of anhedonia at the start of the day. 
Consequently, ketamine is not expected to produce a marked improvement in that 
symptom. Moreover, the drug administration might cause some discomfort to our 
participants and thus the two-hour interval between the infusion and the last administration 
of the SHAPS might not be enough to capture ketamine’s antidepressant action. 
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Take together all these findings highlight the suitability of our cohort for the study 
of the potential mechanisms of the early antidepressant effects of ketamine. Remitted 
depressed individuals, as the ones recruited for our study, seem to more closely resemble 
depressed patients both behaviourally but perhaps also in a brain activations level. In the 
two chapters that follow, we will try to investigate how AM recall and rumination as well we 
reward anticipation might be altered by ketamine, 2h after its administration, in our cohort. 
We will try to discuss the fMRI finding in relation  to the behavioural data presented in this 
chapter and link them to previous research findings. We hope that this would help us 


















The MID task 
1 Introduction  
 
In this chapter we will examine the delayed effects of ketamine on brain areas that 
are important for reward processing. The MID task is a well validated task that has been 
specifically developed in order to study reward processing in the MRI scanner (Knutson et 
al., 2001). In our study the task was performed 2h after the ketamine and placebo 
administration. The reward anticipation and the feedback phases of the task were analysed 
in order to examine ketamine’s delayed effects in  brains activations in our cohort of remitted 
depressed volunteers.  
In order to better understand how ketamine might influence brain activations during 
the MID task, we need to have a good understanding of the brain areas that are important 
for each of the different components of this task. For that purpose, first we isolated the 
placebo group and conducted a whole brain analysis in order to identify those brain regions 
that are significantly activated during reward anticipation and feedback, compared to the 
neutral component of the task. We also examined reward magnitude to identify those brain 
areas that might be implicated in the anticipation and feedback of a high and lower in value 
monetary rewards. Finally, we looked at “no win” trials, focusing only on the feedback phase, 
and aimed to identify brain areas that are important for “no win” feedback, compared to 
neutral feedback. We also looked at how the magnitude of reward during these unsuccessful 
“no win” trials might alter brain activity.  
An ROI analysis was conducted in the placebo group focusing on the role of the 
striatum, the amygdala and the insula for reward processing during the MID. These three 
brain areas are very important for reward processing and have also been identified in the 
literature as areas that present with altered activations in depressed and remitted depressed 
individuals. We examined the role of these ROIs in the different contrasts that were created 






The effects that ketamine administration might have in brain areas that are 
important for the MID was investigated by comparing the ketamine and placebo sessions for 
all the contrasts of interest. A whole brain level analysis was conducted to investigate 
ketamine’s antidepressant action during reward anticipation and feedback. Ketamine’s 
antidepressant effects during reward, different magnitudes of reward as well as during 
feedback for “no win” trials were also examined. Finally, we compared the ROI activations 
between ketamine and placebo in order to examine whether and how ketamine, 2h after its 
administration, would influence the activation of brain areas with a known role during 
reward processing. For this analysis the ROI activations were examined under different task 
conditions and compared between the two study sessions (ketamine session vs placebo 
session). 
The behavioural data of the MID task, including the RT (Reaction Time), the total 
winnings as well as the number of “win” and “no win” trials were also analysed for the 
placebo and ketamine sessions. Poor performance to the task, either during the ketamine or 
the placebo session, could exclude participants from the data analysis as we wanted to 
ensure that only trials from sufficiently engaged participants would be included. The 
behavioural data obtained from the two drug sessions were compared to examine whether 
ketamine would significantly alter performance to the MID task.  
 
Note 
For the analysis and discussion of the MID task we will be referring to the MID trials 
as successful trials when the expected reward was actually earned by the participants. The 
unsuccessful trials are those trials where the signalled reward was not obtained and are 
different to the neutral trials where the cue indicates that this trial is not be associated with 
a reward. Failure to obtain the signalled reward is not referred to as “loss” since in our 
version of the MID, unlike other versions with an actual loss condition, the amount of money 











The MID task is a reaction time task and successful performance of this task requires 
participants to make fast responses in order to win monetary rewards. The magnitude of the 
reward is signalled by the presentation of a specific cue. In order to perform the task 
successfully, participants are required to pay sufficient attention to the cues that precipitate 
the presentation of the target (circle with one line, circle with two line, triangle) and respond 
quickly to the target itself (white square).  
In order to ensure that our participants were appropriately engaged to the task, both 
during the ketamine as well as the placebo session, we looked at individual task performance 
during the two drug sessions and removed from our analysis any subject that exceeded 2SDs 
of the session average either in percentage of hits on win trials or on reaction time. To further 
ensure participants attention to the task, we excluded any individual with a response rate 
less than 66%. Response rate refers to a successful button press within the entire 500ms 
response window, regardless of whether the trial is a “win” or a “no win” trial.  
Although these cut offs are relatively conservative, we believe that they ensure our 
volunteers’ understanding and sufficient engagement to the MID task. Thus, any effects we 
might observe when we look at the placebo data or compare the ketamine with the placebo 
sessions can be attributed to the task and the effects of the drug and not due to fatigue or 
failure to successfully perform the task.  










2.1.1 Response rate and total MID winnings 
 
 Across all the trials of the MID task, including neutral trials where no reward is 
expected, participants maintained sufficient engagement to the task. Overall, our volunteers 
responded to at least 90% of the MID trials that required a button press, namely low win, 
high win and neutral trials.  
 
 
Figure 10.  Cumulative response rate (with SD bars) over duration of the task on trials that required a response 
(neutral trials, low win trials and high win trials). Ketamine did not significantly alter (paired t-test, p>.05) the 
trial wise response performance. 
 
Comparison between the ketamine and placebo sessions did not reveal a significant 











 In terms of the total amount of money that participants won during the ketamine 
and placebo session, no significant changes were identified between the two drug 
conditions. No significant changes were also identified when the reactions times for low, high 
and neutral reward were examined and compared between ketamine and placebo. Although 
in both the ketamine and the placebo sessions, reaction time significantly decreased when it 
was compared between the different reward magnitude trials.  
 
 
Figure 11.  The mean reaction time and the total amount of money won per trial did not significantly change 
between the ketamine and placebo sessions (paired t-test, p> .05). A significant reduction was identified in the 
reaction times of high, low and neutral win trials for both ketamine(Repeated Measure Anova, F(2, 36)=23.17, 


















2.2 Neuroimaging Results  
 
2.2.1 Reward anticipation in the placebo group at a whole brain level 
 
2.2.1.1 Anticipation of all win vs neutral 
 
` The first aim of this analysis was to replicate previous research where the MID task 
was engaging brain areas that have previously been identified as important for the task 
related processes of reward anticipation and feedback. As a result, for this initial analysis of 
the task, we focused on the reward anticipation phase of both high and low win trials and 
compared it to reward anticipation of neutral trials where no reward is expected.   
 
 
When all the win trials (high win trials and low win trials combined) of the task were 
compared to the neutral trials of the MID, during which no reward is expected, very strong 
increases and decreases were found in brain areas that have previously been identified as 
important for reward anticipation and are implicated in this task. Specifically, significant 
clusters of increased brain activations were identified in the SMA (Supplementary Motor 
Area), precentral regions, occipital areas, the cerebellum and the thalamus whereas 
decreases were identified in clusters including the middle temporal gyrus, the angular gyrus 
and the superior frontal gyrus (Figure 12). The significant clusters of increased and decreased 
brain activity are summarised in Tables 6 and 7 respectively. While the ventral striatum is 
included as part of the clusters, but we examined this a priori region using ROI analysis (see 
below). 
 
Figure 12.  A whole brain analysis revealed that several brain regions presented with significant increased (red) 
and decreased (blue) activations in the placebo group. The contrast that was examined here combined the 
anticipation phase of high and low win trials and compared to anticipation phase of the neutral trials, where no 





Table 6.Several significant clusters present with significantly increased activations when the anticipation phase 




Table 7. The clusters that present with significantly decreased activations when the anticipation phase of high 











2.2.1.2 Reward magnitude during reward anticipation 
 
In order to examine the role of reward magnitude during the anticipation phase of the 
task we contrasted the anticipation phase of high win trials to the anticipation phase of low 
win trials.  The brain areas that present with increased activations when a high reward was 
anticipated compared to a low win trial included the cingulum, the SMA and inferior occipital 
areas (Figure 13). Table 8 summarises the voxel clusters that presented with increased 
activation during high compared to low reward anticipation. The ventral striatum is included 




Table 8. The clusters that presented with increased activation, when reward magnitude was examined, are 








Figure 13.  When the anticipation phase of low reward and high reward trials were compared, significant 




2.2.2 Feedback in the placebo group at a whole brain level 
 
2.2.2.1 Feedback from successful high reward and low reward MID trials, compared to the 
feedback of neutral trials 
 
The feedback phase of the successful trials of the MID task (high and low win trials) 
was analysed in the placebo group in order to identify brain areas that are important for this 
phase of the task. We found that earning the signalled reward, despite its magnitude, 
produced significant decreases in brain areas that included the precentral gyrus, superior 
frontal regions, inferior parietal and middle frontal areas (see Figure 14). Significant increases 




Table 9.  The clusters that presented with decreased activation during the feedback phase of the successful MID 







Figure 14. Significant decreases (blue) in the activation of frontal brain areas during the feedback phase of 
successful high reward and low reward trials when compared to the feedback component of neutral trials. 
114 
 
2.2.2.2 Feedback from unsuccessful high reward and low reward MID trials, compared to 
the feedback of neutral trials 
 
When the feedback phases of low and high win unsuccessful trials, where 
participants did not win the expected reward, was contrasted to the neutral phase of the 
task, significant increases were identified in occipital, parietal and temporal brain areas. The 
post central region presented with decreased activations during the feedback phase of 




Table 10. The clusters that presented with significantly increased and decreased activations during the feedback 
phase of the unsuccessful MID trials are presented in this table. The MNI coordinates of the peak of the cluster 








Figure 15.  Occipital, parietal and temporal brain areas presented with significantly increased activations during 
feedback of unsuccessful  trials compared to feedback from neutral MID trials. Significantly decreased 




2.2.2.3 Reward magnitude during the feedback phase of the MID task 
 
When the feedback phase of high win trials was contrasted to the feedback phase of low 
win trials we found that one cluster located in the cingulum presented with significant 
decreases for the high win feedback phase compared to the low win feedback phase of the 
MID task (see Figure 16 and Table 10).  
 
 
Figure 16.  The cingulum presented with significantly decreased activation when the feedback phase of  high 
reward MID trials was compared to the feedback phase of a low win trials. 
 
 
Table 11.  One cluster of significant decreases in brain activity was identified when reward magnitude was 



















2.2.3 The effects of ketamine on the MID task 
 
2.2.3.1 Ketamine and reward anticipation 
 
Ketamine did not produce any significant changes during reward anticipation when 
high win and low win trials were combined and compared to the neutral trials at a whole 
brain level. Moreover, no significant changes were identified when the level of reward 
magnitude (high win anticipation vs low win anticipation) was compared between the 
ketamine and placebo sessions. 
2.2.3.2 Ketamine and feedback 
 
 When the feedback phase of the task, for both successful and unsuccessful MID 
trials, was examined and compared between the ketamine and placebo sessions, we did not 
identify any significant changes on brain activations. Moreover, no significant changes were 
identified when the feedback phase of high win trials was contrasted to the feedback phase 



















2.2.4 ROI Analysis 
 
2.2.4.1 In the placebo group 
 
The role of the a priori identified ROIs was examined during the MID task. The 
striatum, the amygdala and the insula presented with significant activations during reward 
anticipation and feedback of the high and low win reward trials compared to the neutral 
trials of the MID. Moreover, several of these ROIs presented with significant activations 
when the role of reward magnitude during anticipation and feedback was examined.  
Since we did not have a strong hypothesis as to how the different components of the 
MID task –anticipation, feedback and reward magnitude- might alter the role of our ROIs 
concerning their lateralisation, we decided to primarily investigate our ROIs bilaterally. 
However, we did examine the involvement of our ROIs by extracting beta values for the left 
and right ROI as well. This analysis is exploratory, thus we did not apply multiple comparison 
correction to the significant p values obtained from it. The results from this analysis can be 
found in Appendix G.  Table 11 showa only the bilateral ROIs and highlights in red the mean 
beta value and standard deviation of thosethat survived  Bonferroni correction for multiple 
comparisons.  
 
Table 12.The mean activation values are shown here for each bilateral ROI along with the SD. The values in red 






2.2.4.2 The effect of ketamine 
 
The role of our a priori defined ROIs was examined between the ketamine and 
placebo sessions. We investigated the role of our ROIs for all the task contrasts that were 
explored under placebo namely, the reward anticipation, magnitude of reward and the 
feedback components of the MID trials. In this section we will present the task contrasts for 
which significant results were obtained. ROI analysis involved, as in the placebo session, 
bilateral ROIs and the corresponding left and right lateralized brain areas. Bonferroni 
correction was applied to the results of this analysis and only ROIs that survived this 
correction are presented.  
2.2.4.3 Reward Anticipation 
 
We found that during the anticipation phase of low reward trials compared to 
neutral trials, when no reward is expected, ketamine significantly increased the activation of 
the caudate bilaterally. Significant activations were also identified for the left caudate (not 
corrected for multiple comparisons).  In this analysis the anticipation phase of the high win 
trials included both successful as well as unsuccessful MID trials. 
 
Figure 17. Ketamine, during the anticipation of a low reward compared to neutral, significantly increased the 






2.2.4.4 Feedback of a successfully obtained reward 
 
During the feedback phase of the MID we found that ketamine significantly 
increased the activations of the bilateral insula and the ventral striatum during the feedback 
phase of a low win trials compared to neutral.  For this analysis only successful trials were 
included. 
 
Figure 18.  Ketamine, 2h post the drug administration, significantly modulated the activation of the ventral 
striatum and the insula during the feedback phase of a successfully obtained reward. The red asterisk indicates 
that the change was still significant after Bonferroni correction. In our exploratory analysis, the left ventral 













2.2.4.5 Feedback of unsuccessful MID trials 
 
2.2.4.5.1 High Reward loss  
 
When the feedback phase for a high reward unsuccessful trial was compared to the 
feedback phase of neutral trials, it was found that ketamine significantly increased the 
activation of the bilateral insula.   
 
Figure 19.  During the feedback phase of MID trials where a high reward was anticipated, the bilateral insula, 
presented with increased involvement after ketamine compared to the placebo session. The red asterisk 
indicates that the change was still significant after Bonferroni correction. The left and right insula were also 













2.2.4.5.1.1 Low Reward unsuccessful trials 
 
The feedback phase of a low reward unsuccessful trials was compared to the 
feedback phase of neutral trials and it was found that ketamine significantly increased the 
activation of the caudate, bilaterally.  
 
Figure 20. The bilateral caudate appears to be significantly more activated after ketamine compared to placebo 
when feedback for unsuccessful low reward MID trials is presented to participants. The red asterisk indicates 
that the change was still significant after Bonferroni correction. The left and right caudate also present with 















2.2.4.5.1.2 High and Low Reward Loss 
 
When the feedback phase of both high and low reward unsuccessful trials was 
compared and contrasted to feedback from neutral trials, ketamine significantly altered the 
activation of the bilateral VTA, left amygdala and left VS.  
 
Figure 21. When the feedback phase for high and low reward unsuccessful  trials was examined between the 
ketamine and placebo sessions, we found that there increased involvement for the bilateral VTA and the left 
amygdala for that contrast. The red asterisk indicates that the change was still significant after Bonferroni 
correction.  The left ventral striatum and left VTA also present with increased involvement for that contrast. 
 
2.2.4.6 Effect of session 
 
In order to investigate whether there is an effect of session in our study, we analysed 
separately the MID data that were acquired when ketamine was administered on the 1st 
session. These data were compared to the ones acquired when placebo was administered 
on the 1st session.  For this analysis a total of 18 participants were included in each group. 
Reward anticipation as well as feedback and the role of reward magnitude were examined 
and compared between the two groups using a two-sample t-test.  








The MID task has been used in this study in order to examine the delayed effects of 
ketamine on motivational anhedonia in remitted depressed volunteers.  Specifically, we 
investigated whether ketamine, 2hours after its administration, when the antidepressant 
effects of the drug become detectable, would alter the performance and brain activations 
produced by this task, compared to placebo. For that purpose, the anticipation and feedback 
phases of the MID trials were examined in the placebo group and compared between the 
ketamine and placebo sessions. Moreover, the effect of ketamine on reward magnitude 
during anticipation and feedback was also investigated. An ROI analysis was conducted in 
order to detect any delayed effects of ketamine on a priori defined brain areas that are 
important for reward processing.  
Summary of findings in the placebo group 
 
Analysis of the MID task in the placebo group revealed that anticipation of an 
expected reward, despite its magnitude, produced significant increases in the activation of 
precentral brain areas, the cerebellum and the thalamus (see Figure 12). Decreased 
activations were identified, for the same contrast, in temporal areas, the precuneus and 
middle and superior frontal regions.  When the effects of reward magnitude were examined, 
it was shown that during the anticipation of a high reward, compared to a low reward, brain 
activity significantly increased in the anterior cingulum, superior frontal regions including the 
SMA and inferior occipital areas (see Figure 13).  
During the feedback phase of the task, decreased activations were found in inferior 
and superior frontal areas when the monetary reward, despite its magnitude, was 
successfully won by the participants (see Figure 14). When the feedback phase of 
unsuccessful trials- where no reward was obtained - was compared to that of neutral trials, 
it was shown that significant increases were produced in several brain areas including frontal 
superior regions, occipital areas and the fusiform gyrus. Significant decreases for that 
contrast were located in the left post central gyrus (see Figure 15). We also found that during 
the feedback phase of successful high win trials, the activation of the middle cingulum 
significantly decreased, compared to the feedback phase of low win trials(see Figure16).  
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When the role of the striatal ROIs was examined, it was shown that during reward 
anticipation the activation of the insula, the putamen and the VS bilaterally, decreased 
significantly during reward anticipation of “win” compared to neutral trials. Moreover, the 
VS and VTA presented with significantly decreased activation when anticipation of high win 
trials was compared to low win trials. During the feedback phase of the MID the VTA 
presented with decreased activity for unsuccessful low win trials compared to neutral trials 
(see Table 11).  
Summary of findings for ketamine session vs placebo session 
 
Ketamine, 2hours after its administration did not significantly alter the performance 
to the MID task (see Figure 11). Specifically, when the total amount of money that was won 
during the task and the average reaction times for low win, high win and neutral trials were 
compared between the ketamine session and placebo session, we did not identify any 
significant changes between the drug conditions. Moreover, participants maintained 
sufficient engagement to the task since they responded to at least 90% of the trials both after 
placebo and ketamine administration (see Figure 10).  
At a whole brain level, ketamine did not produce any significant changes in any of 
the contrasts that were examined, for the anticipation and feedback phase of the task. 
Ketamine also failed to produce any significant effect when reward magnitude was examined 
in the whole brain analyses.  
When the effects of ketamine on the a priori defined ROIs were examined, we found 
that during reward anticipation, ketamine significantly increased the involvement of the 
bilateral caudate when a low reward was anticipated compared to neutral trials (see Figure 
17). The drug effects were more prominent during the feedback phase of the MID task. 
Specifically, when the feedback phase of successful low win trials was compared to neutral, 
ketamine increased the activation of the insula and the VS, bilaterally (see Figure 18). When 
the feedback phase of unsuccessful trials was examined, it was found that ketamine 
significantly increased the activation of the VTA, bilaterally. Moreover, during the feedback 
phase of unsuccessful high win trials, compared to neutral trials, ketamine significantly 
increased the activation of the bilateral insula (see Figure 19) whereas during the feedback 
phase of unsuccessful low win trials compared to the feedback phase of neutral trials, 
ketamine significantly increased the activation of the caudate, bilaterally (see Figure 20).  
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3.1 The MID task in the placebo group 
 
3.1.1 Whole Brain Analysis 
 
The MID task is a motivation task, specifically designed to examine reward 
processing with the use of fMRI. The design of the task allowed us to distinguish between 
the anticipation and feedback phases of each MID trial and identify brain areas that are 
significantly activated during each phase, in remitted depressed volunteers.   
 One of the brain areas that presented with increased activation during the 
anticipation phase of the MID task was the SMA (Figure 12). The SMA is involved in cue 
related processing and is also important for internal generation and preparation of motor 
activity. In our analysis the SMA presented with increased activation during the anticipation 
phase of trials that could actually bring monetary rewards, compared to the neutral ones, 
this would indicate the increased engagement of the participants during reward related trials 
compared to neutral trials. This finding is in line with previous research for this task, showing 
that the MID is also a motor task and as such it produces activations in the primary motor 
cortex, somatosensory areas as well as the SMA (Knutson et al., 2000).  That increased 
engagement to the task could also be interpreted as increased motor preparation for 
upcoming responses which are controlled by the SMA (Forstmann et al., 2008). The SMA also 
appeared with increased activations when the anticipation phase of high win trials was 
compared to low win trial anticipation (Figure 13), this finding further underlies the specific 
role of that area during the “win” trials of the MID task were a monetary reward could be 
obtained. 
The thalamus is another brain area that presented with increased activation during 
reward anticipation of the MID trials associated with an actual monetary reward (high win 
and low win trials) compared to neutral trials (Figure 12). The thalamus along with the NAc 
and the insula are the three main brain regions that form the reward neurocircuitry (Cho et 
al 2013). The reward neurocircuitry is responsible for translating motivation into motor 
responses. Meta-analyses of reward processing in healthy volunteers have revealed that 
these areas are equally involved during the anticipation of a win or loss (Oldham et al., 2018; 
Wilson et al.,2018) and also during the anticipation and successful outcome of reward trials 
(Oldham et al., 2018) and present with increased activations for these contrasts compared 




The significant involvement of those brain areas both during anticipation and 
feedback could lead to the conclusion that they have a broader role during reward processing 
in general, and their activation is not dependent on the phase of the task. Another potential 
role for the thalamus during the MID task is related to the fact that this brain area acts as a 
hub, processing and transmitting information to and from several neuronal pathways.  
The thalamus, with its role as a hub, receives strong input from the visual system and 
this input plays an important alerting role for salience detection (Usrey and Alitto, 2015). 
Through the thalamus-striatal pathway, the thalamus could relay the visual information to 
cholinergic neurons that could create a substrate for the suppression of ongoing motor 
activity in the face of salient external cues such as the ones that are presented during the 
MID task (Cho et al., 2013, Haber and Knutson, 2010). As a result, the thalamus has a critical 
function to adjusting behaviour to incentives. Since the high and low reward MID visual cues 
have a higher incentive compared to the neutral cues, that area might present with increased 
activations in order to monitor the participants’ behaviours and prevent any premature 
responses. This role of the thalamus could be considered in conjunction with the increased 
activation of the SMA which was present during reward anticipation of high and low win 
trials, compared to neutral trials but also during high reward anticipation compared to low 
reward anticipation. The increased activation of the thalamus could help control the motor 
preparation, signalled by the SMA and thus potentially ensure accurate performance of the 
MID task. 
During the feedback phase of unsuccessful trials, irrespective of the magnitude of 
the lost reward, frontal as well as occipital brain regions along with inferior temporal areas 
appeared with significantly increased activation (Figure 15). These areas have been linked in 
the literature with attentional processing (Arrington et al., 2000). Unsuccessful MID trials 
could be the result of a missed response, when volunteers do not respond at all to the target, 
or they could be the outcome of a not fast enough response to the target. Missed responses 
have been excluded for the analysis and as a result the brain activations that are associated 
with unsuccessful trials arise from the volunteers’ slower reaction to the presentation of the 





When feedback is received about trials that were not successful, the increased 
activation in occipital and temporal areas could reflect the participants increased attention 
to the task, as a response to the negative feedback that they have received. A similar cluster 
of areas was activated during the feedback of successful high and low win trials compared to 
the neutral ones (Figure 16). However, during this contrast these brain areas presented with 
decreased activations for high and low win feedback compared to the neutral feedback. As 
mentioned before the activation of these brain areas is associated with attention (Arrington 
et al., 2000). It is also possible that during feedback for successful trials, despite their reward 
magnitude the attention that our volunteers pay to the task is decreased as they relax their 
cognitive efforts in order to perhaps enjoy the obtained reward.  
3.1.2 The role of the predefined ROIs to the MID task 
 
 Several of the brain areas that were significantly activated during reward 
anticipation and feedback of the MID task in the whole brain analysis have been previously 
identified in the literature as important for this task. However, key regions of the reward 
processing network, do not present with significantly increased activations in our data from 
the placebo session. These key regions include striatal areas, the amygdala, and the insula 
which were part of the clusters that presented with increased activations during reward 
anticipation and magnitude of reward, but their activations do not exceed the significance 
threshold. The position of these areas in the brain is associated with an increased signal drop 
out during fMRI which is mainly localized around the striatum which could be contributing 
to the absence of these areas for our significant results, in the whole brain level.  For this 
reason and because these are areas we know to be involved in this task, we applied an a 
priori defined ROI analysis for these areas allowing us to investigate the changes in activation 
of these regions during reward processing and anticipation of the MID task.  
 The a priori ROIs that we have chosen to examine as part of our MID analysis are 
areas that are associated with reward prediction processing and are also part of the salience 
network. The study of the neuronal mechanisms involved in reward processing, mainly in 
primates, revealed that reward prediction is mediated by dopaminergic neurons in the 
striatum (Schultz, 2016b, Schultz, 2016a, Schultz et al., 1993). Moreover, during the different 
phases of the task, the salience network is activated, which directs the individual’s attention 
towards reward-associated stimuli. The amygdala and the insula are part of that network 
and along with the VTA and the regions of the ventral and dorsal striatum, comprise the ROIs 
we chose for this analysis (Izquierdo and Murray, 2007).  
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Several of our a priori defined ROIs presented with significant activations for the 
different contrasts of the MID task that have been examined in the placebo session (see 
Table 11). Specifically, during reward anticipation of low and high win trials, compared to 
neutral trials, the activation of the insula, the putamen and the VS were increased. Moreover, 
increased involvement of the VTA and VS was also identified when the anticipation phase of 
high win trials was contrasted to that of low win trials.  
Several meta-analyses of fMRI studies that have investigated the neuronal processes 
that underlie reward anticipation and feedback, for both successful and unsuccessful trials, 
have concluded that anticipating as well as receiving a reward involves engagement of the 
VS (for meta-analysis results see (Oldham et al., 2018)). This brain area is involved in reward 
prediction, during the anticipation of the expected reward but is also implicated in positive 
or negative prediction error that arises from the feedback phase of successful or unsuccessful 
trials respectively.  
Although the role of the VS in reward processing is very well established, other 
finding suggest that this brain area could be ascribed a much broader function which also 
extends to motivational processing. In our data, VS activation appears to be increased during 
the anticipation of both high as well as lower in value monetary rewards. This finding is in 
line with animal and human research indicating that the VS, and especially the NAc core, is 
associated with motivation related functions such as behavioural activation, exertion of 
effort and sustained task engagement that are independent of the valence of the expected 
reward (Salamone et al., 2016).  
Many of the above described actions, especially sustained attention and 
engagement to the task are essential during performance of the MID. In our data, whole 
brain analysis revealed that brain areas associated with attention are activated during the 
feedback phase of unsuccessful trials (Figure 15). This finding indicates that sustained 
attention could be essential for successful task performance. Thus, the increased activation 
of the ventral striatum during anticipation of both high and lower value rewards, could be 
contributing to successful performance to the MID, as indicated also by the behavioural data 






In our data VS activity also appeared to be increased during the anticipation phase 
of high win compared to low win trials in the placebo group (see Table 11). As mentioned 
before, the VS and especially the NAc core, have a central role in encoding the motivation 
salience of stimuli (Mannella et al., 2013). MID trials that are associated with higher 
monetary rewards carry a greater salience value compare to low win trials and thus 
activation in brain areas that are associated with motivational processing is expected to be 
increased. The VS and especially the NAc, is also thought to mediate cognitive functions such 
as cognitive control and effort that are important for the MID (Haber et al., 2010). The fact 
that the VTA also appeared with increased activation for this contrast is not surprising since 
the neuronal processes that are important for motivational processing and depend on the 
VS could be directly modulated by the VTA.  This modulation occurs via dopamine producing 
neurons that initiate from the VTA and project to the VS. These neurons modulate VS activity 
during the anticipation of both loss as well as gain (Carter et al., 2009).  
During the feedback phase of the MID task and when unsuccessful low win trials 
were compared to feedback from neutral trials, the VTA presented with increased activation 
for the placebo session (see Table 11).  The VTA is a brain area with an important role in the 
motivational aspects of reward processing and is also functionally and anatomically 
connected to the VS (Carter et al., 2009). A common finding in studies with depressed 
individuals who perform anhedonia related tasks, such as the MID is the blunted responses 
of these individuals to feedback. The blunted response to feedback in depression has been 
associated with reduced activations in the VS (Pizzagalli et al., 2008, Stoy et al., 2012), an 
area that is directly modulated by the VTA (Carter et al., 2009).   
In our study the MID is performed by remitted depressed volunteers who although 
recovered from depression might still present, with some of the characteristics of the illness. 
If a reduced response to feedback which is associated with reduced motivation and effort to 
obtain a reward still persists during remission, this would be much easier detectable in low 
reward trials. These trials would have a lower prediction value, compared to the high reward 
trials, in which the increased value of reward might be sufficient to overcome any deficit. It 
is thus possible that in our cohort of recovered depressed individuals the increased activation 
of the VTA would contribute to increased motivational processing that is required to 





3.2 The Effects of ketamine’s on the MID task  
 
3.2.1 Whole Brain Analysis 
 
Ketamine’s effects on the MID task were first examined on a whole brain level. 
Reward anticipation, feedback as well as reward magnitude were compared between the 
ketamine and placebo sessions and it was shown that ketamine did not produce any 
significant changes in brain activation, 2h after its administration at a whole brain level.  
3.2.2 The role of the predefined ROIs to the MID task 
 
When we examined the drug effects on our a priori identified ROIs during the 
different task conditions, ketamine produced significant changes in the activation of those 
ROIs. Specifically, significant changes were identified, for the ketamine session compared to 
placebo, both during the reward anticipation as well as the feedback phase of the MID trials. 
However, ketamine’s effects 2h after the administration of the drug seem to be more 
prominent during the feedback phase of the MID.  
3.2.2.1 Ketamine’s effects on the task- Reward anticipation 
 
During the anticipation of low win compared to neutral trials, we found that 
ketamine significantly increased the activation of the caudate, compared to placebo (Figure 
17). In the literature the caudate is involved in signalling the reward magnitude of specific 
cues. Specifically, previous studies  (Lutz et al., 2012) which focused on the close inspection 
of the time-course of activation of this region during the different phases of the MID task, 
revealed that the caudate is involved in reward processing but representing not only the gain 
or loss of a reward but also reward magnitude. Moreover, animal as well as human research 
has shown that the caudate, as part of the dorsal striatum, receives various input associated 
with reward and feedback from cortical regions (VMPFC, OFC, ACC) as well as limbic areas 
including the amygdala and the hippocampus. This input is integrated at the caudate and 
translated into action via signalling to the basal ganglia (Haber and Knutson, 2010) . The 
increased activation in that striatal region bilaterally, 2h after ketamine, could thus help 
increase the reward magnitude of cues associated with lower monetary rewards  and 




In depression literature, the two meta-analyses that have looked at reward 
processing in depressed individuals have consistently identified decreased activations in the 
caudate of those patients relative to healthy individuals. Specifically, when the MID task was 
examined, the reduced caudate activity was present both during reward anticipation and 
feedback in patients with MDD (Keren et al., 2018, Zhang et al., 2013). Given the importance 
of the caudate in reward processing and its altered function in depression which is associated 
with blunted responses to feedback and anhedonia that area would be a good target for 
improving anhedonia in MDD. The increases in the activation of the region that we observe, 
2h after ketamine, when the antidepressant effects of the drug are detectable, could indicate 
a possible mechanism for ketamine’s positive effects on anhedonia. 
3.2.2.2 Ketamine’s effects on the task- Feedback 
 
When the feedback phase of successful and unsuccessful trials was examined 2h 
after ketamine administration we found that during successful trials, ketamine increased the 
activation in the insula and VS for low win compared to neutral trials (Figure 18). The VS as 
mentioned before, is an area with very broad function during reward processing as well as 
motivational processing and presents with decreased activation in depressed as well as 
remitted depressed volunteers (Mannella et al., 2013, Haber et al., 2010). Specifically, during 
remission from depression, volunteers presented reduced VS responses to primary 
rewarding stimuli, compared to healthy controls. These reductions in VS activity have been 
associated with reduced response to positive feedback in depression (Must et al., 2013) and 
increased risk for relapse in remission (McCabe et al., 2010). Antidepressant medication has 
been shown to normalise striatal activations, indicating that reward related deficits could be 
reversed after treatment (Stoy et al., 2012).   
Given the role of the VS in depression and in remission, as well as the fact that this 
area is a target for antidepressant treatment action, we could hypothesize that the ketamine- 
induced increases in the activation of the VS would have a positive effect on the feedback 
processing of successful MID trials. The fact that these increases were observed in our cohort 
of remitted depressed volunteers, would further underline, the proximity of reward related 






Another ROI that presented with increased activation during the feedback phase of 
unsuccessful low win trials compared to neutral trials, when the ketamine and placebo 
sessions were compared, was the VTA (Figure 20). The VTA which also presented with 
increased activation in the placebo group for the same contrast, is thought to play an 
important role in signalling prediction errors via dopamine neurotransmission . Moreover, 
along with the NAc, they have a central role in representing the motivational and affective 
valence of unanticipated outcomes (Carter et al., 2009). Specifically, a modulatory role of the 
VTA has been identified in shaping memory, since increased activation of that brain area has 
been positively correlated with improved recall for stimuli associated with greater potential 
rewards (Adcock et al., 2006).  
The increased activation of the VTA in the placebo group during the feedback phase 
of unsuccessful low win trials was associated with the increases motivational salience that 
might be attributed to these trials in order to ensure adequate performance to the task. The 
ketamine induced increase that is observed in that area 2h after the drug administration and 
under the same task contrast, could indicate that ketamine would also works towards 
increasing the salience of those low win unsuccessful trials, making the VTA another possible 

















Ketamine, 2h after its administration, produces significant changes in the activation 
of brain areas that are associated with reward processing and the MID task, in remitted 
depressed volunteers. At this timepoint in the course of our study, when the changes in brain 
activations are detected, the dissociative and psychotomimetic side-effects that are 
associated with acute ketamine administration and might be experienced by some 
participants have completely been resolved. Moreover, while the drug is still present in the 
blood, ketamine’s concentrations are very low any thus any effects on neural processing that 
ketamine might produce, could be attributed to its active metabolites (Zanos et al., 2018) as 
well as the remodelling of neuronal architecture induced by the drug (Li et al., 2017) and 
have been associated with the antidepressant effects of the drug 
Despite the neuronal and molecular mechanisms that underlie those effects, 
ketamine’s delayed effects on the MID task, demonstrate as increases in the activity of 
striatal areas, that are important for reward processing and motivation. Specifically, during 
reward anticipation ketamine increased the activation of the caudate when low win trials 
were contrasted to neutral trials and the ketamine session was compared to placebo. For the 
feedback phase of the MID task, significant increases were identified after ketamine, for the 
insula and the VS, when the feedback phase of unsuccessful trials was compared to that of 
successful trials. Finally, the VTA presented with increased activation, when ketamine was 
compared to placebo, for the feedback phase of unsuccessful low win trials compared to 
neutral.  
In our study, ketamine’s effects on the MID task are more prominent during the 
anticipation and feedback phases of low win trials as well as the feedback phase of 
unsuccessful trials. Altered reward processing in depression has mainly be associated with 
decreased motivation as well as blunted responses to feedback (McCabe et al., 2010, 
Pizzagalli et al., 2008, Treadway and Zald, 2011, Zhang et al., 2013).  The remitted depressed 
volunteers that took part in our study might still present with some of the altered brain 
activations in reward related areas, that is associated with depression. This could explain why 
ketamine’s effects are more prominent in low win and unsuccessful trials since these trials 
would be associated with reduced reward magnitude and could require increased effort and 
motivation and could be associated anhedonia. 
134 
 
Finally, most of the ketamine induced increases in brain activity that we observe in 
our cohort occur in ROIs of the reward processing network that have presented with 
decreased activation in depressed patients, compared to healthy controls, when the MID 
was examined(Keren et al., 2018, Zhang et al., 2013). Some of these areas have also been 
previously identified as antidepressant medication targets that include the VTA, the VS and 
the insula (McCabe et al., 2010). These findings further indicate that ketamine’s delayed 
effects in our study could be directly related to the drugs antidepressant mechanisms and 























The VAMP  
1 Introduction 
 
Overgeneral AM recall is one of the most common characteristics of depressed 
individuals. Several brain areas have been identified in the literature as important for AM. 
However, it remains unknown whether the valence of the recalled memories would 
influence the brain areas that are activated during AM retrieval.  Moreover, very little is 
known about the early antidepressant effects of ketamine on brain areas such as the 
amygdala, the ACC and the PCC that are considered key for AM and are also affected in 
depression.   
For the purpose of this study we have developed the VAMP task, a personalised AM 
paradigm, which allows participants to recall and ruminate about autobiographical positive, 
negative and neutral life events in the MRI scanner. One component of this task involves 
rating, using a VAS scale, how positive or negative individuals feel thinking about the events 
at the time of their participation to the study. This way we can study not only AM recall and 
rumination but also the effects that the subjective emotional valence of the recalled 
memories could have on brain areas that are activated during the task. In the chapter that 
follows we examined the brain activations produced during the VAMP in order to identify 
the brain areas that are activated during recall of positive, negative and neutral AMs, in the 
placebo group.  
This analysis will help us determine which brain regions are significantly activated 
during general AM recall, in remitted depressed volunteers and examine whether the 
valence of the AMs alters the brain areas that are activated during their recall. Moreover, we 
used a PPI analysis to explore the connectivity, during the different task contrasts. Using a 
priori identified ROIs which include the bilateral amygdala, ACC and PCC we compared the 







Ketamine’s effects on the VAMP, 2h after the drug administration, were first 
examined by looking at the VAS ratings for each event. These rating were compared to those 
obtained during the placebo session in order to examine whether ketamine would 
significantly alter the subjective emotional valence of the AM events that are recalled during 
the task.  Furthermore, by examining the different task contrasts between the ketamine and 
placebo sessions, we investigated whether ketamine could significantly change brain activity 
during AM recall of positive, negative and neutral events.  
Using the PPI approach, we examined the effects of the drug on task connectivity. 
Specifically, we investigated whether ketamine, 2h after its administration, would 
significantly alter the connectivity between our pre-selected ROIs and the rest of the brain, 
compared to placebo. Finally, we used the VAS ratings from the two study sessions to 
examine whether brain activity during positive, negative and neutral recall would correlate 























2.1 Behavioural Analysis 
 
 Analysis of the VAMP task started by looking at how many statements were 
recognized as “TRUE” by our participants. During the decision phase of the VAMP task as 
described in our methods (see page 76), participants have 6 secs to decide whether a 
statement referring to a particular event is “TRUE” or “FALSE .Those participants who failed 
to respond within that 6 sec window and/or falsely identified more than 20% of the 
statements from each study session (6 statements out of a total of 30 statements) were 
excluded from the analysis as it was deemed that they were not paying sufficient attention 
to the task. Based on that cut off all participants were included in the analysis. 
In order to get an understanding of the subjective emotional valence of the three 
types of events, positive negative and neutral, that were examined with the VAMP task, we 
averaged separately, the VAS ratings that were obtained for each statement belonging to 
each event type. In our average we included only ratings from statements that were 
recognised as “TRUE” from the participants and were actually true, according to the 
individuals’ original description of the event on the interview day. Moreover, any ratings of 
positive statements that were below 60, any rating of negative statements that were above 
40 and any ratings of neutral statements that were below 40 and above 60 were excluded 
from the analysis. Although these cut-offs are arbitrary, we believe that these statements 
would not be representative of the valence of the event types that they belong to. These 
statements were also excluded from the fMRI analysis.   
Moreover, the individual ratings from the positive and negative event form each 
participant,  were compared to the neutral average and any statements from those events 
(positive and negative) that were rated  within 2SDs from the neutral average were excluded. 
The reason for that is that we believe that participants would consider them neutral at the 
time of the scan.  Only three statements from each different volunteer were excluded based 







2.2 Neuroimaging results 
 
2.2.1 Whole brain analysis of AM recall and rumination in the placebo session 
 
The fMRI data analysis included only statements that were identified as “TRUE” by 
our participants and were actually true, according to the volunteers’ original narrative of the 
events during the interview day. The retrieval phase from these events was then used to 
examine brain activity under different contrasts and compare it between the ketamine and 
placebo sessions. 
2.2.1.1 Positive, negative and neutral events compared to the control condition 
 
In order to identify the brain areas that are important during active recall of the 
VAMP events, compared to the task’s control condition, we examined the retrieval phase of 
true statements of all events (positive, negative and neutral) and contrasted them with the 
control condition. During active recall, several brain areas that have previously been 
identified as important for AM retrieval in the literature present with significantly increased 
activations compared to the control condition.  
 
Figure 22.  Whole brain analysis of the VAMP in the placebo group revealed significant increases (red) and 
decreases (blue) in the activation of several brain areas, during recall of positive, negative and neutral memories 







Table 13. Active retrieval during the VAMP task, compared to the control condition revealed increased 
activations in three clusters and siginificant decreases in two. The MNI coordinated for the peak of each cluster 
are also presented. The valence of the recalled memory in the Placebo group 
 
 
When we compared the retrieval phase of positive and negative memories to that 
of neutral memories and we did not identify any significant changes in brain activity in the 
placebo group. No significant changes were also identified when we compared the retrieval 
phases of the positive to the negative memory trials. These findings could indicate that the 
brain areas that are important for AM recall during the VAMP, do not change when the 
emotional component of the recalled memory changes.  
 
2.2.2 PPI analysis of the amygdala connectivity during the placebo session 
 
PPI analysis allowed us to investigate the connectivity between our seed regions and 
the rest of the brain, under the different task conditions. For the purpose of this analysis we 
looked at the retrieval phase of the positive and negative AMs and compared it to the 
retrieval phase of the neutral memories. From the three seeds that were a priori defined for 
this analysis and included the bilateral amygdala, the PCC and sgACC only the bilateral 










2.2.2.1 Retrieval phase of positive AM recall compared to neutral AM recall 
 
Specifically, in the placebo group and during recall of positive AMs compared to 
neutral, the amygdala showed increased connectivity, bilaterally, mainly with the lateral 
occipital cortex, the precentral gyrus and the occipital/fusiform gyrus. Decreased 
connectivity was observed, during positive AM recall compared to neutral, between the 
bilateral amygdala and the bilateral superior and right middle temporal gyrus, the right 
hippocampus, the putamen and the insula, bilaterally. The results from this analysis are show 
in Figure 23. 
 
 
Figure 23. Significant changes (p<.05, FDR corrected) in the connectivity betweem the bilateral 
amygdala and several brain areas were identified when the retrieval phase of the positive and 
neutral events was examined in the placebo group. The brain areas where connectivity with the 
amygdala increased (red) included a. the precuneus  b. the precentral gyrus(bilateral) c. the lateral 
occipital cortex (bilateral) d. the post central gyrus (bilateral) e. the occipital pole (bilateral) f. the 
temporal pole (bilateral) g. the cerebellum-Crus1(left) h. the insular cortex (bilateral) i. the thalamus 
(right) j. the occipital fusifrom gyrus (bilateral) k.the putanen l. the hippocampus (right). Brain areas 
where connectivity with the amygdala decreased (blue) included: a. the parahippocampal gyrus 
(bilateral) b. the paracingulate gyrus (bilateral) c. the intracalcarine cortex (bilateral) and d. the 
occipital pole (left) d. the middle temporal gyrus (right) e. the superior temporal gyrus (bilateral) f. 









2.2.2.2 Retrieval phase of negative AM recall compared to neutral AM recall 
 
When the retrieval phase of negative AMs was compared to that of neutral AMs, 
increased connectivity was identified between the bilateral amygdala and middle temporal 
gyrus, the orbital frontal cortex, the lateral occipital cortex, the fusiform gyrus, the thalamus 
and posterior and anterior cingulate cortex.  Decreased connectivity was identified between 
bilateral amygdala and the hippocampus, the thalamus, the middle and superior temporal 
gyrus, the angular gyrus and the caudate. The results of this analysis can be seen in more 
detail in Figure 24. All these significant increases and decreases in the connectivity between 




Figure 24. Brain areas that present with increased (red) and decreased (blue) connectivity with the 
bilateral amygdala during recall of negtive compared to neutral events are presented (p<.05 FDR 
corrected)  in this figure. Significant increases in connectivity were identified in the a. orbital frontal 
cortex (bilateral) b. middle temporal gyrus (bilateral) c. precuneus (bilateral) d. middle frontal gyrus 
(bilateral) e. inferior frontal gyrus (bilateral) f. the cerebellum-Crus2 (left) g. the superior temporal 
gyrus (bilateral) h. the lateral occipital cortex (bilateral) i.the occipital fusifrom gyrus (bilateral).  
Significantly decreased connectivity were identified between the bilateral amygdala and a. the 
thalamus (bilatral) b. the hippocampus (bilateral) c. the parahippocampal gyrus (bilateral) d. temporal 








2.2.2.3 The effect of emotional valence on the VAMP  
 
In order to investigate the effect of emotional valence, connectivity of the bilateral 
amygdala with the rest of the brain was examined in the placebo group. For this analysis the 
retrieval phase of the positive AM trials was compared to the retrieval phase of negative AM 
trials. Significantly increased connectivity was observed between the bilateral amygdala and 
the temporal/occipital fusiform gyrus, the lateral occipital and middle temporal cortex as 
well as the SMA for recall of positive memories compared to negative ones.  The inferior 
temporal gyrus, the thalamus, the hippocampus, and the left inferior frontal gyrus  presented 
with decreased connectivity with the bilateral amygdala for the aforementioned contrast. 
Figure 25 shows the results from this analysis. Unless specified, all these significant increases 
and decreases in the connectivity occurred bilaterally.  
 
 
Figure 25.  When the effect of the valence of the recalled memory was examined,  significant  
(p<0.05, FDR corrected) increases and decreases inconnectivity of the bilateral amygdala with the 
rest of the brain were identified. Increased connectivity was identified between our seed region and  
a. the lateral occipital cortex (bilateral), b. the precuneus (bilateral), c. superior frontal gyrus 
(bilateral), d. temporal and occipital fusiform gyrus (bilateral), e. the SMA (bilateral) f. middle 
temporal gyrus. Significant decreases were identified for a. the thalamus (bilateral), b. the 








2.2.3 The effects of ketamine on task performance 
 
The VAS ratings of the positive, negative and neutral statements were averaged and 
compared between the ketamine and placebo sessions. The purpose of this analysis was to 
examine whether ketamine, compared to placebo, would produce any significant changes in 
the emotional valence of the events, as it is perceived by our participants at the time of the 
scan. No significant changes were identified between the VAS ratings of the ketamine and 
placebo sessions. The mean ratings for each event and each session are presented in Figure 
26 and the VAS ratings for each event type are includes in Table 13. 
 
Figure 26 The average VAS ratings of the positive, negative and neutral events. A paired t-test revealed that the 
ratings did not change between the ketamine and placebo sessions (p>0.05) 
 
Table 14. The mean VAS score for the positive, negative and neutral event did not differ (Paired t-test, p<.05) 







2.2.4 PPI analysis of the amygdala connectivity between the ketamine and placebo 
sessions 
 
2.2.4.1 Retrieval phase of positive and negative recall compared to neutral 
 
 Ketamine, 2h after its administration, disrupted the connectivity patterns that were 
identified in the placebo group, between the amygdala and several brain regions. 
Specifically, during recall of positive memories compared to neutral (Figure 27A), increased 
connectivity was observed between the bilateral amygdala and temporal regions including 
the middle and inferior temporal gyri and the temporal pole but also the precuneus and the 
precentral gyrus.  Decreased connectivity was identified between the seed region and the 
lateral occipital cortex as well as the occipital fusiform gyrus and the parahippocampal gyrus. 
Some of these regions, mainly the lateral occipital areas, presented with increased 
connectivity with the amygdala when the same contrast was examined in the placebo group.  
 
Figure 27. A. Ketamine, 2h after its administration significantly increased the connectivity between 
the bilateral amygdala and a. the temporal pole (bilateral), b. middle temporal gyrus (bilateral),and  
c. the inferor temporal gyrus (bilateral)d. the precuneus (bilateral) f. precentra gyrus (bilateral) 
during the retrieval phase of positive memories compared to neutral. Significantly decreased 
connnectivity was identifies between our seed region and a. the occipital fusiform gyrus (bilateral), b. 
the parahippocampal gyrus (bilateral) c. the occipital pole (bilateral) d. the insular cortex (bilateral). 
B. When the connectivity of the amygdala was compared between the ketamine and placebo 
sessions for the retrieval phase of negative memories compared to neutral, significant increases 
were identifies for our seed region and a. precuneus (bilateral), b. the frontal occipital cortex 
(bilateral), c. middle and inferior frontal areas (bilateral) d.  the middle and superior temporal gyrus 
(bilateral). Decreased connectivity during negative memory retrieval was identifies between the 
amygdala and a. the insular cortex (bilateral), b. the parahippocampal gyrus (bilateral),  c.the 





The same pattern of disrupted connectivity between the amygdala and occipital and 
temporal areas was also observed when the retrieval phase of negative memories was 
compared to neutral recall between the ketamine and placebo sessions (Figure 27B). 
Ketamine, 2h post the drug administration, increased connectivity between the bilateral 
amygdala and the superior temporal gyrus, the middle temporal gyrus and the frontal 
occipital cortex. Decreased connectivity, however, was observed for the same contrast, 
between the amygdala and lateral occipital cortex, the fusiform gyrus, the thalamus and the 
left hippocampus. Unless specified, those significant changes in the connectivity of positive 
and negative AMs, between the ketamine and placebo sessions, occurred bilaterally.  
2.2.4.2 The effect of emotional valence of recalled memories on task connectivity 
 
When the effect of valence was examined, and positive AM retrieval was compared 
to negative AM retrieval, ketamine did not produce any significant changes in the 
connectivity of the amygdala with the rest of brain. 
2.2.4.3 The effect of session 
 
Our relatively large sample size (N=36) allowed us to examine whether the order of 
drug administration (placebo on the 1st session or ketamine on the 1st session) would affect 
the performance as well as the brain activations observed during the VAMP. For that 
purpose, the retrieval phase of positive, negative and neutral AM trials was examined in an 
analysis that included only participants who were administered ketamine on the 1st session. 
These connectivity results were compared with those obtained for those participants who 
received placebo on the 1st session. A total of 18 participants were included in the two groups 
that were created for this between-subjects analysis and all the contrasts of interest that 
were examined for the VAMP task as well as the PPI analysis were repeated.  
Ketamine did not produce any significant effect of session on the VAMP compared 










Summary of Findings 
 
The VAMP task has been specifically developed in order to examine ketamine’s 
delayed effects on brain areas that are activated during AM recall and rumination. Since the 
VAMP is a novel variant of autobiographical memory tasks that were previously used in 
research, we first examined the data from the placebo session in order to identify the brain 
areas that are engaged by the task. Using a whole brain approach, the positive, negative and 
neutral memories that are recalled during the task, were compared to the control condition 
and also contrasted to each other. This analysis lead to the identification of those brain 
regions that are important for active recall and rumination (see Figure 22). Several of the 
brains regions that presented with significant activations during the positive, negative and 
neutral AM trials, compared to the control condition, have been previously discussed in the 
literature for their important role during AM recall.  
 The examination of brain areas, at a whole brain level, that are activated during the 
retrieval phase of AM trials with different emotional valence (positive vs negative, positive 
vs neutral and negative vs neutral) lead to the conclusion that during the VAMP, the same 
brain areas are activated for positive and negative memory recall. A task-based connectivity 
analysis revealed that the bilateral amygdala presented with significantly increased and 
decreased connectivity with several brain areas when positive and negative AM recall was 
compared to neutral (see Figure 23 and Figure 24). Moreover, this finding was sensitive to 
the emotional valence of the retrieved memories since the connectivity of the bilateral 
amygdala with the rest of the brain was significantly different for positive compared to 
negative AM recall (see Figure 26).  
Ketamine’s effects on the task, were initially examined, at a whole brain level, and it 
was shown that ketamine, 2h after its administration, did not produce any significant 
changes to the task activations, compared to placebo. Moreover, the emotional valence of 
the recalled memories did not significantly change between the ketamine and placebo 
sessions when the VAS ratings were compared under the different drug conditions (see 




Finally, in order to investigate whether ketamine would alter the task-based 
connectivity between our seed region and the rest of the brain we repeated the PPI analysis 
and compared the ketamine with the placebo sessions for all the contrasts of interest. We 
found that ketamine produced significant disruptions in the connectivity between the 
amygdala and the occipital cortex both during positive as well as negative AM recall (see 
Figure 27). 
3.1 The VAMP task- placebo group 
 
 AM memory retrieval involves the accurate reconstruction of mental 
representations of past events by associating together the details that are related to the 
retrieved event (Sheldon et al., 2019). Specifically, during AM recall, mnemonic processes 
are activated to help recreate a detailed memory representation by associating different 
types of information, processed by disperse neuronal systems such the auditory and visual 
networks (Greenberg and Rubin, 2003). Previous neuroimaging studies of AM recall have 
shown that during this complex and cognitively demanding process, an extensive network of 
cortical and subcortical brain areas are activated in order to contribute to an accurate 
reconstruction of the retrieved AM (Dolcos et al., 2012, Wheeler et al., 2006). Moreover, 
there is evidence supporting an extensive overlap between the encoding and retrieval AM 
networks, since key regions that are implicated in AM recall, such as the amygdala, the 
hippocampus and parahippocampal areas along with the visual cortex are also activated 
during AM encoding (Kim, 2019, Kim et al., 2010). 
In our fMRI analysis of the VAMP task several of the brain areas that form part of the 
AM retrieval network presented with increased activations during the recall of positive, 
negative and neutral memories, compared to the control condition (Figure 22). Among the 
areas that presented with significantly increased activation during AM recall, the precuneus 
has been extensively discussed in AM literature. The precuneus is located in the posterior-
medial portion of the parietal lobe and is considered important for the accurate 
reconstruction of the visual-spatial imagery associated with memory recall (Fletcher et al., 






As part of the DMN, the precuneus is also activated during self-referential 
processing, and thus is important not only during active memory retrieval but also ruminative 
thinking (Utevsky et al., 2014). The increased activations observed in that region during the 
VAMP, could indicate that during active recall of positive, negative and neutral AMs, visual 
reconstruction of the retrieved memories takes place. However, there is evidence supporting 
that the activation of the precuneus is necessary for successful memory retrieval, regardless 
of the imageable characteristics of the retrieved memories (Cavanna and Trimble, 2006). As 
a result, the increased activation of the precuneus could indicate the successful retrieval of 
AMs during the task.  
Another possible function for the precuneus during AM recall, could be associated 
with its role within the DMN. The precuneus as part of the DMN, is important for maintaining 
self-consciousness as well as regulating goal-directed actions (Utevsky et al., 2014, 
Cunningham et al., 2017, Vatansever et al., 2015). Although traditionally thought to be 
activated during rest, the DMN presents with increased activations during several AM tasks 
and is implicated in reward and outcome monitoring paradigms as well as during emotional 
stimulus processing (Vatansever et al., 2015). Specifically, studies have shown that within 
the DMN, the precuneus exhibits connectivity patterns that differ from the larger network. 
It has thus been suggested that this brain area could act as a hub region which links the DMN 
with other, mainly fronto-parietal brain areas (Utevsky et al., 2014). As a hub region the 
precuneus could be activated during the VAMP in order to integrate and process information 
from several networks whose activation is necessary for successful AM retrieval.  
Neuroimaging studies that have examined AM retrieval, have consistently shown 
that temporal areas and more specifically the hippocampus play an important role during 
memory recall (Buchanan et al., 2005, Greenberg et al., 2005). However, examination of the 
VAMP task did not reveal significant hippocampal activations during active recall, compared 
to the control condition. One possible explanation for the lack of significant hippocampal 
activity during the task could be the relatively long recall window (12seconds) that was given 






According to a study by Daselaar et al., which aimed to investigate the temporal 
dynamics of the brain areas engaged in AM retrieval, it was shown that the hippocampus 
might be essential for the early stages of memory reconstruction but could be less involved 
once retrieval progresses have progressed further. In the aforementioned study, when 
participants were given a 10s time-window to think about specific AMs, temporal analysis of 
the data suggested a shift of brain activity, from an initial activation of the hippocampus, 
retrosplenial and right PFC to a later recruitment of the visual cortex, the ACC and the PCC 
(Daselaar et al., 2008). These areas presented with significantly increased activation for 
active retrieval in our task 
During the VAMP, the 12sec retrieval phase is precipitated by a 6 sec decision phase 
during which the statements from each event are initially presented to participants. The 
decision phase of the task would require active retrieval of the specific AM in order the 
volunteers to be able to decide whether the statement is “TRUE” or “FALSE”. Although short 
in duration, the decision phase of the task might be long enough for an initial reconstruction 
of the specific AM which would be further elaborated during the retrieval phase of the task. 
It is thus possible that the hippocampus could be involved during that initial stage of AM 
recall while areas such as the visual cortex and the precuneus, which are important for the 
later stages of retrieval, would present with significantly increased activations during the 
retrieval phase (Daselaar et al., 2008). The very short length of the decision window, which 
is also accompanied by button presses that vary in time, makes it difficult to examine the 
brain areas that are important during that phase of the VAMP task and thus validate this 
hypothesis in our data set.   
 Another interesting explanation for the absence of hippocampal involvement during 
AM retrieval in our task, has recently been proposed by Sheldon et al who suggest that the 
brain areas which are activated during AM recall could vary based on the purpose that drives 
the memory retrieval. Specifically, there is evidence indicating that autobiographical event 
information is stored in a hierarchy, at different levels of abstraction and that during recall, 
information from different levels is assembled to construct the memory (Sheldon et al., 
2019). This constructive feature of AMs means that the same AM could be formed in multiple 
ways, engaging different levels of detail from each hierarchy level which could also be 





When AMs are remembered as conceptual experiences, for example, which could 
contribute to future planning and decision-making, especially during novel or ambiguous 
situations (Pillemer, 2003), focus has been given on the emotional experiences that are 
associated with a specific AM. In that scenario, brain areas that are associated with self-
referential processing such as the dorsal medial PFC and the ventral medial PFC, but also the 
amygdala, that are also involved in emotional evaluation of the memory are activated 
(Binder et al., 2009, Lin et al., 2016). Conceptual recall also involves the activation of 
temporal areas and the hippocampus that are implicated in knowledge-based processing 
(Preston and Eichenbaum, 2013).   
During perceptual retrieval, when AMs are retrieved as formed images of 
experienced events, areas that are important for sensory and perceptual processing are 
activated including visual processing areas (ex. occipital cortex) as well as somatosensory 
brain regions (eg somatosensory cortex, precuneus) that would recreate the specific 
situational elements of an encountered event (Reagh and Ranganath, 2018, Ritchey et al., 
2015). 
We believe that during the retrieval phase of the VAMP task, when memory recall 
occurs in a well-structured scenario where there is little novelty or ambiguity as for the 
purpose of the recall, a perceptual retrieval is more likely to occur. Consequently, there 
would be greater engagement of brain areas that would contribute to an accurate and 
detailed representation of the memory such as the precuneus and absence of activation in 
brain regions that are more involved in conceptual retrieval. Of course, a clear distinction 
between the brain areas that are engaged in these two types of AM reconstruction is difficult 
(Addis et al., 2007, Sheldon et al., 2019), especially during our task which was not designed 
to specifically target perceptual retrieval of past AMs.   
3.2 The effects of emotional valence in AM retrieval 
 
 During the analysis of the VAMP data, at a whole brain level, and in order to examine 
whether the emotional valence of the retrieved memory would alter brain activations, we 
compared the retrieval phase of positive, negative and neutral trials. We found that 
regardless of the emotional valence of the recalled memory, the same brain areas are 




The role of emotion in AM encoding and retrieval has been the subject of several 
fMRI studies. Most of these studies indicate that emotional arousal during the encoding of 
AMs could activate brain areas such as the amygdala and the OFC which are important for 
affective processing(Conway, 2005, Kim et al., 2018). The activation of these brain regions 
could, in turn, boost the strength of the memory by enhancing the activation of regions that 
facilitate the encoding of sensory detail (fusiform gyrus) and consolidation of memory 
(hippocampus) (Kensinger, 2009). As a result, emotional memories are more strongly 
encoded and consequently more easily retrieved. The neuroimaging evidence, however, 
highlights that emotion specific processes do not replace standard memory networks that 
are essential for the successful encoding and retrieval of AMs but can only modulate them 
(Dolcos et al., 2017). These modulations could be rather subtle and thus not easy to capture 
at a whole brain level.  
This finding, however, does not necessarily indicate that the emotional valence of 
the recalled memory does not influence the connectivity between different brain areas, 
which could change based on the emotional component of the retrieved AM. For that 
purpose, we conducted a PPI analysis which would enable us to examine with more 
sensitivity the connectivity between different brain areas and how this could change based 
on different task conditions.    
Task-connectivity analysis in the placebo group 
 
The role of the amygdala 
 
When the task connectivity was explored during the retrieval phase of positive and 
negative memories compared to neutral, it was shown that in the placebo group, the 
bilateral amygdala presents with significantly altered connectivity with several cortical and 
subcortical regions (Figure 23 and Figure 24). The connectivity analysis using the PCC and the 
sg ACC did not produce any significant findings. The significant involvement of the amygdala 
during the recall as induced by the VAMP is not surprising given the central role that the 







Autobiographical memories, as mentioned before, are contextually rich memories, 
and their retrieval would activate brain areas that are important for sensory and emotional 
processing (Kensinger, 2009, Kim, 2019). The amygdala, a brain area with a central role in 
emotional processing, is also a pivotal component of the affective network which is 
important for emotional regulation. The role of the amygdala activation however, during AM 
encoding and retrieval is rather unclear. In the literature there is some evidence indicating 
that increased amygdala activity could either enhance (Kensinger and Schacter, 2005) , have 
no effect (Dougal and Rotello, 2007, Onoda et al., 2009) or even impair (Strange et al., 2003) 
the formation of certain memories.  
Despite the unclear role of the amygdala during AM processing, this brain area has 
been consistently identified as one that presents with altered connectivity with several other 
brain regions, in depressed compared to healthy individuals (Young et al., 2018) . Moreover, 
altered amygdala activation has been shown to persist in remission (Young et al., 2016). As 
a result, the study of the amygdala connectivity during AM retrieval of emotionally valenced 
memories, is not surprising and would help us better understand AM recall in our cohort of 
remitted depressed individuals but also identify any effects related to ketamine’s 
antidepressant action on that brain area.  
The amygdalae are functionally and anatomically connected with several brain areas, 
including the hippocampus and parahippocampal regions, the insulae, the caudate nuclei 
and regions in the orbitofrontal cortex (Bickart et al., 2014). During the VAMP task, the 
connectivity between the bilateral amygdala and the rest of the brain was examined for 
positive and negative memory recall, compared to neutral. This analysis revealed significant 
increases and decreases in the connectivity between the amygdala and several cortical and 
subcortical brain areas. The increased connectivity identified between the amygdala and 
lateral occipital regions involved in visual processing as well as the decreased connectivity 
between the amygdala and the left hippocampus of particular interest to our study. These 
findings were present during positive recall compared to neutral and negative recall 
compared to neutral. The amygdala also presented with decreased connectivity with the 
insula, bilaterally, during positive AM recall compared to neutral and that is another 





Retrieval of AMs, as already mentioned, involves the emotional re-experience of an 
event, and this aspect of memory recall is the foundation of episodic memory (Kensinger, 
2009, Kim and Moore, 2019). Consequently, it is not surprising that during recall of 
emotionally valanced AMs brain areas that are important for sensory and emotional 
processing would be connected to each other. One such area, that presents with increased 
activation during AM recall (whole brain level analysis) as well as increased connectivity with 
the amygdala during the VAMP task (PPI analysis) is the visual cortex. The visual cortex has 
been associated with elaboration during memory retrieval and its activation could be 
influenced by emotional modulation (Hofstetter et al., 2012). The fact that it appears to be 
significantly more connected to the amygdala during the retrieval of positive and negative 
memories compared to neutral, could indicate the stronger interplay between emotional 
and sensory related brain areas for the recall of memories that are emotionally valenced. It 
could also point to a more elaborate and accurate recall of those memories. 
When the connectivity between the amygdala and the rest of the brain was 
examined for the retrieval phase of positive as well as negative memories and compared to 
neutral, decreased connectivity was identified between the seed region and the left 
hippocampus (see Figure 23 and Figure 24). The amygdala and the hippocampus are adjacent 
brain areas within the medial temporal lobe and are richly connected to each other. The 
hippocampus is thought to support the retrieval of AMs with rich contextual input (Maguire, 
2001, Svoboda et al., 2006) whereas amygdala activity seems to be mostly related to 
processing of affectively rich, internal information (Bickart et al., 2014). The interplay 
between the two brain areas is thought to be important for memory reconsolidation 
(McGaugh, 2002) and the connectivity between those two brain areas appears to be elevated 
during negative memory recall in depression. Dore and colleagues using a very similar AM 
task and this increased connectivity was associated with altered emotional regulation (Dore 
et al., 2018). The decreased connectivity between the amygdala and the hippocampus that 
we observe during emotional memory recall, compared to neutral in our task could indicate 








The effect of valence 
 
 When the effect of the emotional valence of the retrieved memories was examined 
using PPI, we observed that during the retrieval phase of positive AMs compared to negative 
AMs, there was increased connectivity between the amygdala and the visual occipital areas 
(see Figure 26).  Since we propose that the functional connection between the amygdala and 
the visual processing areas reflects the emotional reconstruction of the recalled memory, 
this increased connectivity could be an indication of the increased cognitive effort required 
for the successful recall of positive memories in remitted depressed volunteers. We know 
from the existing literature that the cognitive bias towards negative memory recall along 
with increased amygdala activations could persist during remission (Young et al., 2018). Thus, 
it is possible that more interplay between the amygdala and the visual cortex is required for 
a successful retrieval of positive memories compared to negative ones in our cohort.  
Retrieval of positive AMs, in the placebo group, significantly decreased the 
connectivity between the amygdala and the left hippocampus (see Figure 26). As we 
mentioned before, connectivity between the amygdala and hippocampus, is important for 
emotional regulation (Dore et al., 2018). The reduced connectivity between these two areas 
during recall of positive AMs compared to neutral, could be associated with the reduced 
emotional burden that positive AM would have on our volunteers. As a result, less emotional 
regulation would be required during recall of these memories compared to negative AMs.  
Ketamine’s effects on task connectivity 
 
 When the effects of ketamine on the VAMP task were examined, 2h after the drug 
administration, ketamine did not produce any significant changes in the VAS ratings of the 
positive, negative and neutral events (see Figure 25). Moreover, when whole brain analysis 
was used to examine the effects of ketamine on the VAMP task no significant changes were 
identified in the activation of brain areas that are important for active recall, compared to 
the control condition. No significant changes in brain activations were identified when 






When VAMP connectivity was examined using PPI, and compared between the 
ketamine and placebo sessions, significant changes were identified only between the 
connectivity of the amygdala with the rest of the brain. The most important of these changes 
included the disruption in the connectivity pattern between the amygdala and the visual 
cortex, produced by ketamine 2h after its administration. Specifically, the visual cortex 
presented with decreased connectivity with the amygdala when positive and negative AM 
recall were respectively contrasted to neutral AM recall and compared between the 
ketamine and placebo sessions (see Figure 27A and 27B).  
The amygdala and the visual cortex appeared with increased connectivity for positive 
AM recall, compared to neutral in the placebo group and this finding was interpreted as an 
indication of the increased effort that is required for an accurate and detailed recollection of 
positive memories compared to neutral in our cohort of remitted depressed volunteers. 
Ketamine, 2h after its administration, decreased the connectivity between the amygdala and 
the visual cortex, for negative as well as positive AM recall when compared to neutral. This 
decrease which appears to be independent of the emotional valence of the recalled memory, 
could be indicative of the reduced cognitive effort that is required for the accurate 
recollection of both positive as well as negative memories after ketamine administration. 
Another possible explanation for the decreased connectivity between the amygdala 
and the visual cortex, observed 2h after the drug administration and for the emotionally 
valenced memories compared to neutral, could be associated with less imagery related to 
the recall of those memories after ketamine. Recent theories about human memory propose 
that AM s when recalled, enter a labile state and thus they need to be reconsolidated (Agren, 
2014, Nadel et al., 2000). In a study by Schwabe and Wolf (2009), recall of AMs under 
different contexts, lead to altered details during their subsequent recollection. Although only 
neutral memories were disrupted in that experiment, that was associated with the increased 
emotional valence of positive and negative AMs which leads to their stronger encoding, 
making it more difficult to temper with those memories during reconsolidation (Kensinger, 









If the positive and negative AMs become labile during their recall for the VAMP task, 
it is possible that ketamine, by altering the imagery associated with those memories could 
affect the re-encoding of those memories and subsequently their future retrieval. This would 
be in line with research showing that the visual vividness of memories during encoding, could 
influence their subsequent retrieval (D'Angiulli et al., 2013). The design of our task, which did 
not involve any assessment of the quality of memory recall after ketamine and placebo does 
not allow us to directly validate this hypothesis. If, however, ketamine 2h after its 
administration, interferes with the reconsolidation processes of emotional memories, this 
could be provide a neuronal mechanism for its antidepressant action and make ketamine a 
good candidate for combination treatments that would include cognitive therapies. 
 
Ketamine, 2h after its administration, also decreased the connectivity between the 
bilateral amygdala and the hippocampus, and this finding was present during negative AM 
recall compared to neutral. As we mentioned before the interplay between the amygdala 
and the hippocampus is particularly important for emotional regulation. Depressed 
individuals present with an increased connectivity between those brain regions during recall 
of negative memories and distancing strategies could lower the hypeconnectivity between 
those two areas and help regulate their emotional responses to negative events (Dore et al., 
2018). The decrease in the connectivity between the amygdala and the hippocampus, under 
ketamine, compared to placebo might reflect the reduced cognitive effort required for the 
















 The VAMP task, that was for the first time tried in this study produced, at the whole 
brain level and in the placebo group, significant activations in brains areas that are important 
for autobiographical memory recall. When the connectivity of the amygdala and the rest of 
the brain was examined it was shown that during recall of positive and negative memories 
the amygdala presented with increased connectivity with the visual cortex and decreased 
connectivity with the hippocampus. The interplay between the amygdala and those brain 
areas could be linked to the visual imagery associated with emotional memory recall as well 
as emotional regulation processes. These findings indicate these cognitive processes are 
engaged during recall of emotionally valenced memories when remitted depressed 
volunteers perform the task.  
Ketamine, 2h after its administration, when the drug levels in the blood are low and 
participants have recovered completely from any psychotomimetic/dissociative effects that 
the drug might produce, disrupted the connectivity between the amygdala and the visual 
cortex as well as the amygdala and the hippocampus. This disruption was significant when 
the retrieval phase of positive and negative memories was separately compared to retrieval 
of neutral AMs. These findings indicate that the delayed effects of ketamine might be linked 
to brain areas that are important for emotional memory recall. This could indicate a possible 
antidepressant mechanism for the ketamine’s antidepressant action which be associated 














Major Depressive Disorder is a chronic and debilitating mood disorder, affecting 
approximately 320 million people worldwide  The symptomatology of depression comprises 
low mood and in some cases suicidality along with anhedonia (Treadway and Zald, 2011) and 
cognitive symptoms. The cognitive symptoms of depression include intense rumination 
about past AMs, overgeneral memory recall as well as a bias towards negative memories  
(Connolly and Alloy, 2018, Hamlat et al., 2015). Rumination in particular has been in the 
centre of several cognitive models that try to explain the initiation of a depressive episode 
and the persistence of low mood in MDD and is also considered as a risk factor for depression 
(Hamlat et al., 2015, Williams et al., 2007). Several depressive symptoms, including 
rumination and anhedonia, are also present during remission from depression. Despite their 
prevalence and debilitating nature however, anhedonia and rumination are not easily 
targeted by commonly prescribed antidepressants.  
Current common antidepressant treatments not only fail to successfully target 
anhedonia and rumination, but also present with certain limitations associated with their 
mechanism of action. A relatively long time is required for their effects to become 
detectable; they have a rather low response rate and approximately 1/3 of patients with 
MDD do not respond to current treatments (Cipriani et al., 2018). Ketamine, that has 
emerged, in the last two decades, as a potent antidepressant with robust effects, is regarded 
as a major advancement in the treatment of mood disorders (Zanos and Gould, 2018). Its 
fast-acting and relatively long lived antidepressant action along with the pharmacology of 
the drug and its metabolites, that target glutamate (ketamine, norketamine) and AMPA 
((2R,6R)-HNK) receptors in the brain could not only help with the  development of future 
treatments but could also enrich our knowledge of the biology of depression. Moreover, 








In order to understand however, how ketamine exerts its antidepressant action in 
the brain, we need to have a good understanding of the brain areas that are important for 
depression and could potentially be targeted by ketamine as an antidepressant. Several MRI 
studies have used resting state as well as fMRI paradigms in order to identify the brain areas 
that present with altered function in depression (Drevets et al., 2008a). However, most of 
these studies have recruited depressed individuals who were receiving antidepressant 
treatment at the time or shortly before the time of the scan. As a result, the findings of these 
studies could be obscured by the effects of antidepressant treatment in the brain. The MRI 
studies that have used drug naïve individuals and resting state to examine changes in brain 
connectivity in MDD are summarized in a table that can be found in Appendix A. Due to the 
relatively small number of these studies as well as the different methodologies that they 
apply to their data, it is rather difficult to draw robust conclusions as to the brain areas that 
appear to be consistently affected in drug-naïve, depressed individuals. Some of the findings 
from these studies point to an increased connectivity within the DMN during resting 
state(Zhang et al., 2011).  More research is thus required in order to understand the brain 
areas and networks that are affected in depression. 
The study of depressed individuals, however, presents not only with practical 
difficulties due to the confounding factor of antidepressant medication but also with several 
ethical issues. These issues evolve around the well-being of research participants and the 
effect that a potential discontinuation of their treatment might have on their mental health.  
Remitted depressed volunteers, on the other hand who do not present with depressive 
symptoms, have stable mood and are not on antidepressant treatment could prove a much 
easier cohort to study. Moreover, research has shown that remitted depressed individuals 
still experience increased anhedonia and rumination as well present with altered brain 
activity (Lally et al., 2015, Young et al., 2016), similar to that associated with depression. 
Specifically, the presence of anhedonia and increased rumination, although not clinically 
significant, could indicate that the brain areas and networks that underlie these processes 
and are affected in depression could still present with altered function in remission (Lally et 
al., 2015, Young et al., 2016, Young et al., 2018). As a result, these volunteers are a useful 
cohort to study, in a controlled, experimental setting, some of the key depressive symptoms 
and investigate how drugs with antidepressant actions could alter activation in brain areas 




In the present study we have used, remitted depressed volunteers who have been 
treatment naïve at least three months prior to taking part in the study in order to examine 
the effects of ketamine, 2h after the administration of the drug, with the use of fMRI. We 
have focused on reward processing that is related to anhedonia as well as AM recall and 
rumination. Our aim was to identify brain areas that present with altered activation in our 
cohort and are modulated by ketamine, 2h after the drug administration, when its 
antidepressant effects first become detectable.  
These brain areas could be viewed as neuroimaging markers that would help us 
understand the delayed effects of ketamine’s administration. In the chapter that follows, we 
will briefly summarize our main findings and discuss them in relation to the literature around 
the antidepressant actions of ketamine in the brain. Moreover, we will examine changes in 
brain activity produced by ketamine in association to the effects that common 
antidepressant medications produce in brain areas associated with Am recall and rumination 
as well as anhedonia. Finally, we will discuss some important considerations around this 
















1 Anhedonia and reward processing in remitted depressed volunteers 
 
Anhedonia was measured in our study with the use of the SHAPS scale. This scale 
was administered at the start of each study days as well as 2h after the drug administration. 
As we expected, the baseline levels of anhedonia in our cohort of remitted depressed 
volunteers were very low. Ketamine, 2h after its administration did not produce any 
significant changes in the SHAPS scores. However, studies that have looked at anhedonia 
during depression and used  the SHAPS reported that ketamine produces a rapid decrease in 
anhedonia, as early as 40min after the drug administration and that these anti-anhedonic 
effects could last up to three days after a single ketamine infusion without additional 
antidepressant  treatment (Lally et al 2015).   
The absence of a significant effect of ketamine on the SHAPS scores in our cohort 
could be attribute to either the recovery of our participants from all depressive symptoms 
including anhedonia or could be due to the reduced sensitivity of the SHAPS. The SHAPS is 
specifically designed to capture anhedonia during the depressed state (Snaith et al., 1995). 
As a result, the scale might not be sufficiently sensitive to depict the very low levels of 
anhedonia that could be present in our group as well as capture any subtle changes that 
ketamine might produce 2h after its administration. Examination of the available anhedonia 
questionnaires however, failed to provide us with a more sensitive and equally well-validated 
measure.  
The neuronal correlates of ketamine’s effects on anhedonia have mainly been 
examined using PET, in order to capture the changes in glucose metabolism that could 
underlie the anti-anhedonic action of ketamine. Specifically, PET studies have shown that 
ketamine, 2h after its administration produced a significant increase in glucose metabolism 
in the dACC and the putamen but not the VS (Carlson et al., 2013). Moreover, the baseline 
glucose metabolism of the dACC under placebo, was correlated with the improvement of 
depressive symptoms under ketamine. The dACC and the putamen are areas that are 
involved in reward processing, learning and decision making and have a known role in mood 
disorders. The increase in glutamate metabolism that ketamine produces, 2h after its 
administration, in these brain areas was associated with increased motivation towards or 
ability to anticipate pleasurable experiences (Carlson et al., 2013). 
162 
 
1.1 The mid task  
 
Our study has used the MID task, a task that allows the examination of anticipatory 
and feedback-related processes while performing a monetary reward task (Knutson et al., 
2000, Knutson et al., 2001). The MID was used  in order to capture any effects that ketamine 
might have, 2h after its administration in brain areas that are important for reward 
anticipation and feedback. Analysis of the MID task has shown that deficits in brain activity 
during reward in depression are mainly associated with decreased activations in the NAc 
(Epstein et al., 2006, Keedwell et al., 2005). However, the decreased activation of the NAc 
could be an effect of antidepressant treatment since studies in drug-naïve MDD patients 
(Knutson et al., 2008) as well as non-depressed individuals with high anhedonia (Harvey et 
al., 2007) have failed to replicate this finding. A recent meta-analysis of fMRI studies that 
have used the MID task in depression revealed that depression is characterised by reduced 
striatal activity, especially during the feedback phase of the task (Keren et al., 2018).  
In our study, and in the placebo group, when activity was examined in brain areas 
that are important for reward processing in the MID (a prior defined ROI analysis in the 
striatum, VTA, insula and amygdala), we found during the for anticipation of win trials, 
compared to neutral trials, remitted depressed volunteers presented with significantly 
decreased activations in the VS, the insula and the putamen.  For the anticipation of a high 
win trials, compared to a low win trials, the VS and the VTA were decreased in activation. 
When the feedback phase of the task was analysed, we found that the VTA presented with 
decreased activity during unsuccessful low win trials compared to neutral ones. There is no 
control group in this study, but the overall pattern of decreased activity is supportive of a 
hypothesis of persistent deficits in reward processing during remission. 
 Ketamine, 2h after its administration, did not significantly alter task performance 
but did produce significant changes in our a priori defined ROIs. These changes were more 
prominent during the feedback phase of the MID. Specifically, ketamine increased the 
activation of the VS and the caudate during the feedback phase of successful low win trials 
and unsuccessful low win trials respectively.  Activity in the VTA was also increased during 





To our knowledge, our study is the first to examine the effects of ketamine on the 
MID task, 2h after the drug administration, so direct comparisons of our findings with the 
existing literature are not possible. However, in depressed individuals ketamine induces an 
increase in VS metabolism (Carlson et al., 2013) that related to the decrease in anhedonia. 
When previous findings are combined with our results of increased activations in striatal 
regions, we can hypothesise that ketamine’s delayed effects on reward feedback underlie a 
positive influence of the drug on those individuals with higher levels of anhedonia. 
Interestingly, the increased striatal and VTA activity after ketamine on the MID were most 
prominent for unsuccessful trials and/or trials associated with lower monetary rewards. This 
finding considered together with the meta-analysis findings which demonstrate reduced 
striatal activity during the feedback phase of the MID task in depression, could also point 
towards ketamine increasing the sensitivity to feedback. This increase was not detected for 
the higher reward trials, where the magnitude of the reward could be sufficient to mask 
deficits in motivational processing in the remitted depressed group of our study.  
2 Current antidepressants and anhedonia 
 
Current first-line treatment for depression includes tricyclic antidepressants as well 
as serotonin and noradrenaline reuptake inhibitors, focusing most of the research around 
depression on these two neurotransmitter systems. Anhedonia, however, is directly linked 
to dopaminergic pathways and as such the partial inability of common treatments to 
significantly improve this symptom is not surprising. Evidence suggests that standard 
medication for depression are poor in alleviating anhedonia, which is often the last symptom 
to be improved by SSRIs (Boyer et al., 2000, Shelton and Tomarken, 2001). There is also 
evidence suggesting that SSRIs might induce some aspects of anhedonia (Hindmarch, 1998, 
Price et al., 2009). In a review discussing the role of dopamine-targeting drugs for treatment 
of depression, Agyropoulos and Nutt (2013) suggest that dopamine enhancing agents could 
be helpful for the treatment of the anhedonia-related symptoms of depression especially in 






Several fMRI studies as well as recent meta-analysis around antidepressant effects, 
have shown that antidepressant treatment increases the activation in brain areas associated 
with reward processing, such as the caudate, the NAc, as well as the insula (Zhang et al., 
2013, McCabe et al., 2010). However, some of these studies have employed emotional 
processing tasks that do not directly target  motivational anhedonia (as the MID) so we can 
only hypothesize that the changes observed in these studies could also be associated with 
our findings and indicate the positive effect of antidepressants and ketamine in reward 
related processes.   
Ketamine, which primarily targets glutamate receptors, increases activation in the 
reward circuit. Reward processing, however, is mainly mediated  by dopamine. At the neural 
level, as far as the interplay between ketamine and dopamine is concerned, there is evidence 
that ketamine acts as a partial agonist of the dopamine D2 receptor and has been found to 
increase dopamine levels in the striatum including the caudate and the putamen (Lally et al., 
2014). In addition to this direct effect, the glutamatergic system which is ketamine’s primary 
target produces downstream effects on dopaminergic activity, and this may also be a 
potential route for ketamine’s anti-anhedonic action. However, these studies concern the 
effect of ketamine during its infusion and do not speak to its delayed action. In order to 
demonstrate the link between the dopamine system and the delayed effects on reward 
processing after ketamine, a combined PET-MR study of both dopamine release and MID-













Rumination is measured in our study with the use of the RRS which is administered 
on the screening day in order to provide us with a baseline measure of ruminative thinking 
in our cohort of remitted depressed volunteers. This scale was specifically developed to 
measure rumination that is not confounded by depression (Treynor et al., 2003). In our 
group, we found increased scores in the RRS that exceeded the average reported in the 
literature for the healthy population (Nolen-Hoeksema, 1997). Moreover, the reported 
difference in the RRS scores, between males and females, with females usually reporting 
higher scores than males, is not present in our group which is rather well gender-
balanced(Johnson and Whisman, 2013). This finding indicates the presence of rumination in 
our cohort.  
Ruminative thinking has mainly been examined in depression using resting state 
fMRI. This is not surprising since rumination has been linked to an increased self-focus and 
increased activation in the DMN (Lehmann et al., 2016, Sheline et al., 2009).  Thus, 
examination of this network would be useful to understand the neuronal correlates of 
rumination in depression. Patients with MDD show increased resting state activity, 
compared to healthy controls, in several DMN regions including the PCC, which is a key node 
of the DMN. Whereas increased connectivity between the PCC and sgACC has also been 
identified in MDD during rumination (Berman et al., 2011). The increased connectivity of the 
DMN has been associated with higher levels of maladaptive rumination (Hamilton et al., 
2015) which is linked to increased negative affect and depression. 
 Ruminative thoughts, in healthy as well as depressed individuals mainly evolve 
around past autobiographical events. In depression, overgeneral AM recall that is one of the 
most common cognitive characteristics of the illness (Williams et al., 2007), as well as the 
bias toward negative memory retrieval (Connolly and Alloy, 2018), direct ruminative thinking 
towards negative AMs. Studies that have used the AMT have confirmed overgeneral AM in 
depression (Young et al., 2014) as well as a bias towards a more detailed recollection of 
negative memories which also persists in remission (Young et al., 2016). The DMPFC along 
with temporal regions, the caudate and the amygdala have been implicated in this biased 





3 Emotionally valenced AM recall in remitted depressed volunteers 
 
 In our study we have developed a novel task, the VAMP, which would help us 
examine rumination and AM recall in our cohort of remitted depressed volunteers and 
identify any changes that ketamine might produce in the activation of brain areas that are 
significantly engaged during task performance. During the VAMP task a 12 sec long window-
retrieval phase-is given to participants in order to focus on and recall specific 
autobiographical events, with different emotional valence: positive, negative and neutral. 
Whole brain analysis of the task revealed that in the placebo group and during active recall 
compared to the control condition, the task alters brain activation in areas that are important 
for successful memory retrieval and the visual imagery associated with the retrieved 
memory, namely the precuneus, the middle frontal gyrus and the thalamus.  
A task-based connectivity analysis was also performed for the retrieval phase of the 
task and the aim of this analysis was to examine the connectivity between seed regions that 
are important for rumination and AM retrieval, namely the amygdala, the PCC and the sgACC, 
with the rest of the brain during recall of emotionally valenced AMs. The connectivity of the 
amygdala with the rest of the brain was significantly different between the VAMP contrasts 
and modulated by ketamine.  
Specifically, for the placebo session, increased connectivity was identified between 
the amygdala and the visual cortex as well as the amygdala and the hippocampus when recall 
of positive and negative memories was, separately, compared to neutral memories. 
Moreover, when positive AM retrieval was compared to negative, connectivity between the 
amygdala and the visual cortex increased for positive AMs, compared to neutral. The 
connectivity between the amygdala and the hippocampus decreased for the same contrast. 
These findings could indicate the increased visual imagery associated with positive memory 
recall in our cohort as well as the reduced emotional regulation that might be associated 
with positive memory recall compared to negative, in order to successfully perform the 







When VAMP connectivity was examined using PPI and compared between the 
ketamine and placebo sessions, significant changes were identified only between the 
connectivity of the amygdala with the rest of the brain. Ketamine, 2h after its administration, 
decreased the connectivity between the bilateral amygdala and the hippocampus, and this 
finding was present during negative AM recall compared to neutral.   
Ketamine also disrupted the connectivity pattern between the amygdala and the 
visual cortex, Specifically, the visual cortex presented with decreased connectivity with the 
amygdala when positive and negative AM recall were respectively contrasted to neutral AM 
recall and compared between the ketamine and placebo sessions. The decreased 
connectivity between the amygdala and the visual cortex could be associated with reduced 
visual imagery during recall of those memories, after ketamine which could interfere with 
reconsolidation processing and consequently alter the way these memories are 
remembered.  
4 The effects of ketamine on the VAMP task 
 
In the literature, the delayed effects of ketamine, in recall and rumination of AMs 
are very poorly examined and understood. Two resting state connectivity studies in healthy 
volunteers showed that 24h post ketamine, DMN connectivity decreases (Lehmann et al., 
2016, Scheidegger et al., 2012). Both these studies have tried to relate the delayed effects of 
ketamine on the DMN connectivity, with the increased rumination that is observed during 
depression as well as the bias towards negative affect in order to draw conclusions about the 
antidepressant actions of the drug. They suggest that ketamine, by reducing DMN 
connectivity, would have a positive effect on rumination in depression. However, the luck of 
replication of these findings as well as the fact that they have used healthy controls makes it 









In depressed volunteers, to our knowledge, there are so far only three studies that 
have examined the delayed, 24h post administration, effects of ketamine with the use of 
fMRI, and compared them to healthy controls. In these studies, ketamine was administered 
to depressed individuals as a treatment and the main focus of these studies was to relate 
ketamine’s change in brain activations with the changes in the depressive symptoms 
produced by the drug. These studies in general identified ketamine-induced increases in the 
brain connectivity (Abdallah et al., 2017) as well as increased BOLD responses in the sgACC 
(Downey et al., 2016), the insula and the caudate (Murrough et al., 2015). These changes 
were positively correlated with the improvement of depressive symptoms produced by the 
drug. Most importantly, Murrough and colleagues used a facial emotion-perception task and 
showed that ketamine enhanced neuronal responses to positive emotion in the right caudate 
in depressed patients, compared to placebo.  
 Our findings in remitted depressed volunteers and 2h after ketamine administration, 
show that the drug, disrupts the connectivity between the amygdala and the visual cortex as 
well as the hippocampus during emotional memory recall. This disruption in the connectivity 
could be linked to cognitive processes that include memory retrieval and reconsolidation as 
well as emotional regulation. Taken together, our findings along with ketamine’s delayed 
effects on depressed as well as healthy volunteers point towards the drug targeting cognitive 
processes such as rumination and memory recall with a specific effect on the emotional 
components that underlie these processes.  
 These findings become particularly interesting when viewed in association with the 
cognitive models that have been proposed in the literature and try to explain the initiation 
and prolongation of depressive episodes. According to these models altered emotional recall 
as well as a bias towards negative memories and brooding (maladaptive rumination) are the 
cognitive processes that are mainly affected in depression(Connolly and Alloy, 2018, 
Thomsen, 2006). In summary, these models propose that bias towards negative memory 
recall, along with increased rumination about those negative AMs and the reduced positive 
affect that is associated with depression create a cognitive “vicious” circle that is very hard 
to break and could even persist in remission (Beck and Bredemeier, 2016, Williams, 2006). 
The delayed effects of ketamine in decreasing resting state connectivity which could be 
positive for rumination and the increased responses to positive emotions along with 
alterations in memory retrieval and reconsolidation processes could have positive effects on 
the cognitive processes that are affected in depression.  
169 
 
These findings, however, arise from studies that have used different samples 
(depressed, remitted depressed and healthy controls), have looked at different time points 
during the ketamine infusion (2h as well as 24h) and used different MRI paradigms. More 
research is needed that uses consistent paradigms among studies in all of these groups to 
provide us with a broader understanding of ketamine’s delayed effects in the brain. The drug 
effects should also be examined at different time points during ketamine’s antidepressant 
action in order to determine whether and how ketamine’s delayed effects change overtime. 
Moreover, it would be useful to study ketamine in relation to other antidepressant 
medication, with similar and different mechanisms of action in order to examine  whether 
ketamine’s effects could be linked to those of other antidepressant treatments.  
5 Current antidepressants and rumination 
 
 Research around the effects of current antidepressant treatment on rumination is 
rather limited. Most of the fMRI studies focus on the effects of antidepressant medication 
on emotional processing and have shown that that the affective network and mainly the 
amygdalae are a common target of current antidepressant treatment (Wessa and Lois, 
2015). These effects seem to be more prominent in emotional tasks.  
Specifically, it has been shown that the increased reactivity of the amygdala 
observed in depressed patients during an emotional-processing task normalises after 
treatment with SSRIs. This normalization occurred after 8 weeks of antidepressant 
medication treatment (Sheline et al., 2001) and since increased amygdala reactivity is 
associated with a bias towards negative memories, it was suggested that this reduction could 
help with maladaptive rumination. In another study that investigated the effects of 
fluoxetine (8 weeks) during processing of sad faces, it was shown that in MDD, amygdala 
activity is positively correlated with medial temporal and ventral occipital regions and 
anticorrelated with the ACC (Tao et al., 2012). Moreover, antidepressant medication 
significantly increased the coupling of the amygdala with frontal regions (lateral PFC), the 
thalamus and the striatum and this result could indicate the role of antidepressant 
medication in altering the interplay between emotional reactivity, mediated by the 
amygdala, and cognitive control mainly associated with frontal region thus leading to a 
normalisation of the heightened emotional responses observed in depression(Chen et al., 
2006) (Chen et al., 2008). 
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Ketamine’s delayed effects also alter amygdala activity and this has been linked to 
improved emotional processing in both healthy as well as depressed individuals (Murrough 
et al., 2015, Scheidegger et al., 2012). As result the amygdala could be a prominent target 
for the mechanisms of action of antidepressant medication including ketamine.  
Considerations and limitations 
The findings of our study in general, indicate that ketamine, 2h after its 
administration, produces significant changes in the activation of brain areas that present 
with altered function in depression. These brain areas also play a key role in mediating 
anhedonia and emotional memory recall that could be linked to rumination. Most of the 
significant changes in brain activity that we identified, 2h after the ketamine administration 
and in our cohort, were increases. This could lead to the conclusion that ketamine would 
produce a general increase in brain activity, 2h after its administration, that is not specifically 
related to the antidepressant actions of the drug. However, the increases that we observed 
in our data set, occurred under task contrasts specifically designed to explore those aspects 
of emotionally valenced AM recall and anhedonia that are associated with depression. 
Moreover, the fact that ketamine’s significant changes in brain activations were identified 
only when our a priori ROIs were examined and not at a whole brain level, further indicates 
that ketamine’s effects were targeted to specific neuronal processes. Finally, ketamine also 
produced decreases in the activation of several ROIs during the MID task contrasts, however, 
most of these decreases did not survive correction for multiple comparisons. 
In our study, a single dose of ketamine, assessed 2h after its administration, did not 
produce any significant changes in anhedonia as measured by the SHAPS and the SHAPS 
scores did not correlate with the changes in brain activity that ketamine produced. 
Additionally, during the VAMP task, emotional valence of the positive and negative AMs did 
not change after ketamine, and no correlations were identified between the effects of 
ketamine on brain activation and those ratings. Since in our cohort, ketamine did not 
produce any significant behavioural changes that could relate to the drug’s antidepressant 
actions, we would refrain from calling the effects that ketamine produced in the brain as 
antidepressant. This, however, does not diminish the importance of those effects which in 





One major consideration in our study as well as generally in research using ketamine, 
is the lack of an effective placebo. In our study the dissociative and psychotomimetic effects 
of ketamine were very pronounced and not only jeopardised the design of the study but also 
caused a significant burden in the well-being of our volunteers during and around the time 
of the infusion. The unpleasantness of the dissociative and psychotomimetic effects as well 
as the physical symptoms that ketamine administration produces, were captured in our 
study as increased anhedonia during the infusion (PSI anhedonia sub-scale) as well as 
reduction in the SNK-W scores for well-being.  
We anticipated that ketamine would produce robust side-effects that could 
potentially affect the integrity of data collection since both the investigators as well as the 
volunteers were able to, most of the time, accurately distinguish the ketamine from the 
placebo session. For that reason, we recruited sufficient remitted depressed volunteers, in 
order to be able to detect a potential effect of session by separately analysing the sessions 
were ketamine was administered first and comparing them to the placebo sessions. No 
effects of the drug administration order were identified in the behavioural as well as the 
fMRI data from this study. While the unblinding of ketamine could not be avoided in this 
study a number of steps were taken to minimise its impact. First, the drug was administered 
blind to the researcher conducting all the testing. Second, the main outcome measures 
(VAMP and MID) were fully automated tasks in the scanner. Third, with the testing occurring 
distant from the infusion it was ensured that all dissociative and psychotomimetic effects of 












 In our study the brain areas that appear to be particularly sensitive to the effects of 
ketamine, 2h after the drug administration include the amygdala and hippocampus, during 
emotionally valenced recall of AMs as well as the VS and VTA during the feedback phase of 
the MID. These areas could thus serve as potential neuroimaging markers in order to 
examine the delayed effects of ketamine and how these effects are associated with the 
antidepressant actions of the drug. Future studies of these brain areas in remitted depressed 
individuals could answer questions around the neural processes that are mediated by these 
regions and what is their potential role in cognitive processing that could also be affected in 
depression. In depressed volunteers the study of these areas would allow for a more direct 
link between the antidepressant effects of ketamine and the changes in the brain activity 
that are produced by the drug. Moreover, these areas could be useful in the study of other 
compounds that target the glutamatergic system and could have antidepressant action. 
 In the VAMP task, the delayed effects of ketamine during the recall of positive and 
negative memories, compared to neutral, ware associated with disruption in the connectivity 
of the amygdala with the visual cortex as well as the amygdala and the hippocampus. The 
decreased connectivity between these areas during emotionally valenced AM recall, which 
could be associated to emotional memory recall and reconsolidation processes, could 
indicate that ketamine might be particularly helpful in depression when combined with 
psychotherapy of cognitive behaviour therapy. Several therapeutic techniques, including 
MEST (Memory Specific Training) as well as Mindfulness based training , try to reverse the 
cognitive bias towards negative memory recall that is observed in depression by inducing 
negative AM recall and subsequent re-consolidation of these memories in a controlled 
environment(Kohler et al., 2015). Ketamine’s delayed positive effects in the neural processes 
that might mediate the reconsolidation of those memories might be might particularly 








More research is required in remitted depressed volunteers as well as depressed 
individuals in order to better understand how ketamine manipulates these processes. The 
delayed effects of ketamine at multiple time points during the window of its antidepressant 
action could be examined in order to detect the best point in time for the induction of AM 
recall that would coincide with the peak of ketamine’s antidepressant effects on those 
memory processes. Additionally,  if ketamine, as an antidepressant could interfere with 
memory recall and reconsolidation, special attention should be given during and after its 
administration since exposure of individuals to stressful or traumatic events during the 
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Adjustment of the LEDS interview for the identification of Positive, 


















Now I would like to ask you about last year, and by that I mean from ... since … and perhaps 
a bit further back.  
 
We will be focusing on the positive and negative things that may have happened to you or 
to people close to you during that time.  
 
So, I will need to find out a little bit about those people  
 
By people close to you I mean:  (ask each next questions with an interrogative tone of voice, 
as if to say “Do you have one”) 
 
              Husband /wife or boyfriend/girlfriend? 
  
              Children? 
 
              Brothers/Sisters? 
 
              Parents? /Step-parents? 
 
              Other household members? 
 




At the end of this interview, I would also like you to describe one of your daily routines that 
feels neutral to you.  
 
For example, a day at work/university/home that was not particularly exciting or sad. 
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Positive Event  
 
First of all lets start with what you think was the most positive thing that happened to you 
during the last 12 months. 
 
Make sure to find out:  
a. When exactly did it happen? 
b. Was someone else involved? 
c. How did you feel about it then and how did you feel about it a couple of    weeks 
after?  
 

































During the same year, did anything else happen that was also very positive/exciting? 
 
Make sure to find out:  
a. When exactly did it happen? 
b. Was someone else involved? 
c. How did you feel about it then and how did you feel about it a couple of    weeks 
after?  
 



































If nothing else positive happened during the last year or the participant can recall only one 
positive event then say: 
How about going a bit further back in time? Let’s say the year before that.  
Did anything really positive happen from … since … 
 
Make sure to find out:  
a. When exactly did it happen? 
b. Was someone else involved? 
c. How did you feel about it then and how did you feel about it a couple of    weeks 
after?  
 

































If two or more events are being mentioned then ask the participant.  
 
 




Which one?  
 
 
























And how about the most negative and sad experience that you had during the last year?  
 
Make sure to find out:  
a. When exactly did it happen? 
b. Was someone else involved? 






































Did anything else happen that was also very sad? 
 
Make sure to find out:  
a. When exactly did it happen? 
b. Was someone else involved? 








































If nothing else negative happened during the last year or the participant can recall only one 
negative event then say: 
How about going a bit further back in time? Let’s say the year before that.  
Did anything negative happen from … since …? 
 
Make sure to find out:  
a. When exactly did it happen? 
b. Was someone else involved? 




































If two or more events are being mentioned then ask the participant.  
 
 






























Now, as I have mentioned at the beginning, I would like you to describe one of your daily 
routines.  
This question could be adjusted according to participants… For example, if the volunteer is 
a university student you could ask them to describe a normal day at the university.  
Say for example:  
How about a usual day at uni? Is that day associated with something particularly positive or 
negative? Does it make you feel sad or happy thinking about it?  
Make sure to find out:  
a. When exactly did it happen? 
b. Was someone else involved? 


































If the participant says that they have particularly strong feeling about that routine or they 
associate it with something very sad. For example, hate waking up very early in the 
morning, have a class with a professor that they particularly dislike or learning that 
something very sad or happy happened while they were at uni… ask them for another daily 
routine.  
Make sure to find out:  
a. When exactly did it happen? 
b. Was someone else involved? 





































When trying to obtain contextual information about the negative events make sure you 





 A. FOR ANY KEY ILLNESS EVENT/DIFFICULTY, SOME SUGGESTED 'PROBES':  
             
  FROM DOCTORS:            
  Reasons for llness. 
  Chances recovery/outlook.     
  Treatability. 
            Future health; implications for work.         
  Has anyone else had it in the family?          
  Lack of information from doctor.               
  Shortcomings in care.      
 IMPACT ON:             
  Employment; chance of losing job.     
  Sick pay;  problems obtaining suitable care.   
  Manifestations.         
  Handicap. How needed to cut  down? 
      Pain, symptoms.                               
  How long in bed?                              
  Interference with everyday life/hobbies/ future plans.  
  Had before? Outcome.       
 
ILLNESS OF OTHERS ONLY:  
  Was it expected?       
  How involved were you? 
       Nursing; infectiousness.    
  Worry about dying. 
       Worry handicap.           
  Diet; incontinence; lifting.             
211 
 
  Change behaviour/personality e.g. anger, irritability,  
 ingratitude, blame? 
  Stigma/embarrassment?               
 
ROLE CHANGES  
 
B.  FOR ANY INTERACTION CHANGE EVENT:      
                                                            
          Temporary. How long away.                    
          How often seen before the change?  
          How much did you do together?                 
          How often do you see now?                                         Distance.                                    
          Telephone contact.  
          How did you get on?  How about now?          
          Preparation. Evidence rejection/guilt.       
                                                       
          INCREASE IN INTERACTION:  
      How fitted in - space/tension. 
    
     
C.  FOR ANY MARRIAGE/ENGAGEMENT INVOLVING S:          
                                                           
          How long known.                                 
          Complications/'delaying tactics'/rejections.  
          Family reactions.                            
          Was there anything about him made you uneasy?       
     
D. FOR ANY DIVORCE/SEPARATION INVOLVING S:           
                                                           
          Reasons.                                     
          Preparation; anticipation.                   
          Who left? What circumstances.                 
          Forced to leave.                   
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          Anyone else involved.                        
          'Alternative' relationship by either spouse.  
          Finance/housing.                             
          Custody.                                     
          Children - their reactions etc.              
          Clean break/pestering/violence.              
          Family's reaction.                           
          Legal advice. When.                          
          Maintenance arrangements.                    
          Often seen now.  
LEISURE AND INTERACTION 
Have you made any new friends, of either sex, at all?    
 Have you lost someone you were close to - either because they've   moved a
 way, or died, or just drifted apart?     
Have there been any big changes in the amount you see of your friends or relatives?  
Have there been just the ... of you at home during the time…. since ... 
 Has anyone left the household at all? 
 Is there anyone you see much less of?  
   
HOUSING 
E. FOR ANY RESIDENCE CHANGE EVENT, PROBE:   
                                         
 Why did you move? What happened?       
 Decision to move. 
 Were there any difficulties?  
 Have there been any since then? 
 Expense.                               
 Consequences.  
 Did you feel cut off? Baby-minders etc.   
 New friends.                          
 Impact on job.                        




EMPLOYMENT AND SCHOOL 
 
F. IF ANY IMPORTANT CHANGE ESTABLISHED, FIND OUT:                                
                                                  
            How came about, whose decision.     
            Financial implications.             
            Convenience, hours etc.             
      
   IF FOR S:            
                     
            Travel, babysitting/ arrangements for children.          
            Responsibility/demandingness.       
            Interest; importance.               
            Plans for future.                   
CRISES  
G. FOR ANY COURT APPEARANCE EVENT:     
             
          Nature of offence.  
          First time done it.   
          First time in court.  
          Other convictions.  
          Verdict.  Sentence.  
          Financial implications.                  
          What have other people said?   
          What have they said at work?    
          Driving affected (if licence lost etc).   
          Implications re other people involved.    
          Were you afraid they would try to get  






     H. FOR ANY BURGLARY OR LOSS OR DAMAGE TO PROPERTY:    
             
            How did it come about? (S's 'fault'?)    
            Did you see the burglar?     
            How much was taken?      
            Problems with insurance?      
            Anything irreplaceable.     












































Snaith-Hamilton Pleasure Scale 
This questionnaire is designed to measure your ability to experience pleasure in the last few 
days. It is important to read each statement very carefully.  
Tick one of the boxes [   ] to indicate how much you agree or disagree with each statement.  
1. I would enjoy my favourite television or radio programme: 
 
Strongly disagree    [   ]                        
Disagree [   ]                                                
Agree     [   ]                                                
Strongly agree [   ]                                
 
2. I would enjoy being with my family or close friends: 
 
Definitely agree [   ] 
Agree [   ] 
Disagree [   ]    
Strongly disagree [   ] 
 
3. I would find pleasure in my hobbies and pastimes: 
 
Strongly disagree [   ] 
Disagree [   ] 
Agree [   ] 
Strongly agree [   ] 
 
4. I would be able to enjoy my favourite meal: 
 
Definitely agree [   ] 
Agree [   ] 
Disagree [   ] 
Strongly disagree [   ] 
 
5. I would enjoy a warm bath or refreshing shower: 
 
Definitely agree [   ] 
Agree [   ] 
218 
 
Disagree [   ] 
Strongly disagree [   ] 
 
6. I would find pleasure in the scent of flowers or the smell of a fresh sea breeze or 
freshly baked bread: 
 
Strongly disagree [   ] 
Disagree [   ] 
Agree [   ] 
Strongly agree [   ] 
 
7. I would enjoy seeing other people’s smiling face: 
 
Definitely agree [   ] 
Agree [   ] 
Disagree [   ] 
Strongly disagree [   ] 
 
8. I would enjoy looking smart when I have made an effort with my appearance: 
 
Strongly disagree [   ] 
Disagree  [   ] 
Agree [   ] 
Strongly agree [   ] 
 
9. I would enjoy reading a book, magazine or newspaper: 
 
Definitely agree [   ] 
Agree [   ] 
Disagree [   ] 
Strongly disagree [   ] 
 
10. I would enjoy a cup of tea or coffee or my favourite drink: 
 
Strongly disagree [   ] 
Disagree [   ] 
Agree [   ] 
Strongly agree [   ] 
 





Strongly disagree [   ] 
Disagree [   ] 
Agree [   ] 
Strongly agree [   ] 
 
12. I would be able to enjoy a beautiful landscape: 
 
Definitely agree [   ] 
Agree [   ] 
Disagree [   ] 
Strongly disagree [   ] 
 
13. I would get pleasure from helping others: 
 
Strongly disagree [   ] 
Disagree [   ] 
Agree [   ] 
Strongly agree [   ] 
 
14. I would feel pleasure when I receive praise from other people: 
 
Definitely agree [   ] 
Agree [   ] 
Disagree [   ] 
Strongly disagree [   ]  
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